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Epithelia are an essential organising feature of multicellular organisms and the 
selective permeability of these barriers is regulated by the junctional repertoire of tight 
junction proteins. The regulation of epithelial permeability is essential for the 
physiological function of various organs and is often pathologically deregulated, for 
example in inflammatory disease and cancer. Tight junctions are dynamically regulated 
in response to diverse stimuli through multiple signalling pathways. The RAF/MEK/ERK 
pathway has been reported to mediate junctional remodelling in response to various 
growth factors and hormones, although the unique contribution of this pathway and the 
mechanisms of reorganisation remain unclear. To address this, specific activation of 
the RAF/MEK/ERK pathway was achieved through the expression of BRAFWT or 
oncogenic BRAFV600E in Madin-Darby Canine Kidney (MDCK) II cells, a model epithelial 
cell line used to study tight junctions. 
 
Specific activation of the RAF/MEK/ERK pathway generated a transient increase in 
transepithelial resistance, which occurred concurrently with the differential regulation of 
tight junction protein expression levels and subcellular distribution. Claudin-2 protein 
levels were decreased, while junctional levels of claudin-4 were increased. Total levels 
of claudin-1, occludin and ZO-1 were unchanged and were retained at areas of cell 
contact although showing varying degrees of cytoplasmic accumulation. 
 
Conditionally active CRAF:ER fusion proteins were expressed to provide increased 
control of RAF/MEK/ERK signal duration and to study the rates of TJ protein synthesis, 
degradation and localisation. RAF-mediated downregulation of CLDN2 mRNA caused 
subsequent claudin-2 protein depletion without influencing rates of internalisation or 
degradation. In contrast, RAF activation caused the redistribution of claudin-1 and -4 
from the lateral membrane to the apical junction. This junctional accumulation could not 
be attributed to changes in claudin protein levels, stability or endocytic trafficking. 
Taken together, these data reveal surprising diversity in RAF/MEK/ERK-mediated TJ 
control, where distinct combinations of claudin-specific regulatory mechanisms act in 
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Chapter 1: Introduction 
  





1.1 Epithelial structure 
Epithelial cells form multicellular sheets, which compartmentalise the body by lining 
external and internal surfaces, cavities and organs. Epithelia are characterised by a 
highly polarised structure, with an apical plasma membrane that faces the central 
lumen, a lateral domain that contacts neighbouring cells and a basal membrane that 
interacts with the underlying extracellular matrix through focal adhesions (Figure 1.1). 
These membrane domains are distinct in terms of their lipid and protein composition 
and the maintenance of this polarised structure is essential for the directional transport 
of water, ions and other molecules across the monolayer.  
 
Individual cells are connected by four junctional complexes; the tight junction (TJ) or 
zonula occludens, the Adherens junction (AJ) or zonula adherens, desmosomes or 
macula adherens and gap junctions (GJ), which succeed each other in an apical to 
basal direction along the lateral plasma membrane and have distinct biological 
functions (Figure 1.1). Gap junctions are composed of pannexins and connexins, which 
form intercellular pores that allow intercellular communication through the transfer of 
ions, secondary messengers and metabolites between cells (Meşe et al., 2007). The 
cadherin-based AJ and desmosomes form strong intercellular adhesions and provide 
structural integrity to  the cell monolayer (Green et al., 2010). The TJ is a specialised 
structure that is generally confined to the apical-most tip of the lateral plasma 
membrane and defines the boundary between the apical and basolateral plasma 
membrane domains (Shin et al., 2006). The TJ plays a minor role in cell adhesion, but 
confers a number of properties that are essential for physiological epithelial function 
(Steed et al., 2010). 
 
 
Figure 1.1: A schematic of cell-cell junctions present in an epithelial monolayer. Individual 
epithelial cells form multicellular sheets that line body organs and cavities. These epithelia are 
characterised by a highly polarised structure, with an apical membrane facing the central lumen, 
and a basolateral surface that interacts with neighbouring cells and underlying tissues. Cell-cell 
adhesion is primarily mediated through cadherin-based Adherens junctions (AJ) and 
desmosomes (D), while the monolayer is anchored to the extracellular matrix (ECM) through 
focal adhesions (FA). The tight junction (TJ) is confined to the apex of the lateral membrane and 
has a key role in regulating paracellular permeability, apicobasal polarity and intracellular 
signalling cascades. 





The TJ initially appears as an area where the intercellular space becomes extremely 
narrow, and at higher magnifications as a series of “kissing points” where neighbouring 
plasma membranes appear to fuse (Figure 1.2A) (Farquhar and Palade, 1963). As 
epithelial cell membranes are relatively impermeable, solutes more readily traverse the 
epithelium by moving between, rather than through cells (Cereijido et al., 1983). The TJ 
regulates the permeability of this paracellular route by sealing the intercellular space, 
hence its designation as the “zonula occludens”, Latin for “closing belt”, with “tight 
junction” used as descriptive term for its structural features (Claude and Goodenough, 
1973; Farquhar and Palade, 1963). 
 
1.2 Functions of the tight junction 
1.2.1 Paracellular permeability 
Further characterisation of the TJ by freeze-fracture electron microscopy (FFEM) 
revealed that the TJ forms a complex meshwork of branching and anastomosing 
strands (Figure 1.2A) (Claude and Goodenough, 1973). The number of strands varies 
in TJs from different tissues and roughly correlates with the “tightness” of epithelial 
permeability (Claude and Goodenough, 1973). Highly permeable, or “leaky” epithelia, 
such as those in the proximal renal tubule, have a single TJ strand, whereas “tight” 
epithelia, like those found in the essentially leak-proof urinary bladder, consist of 5 or 
more TJ strands arranged in series (Claude and Goodenough, 1973). Conductance is 
not distributed evenly along each strand, suggesting that otherwise impermeable belts 
are studded with conducting channels (Figure 1.2A) (Cereijido et al., 1983). 
 
The overall electrical resistance of the TJ is dependent on the probability of these 
channels being found in an open, rather than closed state, as well as the number of 
strands constituting the TJ, and is described by the equation,       
  , where RT is 
transepithelial resistance, PO is the probability of a channel being open and n is the 
number of TJ strands (Figure 1.2B). As each TJ strand has numerous channels, there 
is a high probability that at least one channel is “open” at any given time, allowing 
current to flow. In this scenario, resistance increases in a linear fashion with increasing 
strand number (Figure 1.2C). However, experimental observations show that by 
doubling the strand number, resistance is actually increased four-fold (Cereijido et al., 
1989). The frequent anastomoses between strands observed by FFEM act to segment 
these flickering ion channels and maintain the exponential relationship between strand 









Figure 1.2: The complex branched structure of the tight junction determines paracellular 
permeability. (A) In cross-section, the TJ appears as a series of kissing points where 
neighbouring membranes are tightly apposed. En face, the TJ consists of multiple branching 
and anastomosing strands. These impermeable strands (red) seal the intercellular space and 
limit paracellular diffusion to dynamically opening and closing channels (blue). Paracellular 
permeability is determined by strand number and the probability of channels being in an open 
state. (B) To traverse the TJ, an ion must pass through multiple channels. In the case of single 
channels arranged in series, resistance increases linearly with strand number. (C) This 
relationship is maintained for multichannel strands arranged in parallel, as only a single channel 
needs to be open in each strand for ionic transport to proceed. (D) Segregation of ion channels 
by strand branching is required to model the exponential increase in epithelial electrical 
resistance observed with increasing strand number. Images adapted from Tsukita (2001). 
 
 
Paracellular permeability, or “gate” function, is comprised of two complimentary pore 
and leak pathways (Figure 1.3A and B). The pore pathway is a high-capacity, charge 
and size-selective route and its specific properties are determined by the specific 
subset constituent claudin proteins that are expressed (Table 1.1) (Shen et al., 2011). 
Ionic permeability is mediated by the dynamic opening and closing of claudin-based 
pores within the TJ (Figure 1.3A) (Weber, 2012). In contrast, zonula occludens (ZO) 
and occludin proteins are the molecular determinants of leak pathway permeability, a 
low-capacity paracellular route that does not discriminate between solutes based on 
charge and allows the limited flux of larger molecules across the epithelium (Figure 
1.3B and Table 1.1) (Shen et al., 2011). This paracellular leak is thought to be 
mediated by infrequent openings that are large enough to allow macromolecules to 
pass, but are rare enough in frequency to maintain the overall ion selectivity of the 
tissue (Weber, 2012). These “leak events” may be due to transient breaking and 
resealing of individual TJ strands, allowing the gradual movement of molecules through 
the multistrand structure (Figure 1.3B) (Sasaki et al., 2003). The relatively high 





frequency of pore opening compared to leak events may explain the relative 






Figure 1.3: The TJ regulates paracellular permeability and membrane protein distribution. 
Paracellular permeability is comprised of distinct pore and leak pathways. (A) The pore pathway 
determines ionic conductance through charge- and size-selective claudin-based pores. (B) The 
leak pathway permits the passage of larger uncharged solutes and is thought to proceed via 
transient and infrequent breaking and resealing of the TJ, allowing solutes to gradually progress 
across the junction, while maintaining the overall ionic specificity of the tissue barrier. (C) The 
tight apposition of neighbouring membranes is also thought to prevent the free diffusion of 
membrane proteins and lipids between apical and basolateral plasma membrane domains, 






Paracellular pathway Pore Leak 
Charge-selective? Yes No 
Size-selective? Yes (radii less than ~4Å) 
Yes - permeability is inversely 
correlated with increasing 
molecular weight 
Capacity High Low 
Molecular determinants Claudins Occludin, ZO-1 
Techniques for measurement 
Transepithelial resistance 
Permeability to fluorescently 
tagged, radiolabelled or 
biotinylated carbohydrates or 





Table 1.1: Properties of paracellular pore and leak pathways. The claudin-based pore 
pathway allows rapid, bulk transport of ions in a charge- and size-selective manner. The leak 
pathway, regulated by occludin and ZO-1, permits the relatively slow passage of large solutes, 
independently of their charge. Information obtained from Shen (2011). 





1.2.3 Apicobasal polarity 
Epithelial cells are polarised into apical and basolateral membranes with distinct lipid 
and protein compositions (St Johnston and Ahringer, 2010). Several cues combine to 
initiate the formation of this polarised structure, with important signals generated by 
initial cell-cell and cell-matrix interactions (St Johnston and Ahringer, 2010). 
Mechanistically, epithelial polarisation is regulated by three main polarity complexes; 
the Crumbs complex (Crb1-3, PALS1, PATJ) is crucial for forming the apical domain 
and TJs, the Par3/Par6/aPKC complex establishes the boundary between apical and 
basolateral domains and the Scribble complex (Scribble, Lgl, Dlg) localises to the 
lateral membrane and excludes apical proteins from the basolateral domain (St 
Johnston and Ahringer, 2010). Mutual antagonism of these apical and basolateral 
determinants maintains the polarised distribution of target proteins within the cell (Shin 
et al., 2006; St Johnston and Ahringer, 2010). The evolutionarily conserved Crumbs 
and Par complexes localise to the apical junction and are important both for TJ 
formation and epithelial polarisation (Shin et al., 2006). The mechanism through which 
the Par3/Par6/aPKC complex mediates TJ assembly is poorly understood (Matter and 
Balda, 2003); aPKC appears to be dispensable for initial cell adhesion, but is required 
for the maturation of primitive junctions into distinct TJ and AJ regions (Suzuki et al., 
2002). Therefore, there is extensive and complex crosstalk between the TJ and key 
polarity regulators; Crumbs and Par complexes mediate TJ maturation and the TJ is 
important for the proper localisation of these complexes. 
 
The tight apposition of neighbouring membranes is also thought to generate a 
molecular “fence”, which prevents the free diffusion of membrane proteins and lipids 
between apical and basolateral plasma membrane domains, therefore contributing to 
the characteristic polarised structure of the epithelium (Figure 1.3C) (Tsukita et al., 
2001). 
 
Additionally, epithelial cells use endocytic sorting and trafficking machinery to generate 
and maintain the unique compositions of the apical and basolateral plasma membrane 
domains (Köhler and Zahraoui, 2005). The TJ plays a key role in membrane transport 
as it appears to be a preferred site for the initial delivery of plasma membrane proteins, 
before they diffuse into the correct domain (Zahraoui et al., 2000). Small GTPases, 
including Rab3b, Rab8 and Rab13 are localised to the TJ (Zahraoui et al., 2000). Rab8 
is implicated in trafficking vesicles from the trans-Golgi network to the basolateral 
membrane (Zahraoui et al., 2000). Furthermore, the exocyst, a multiprotein complex 
that mediates the docking of transport vesicles to their target membrane, closely 
associates with the TJ (Zahraoui et al., 2000). Therefore, the TJ appears to acts as a 





“switching station”, which coordinates cell signalling, membrane trafficking and the 
orientation of polarised membrane protein distribution (Köhler and Zahraoui, 2005; 
Zahraoui et al., 2000). 
 
1.2.4 Tissue morphogenesis 
The presence of claudins that promote paracellular permeability is essential for normal 
lumen formation, both in vitro and in vivo (Lu et al., 2014). For example, in zebrafish, 
knockdown of claudin-15 disrupts the normal development of the gut, leading to the 
formation of multiple lumens (Bagnat et al., 2007). Similarly, MDCK cells depleted of 
claudin-2 also form multiluminal cysts (Gálvez-Santisteban et al., 2012). This may be 
driven by luminal fluid accumulation, and highlights the importance of the TJ in 
regulating the overall architecture of the epithelium (Bagnat et al., 2007). 
 
1.2.5 Intracellular signalling 
Different types of signalling proteins and transduction pathways are associated with the 
TJ. This signalling is bidirectional; TJs receive signals from the cell interior to modulate 
epithelial permeability and transmit signals to modulate gene expression and behaviour 
(Matter and Balda, 2003). Various signalling pathways, including those mediated by 
protein kinase A, protein kinase C, heterotrimeric G proteins, Rho family GTPases and 
mitogen-activated protein (MAP) kinases can influence TJ formation, disassembly or 
properties (Matter and Balda, 2003; Zihni and Terry, 2015). Studies involving the fusion 
of biotin ligase to junctional components, including ZO-1, occludin and claudin-4 have 
identified a huge number of cytoskeletal, signalling and endocytic trafficking proteins 
that are associated with the TJ (Fredriksson et al., 2015; Van Itallie et al., 2013; Van 
Itallie et al., 2014). There are also a growing number of dual residence proteins that 
appear to function in the nucleus as well as localising to the TJ (Keon et al., 1996; 
Matter and Balda, 2003). For example, the Y-box transcription factor, ZO-1-associated 
nucleic acid-binding protein (ZONAB), is sequestered at the TJ and plays a role in 
regulating cell proliferation in a cell density-dependent manner (Balda et al., 2003), 
while symplekin is associated with the machinery involved in 3’-end processing of pre-
mRNA and polyadenylation (Keon et al., 1996; McCrea et al., 2009). Furthermore, 
claudin-2 knockdown increases the rate of recovery in an MDCKII scratch wound 
migration assay, in a manner dependent on the transcriptional upregulation of 
proteases involved in extracellular matrix remodelling (Ikari et al., 2011a). Therefore, in 
addition to its interactions with mediators of polarity and trafficking, these studies 
implicate the TJ in regulating gene expression, mRNA processing, cell proliferation and 
migration. 





1.3 The nature of tight junction strands: lipid, protein and hybrid models 
FFEM observations revealed a series of raised TJ ridges and complementary grooves 
on the corresponding fascia, suggesting that intramembranous strands can bind 
laterally with paired strands in the adjacent cell, forming discrete areas of membrane 
fusion. Lipid-based models involve the formation of lipid “tunnels” that essentially form 
a continuous membrane between neighbouring cells (Figure 1.4A) (Lee et al., 2008). 
Alternative protein-based models involve the polymerisation of individual proteins into 
TJ strands, which interact in trans to form a paired TJ strand between neighbouring 
cells (Figure 1.4B) (Furuse et al., 1999; Lee et al., 2008). Following the initial discovery 
of the peripheral TJ-associated protein, ZO-1, and subsequent identification of integral 
transmembrane proteins including occludin and the extensive family of claudins, 
support for the lipid-based model has waned and attention has focussed on a protein-
centric model (Lee et al., 2008).  However, a protein-only model is disputed as the 
close apposition of hydrophobic membranes requires the displacement of water, which 
is a thermodynamically unfavourable process. The energy required would have to be 
accounted for by strong membrane-bridging contacts, which cannot currently be 
accounted for by relatively weak claudin- or occludin-mediated interactions (Lee et al., 
2008). Furthermore, lipid probes can readily diffuse, depending on their size, between 
neighbouring cells via an intact TJ, suggesting some degree of lipid membrane 
continuity (Lee et al., 2008). Although a critical role for proteins, including claudins and 
occludin, is not disputed, lipid-protein hybrid models may more accurately reflect the 
composition of the TJ (Lee et al., 2008). Although TJ membranes are widely 
recognised as cholesterol-enriched, raft-like microdomains (Nusrat et al., 2000), the 
exact conformation of proteins and lipids in the junctional complex is not well-defined. 
 
The width of a TJ strand is approximately 10nm and similar to the diameter of a 
connexin hexamer, the basic unit of the gap junction (Furuse et al., 1998a; Markov et 
al., 2015; Tsukita et al., 2001). Like most conventional ion channels, connexins 
oligomerise to form a channel with a central pore, through which ions can pass (Meşe 
et al., 2007). The diameter of the pore, together with the electrostatic properties of 
residues that line it, determines the ion selectivity (Yu et al., 2009). Connexins and 
claudins are both tetraspan integral membrane proteins, and in vitro claudins have 
been shown to form various oligomers, including dimers, hexamers and higher order 
linear polymers (Krause et al., 2008). It is conceivable that the basic unit of the TJ 
strand may be a hexamer or other oligomer of claudins, which form ion channels 
comparable to those of connexin-based gap junctions (Krause et al., 2008). Current 
models suggest that transcellular ion transport, for example via gap junctions, is likely 
to be very different to paracellular ion transport across the TJ (Yu et al., 2009). 





Conventional transcellular channels mediate the movement of ions in the plane 
perpendicular to that of the lipid membrane, with the pore consisting of the 
transmembrane domains of the pore protein. In contrast, for paracellular transport, ions 
move in a plane parallel and extracellular to that of the lipid membrane, where the pore 
would presumably consist of residues belonging to the extracellular loops of claudins 
interacting in trans (Yu et al., 2009). It is tempting to speculate that a lipid-protein 
hybrid model may facilitate the organisation of claudins into a more conventional ion 
channel, where ions would pass through a central pore (Figure 1.4C) (Lee et al., 2008). 
It is unclear how such a model would be consistent with the organisation of claudins 
into continuous belt-like strands, though it is possible that higher order complex strands 
contain lower order oligomers that form discrete pores (Günzel and Yu, 2013), with the 
specific composition of these claudin “clusters” determining epithelial barrier properties 
(Markov et al., 2015). The opening and closing of ion channels could then be achieved 
through the dynamic assembly and disassembly of these pore-like structures from the 




Figure 1.4: Lipid-, protein- or lipid-protein hybrid models of TJ strand formation. (A) Lipid-
based models were proposed following the early observation that the outer leaflets of tightly 
apposed membranes appear to physically fuse and form a continuous membrane. (B) Protein-
based models explain the detergent-insoluble nature of the TJ and found favour following the 
identification of TJ-associated ZO, occludin and claudin family proteins. Recent observations, 
including the TJ-facilitated diffusion of lipids between neighbouring plasma membranes, may be 
explained by lipid-protein hybrid models (C). (D) In the current protein-based TJ model, 
paracellular movement of ions proceeds in the plane parallel and extracellular to the lipid 
membrane. The ion pore consists of residues of the transmembrane domains of the pore 
proteins. (E) A lipid-protein hybrid model could generate a pore more akin to conventional ion 
channels, which facilitate ion movement perpendicular to the plane of the lipid membrane. 
Images adapted from Lee (2008) and Yu (2009). 





1.4 Tight junction proteins 
Protein-based models of TJ strand formation were initially proposed on the basis that 
TER development is prevented by inhibition of protein synthesis and that TJ structure is 
maintained when cells are treated with detergents that would disrupt normal lipid 
environments (Cereijido et al., 1983; Furuse et al., 1993). However, this does not 
necessarily exclude a lipid-based structure as TJ-associated lipid rafts may be 
detergent-resistant (Nusrat et al., 2000). A critical role for proteins has been 
established since the discovery of the first TJ-associated protein, zonula occludens 
(ZO)-1 (Stevenson et al., 1986) and the subsequent identification of integral 
transmembrane proteins belonging to three families: i) claudins, ii) tight junction-
associated MARVEL proteins (TAMPs) and iii) junction adhesion molecules (JAMs) 






Figure 1.5: Core proteins of epithelial tight junctions. The TJ is composed of 
transmembrane proteins belonging to three families: i) claudins, ii) tight junction-associated 
MARVEL proteins (TAMPs) and iii) junction adhesion molecules (JAMs). These transmembrane 
proteins bind to ZO family scaffold proteins, which regulate their stability at the TJ, partially 
through mediating interaction with the perijunctional actin cytoskeleton. ZO proteins act as 
scaffolds, which mediate the attachment of various adaptor and signalling plaque proteins. 
Image adapted from Shen (2011). 
 
 
These proteins form oligomeric TJ strands within the plasma membrane, which then 
dimerise between adjacent cells to form paired TJ strands (Furuse et al., 1999). The 
transmembrane proteins interact with cytoplasmic scaffold proteins such as ZO-1, -2 
and -3, which regulate their polymerisation into strands, couple the TJ to the actin 
cytoskeleton and act as platforms that mediate the formation of “cytoplasmic plaques”. 
These plaques are large multiprotein complexes composed of an extensive number of 
diverse TJ-associated proteins including signalling proteins, transcriptional and post-





transcriptional regulators and complex-forming proteins (Balda and Matter, 2009; 
Traweger et al., 2013). The overall properties of the TJ are determined by the specific 
repertoire of proteins that are expressed and incorporated into this structure.  
 
 
Experiments described in this thesis will utilise Madin-Darby canine kidney (MDCK) 
type II cells, an immortalised renal cell line that is widely used as a model for studying 
epithelial TJs in vitro (Dukes et al., 2011a). The cell line used in this thesis is a verified 
MDCKII strain sourced from the European Collection of Cell Cultures (ECACC). 
However, several low-resistance MDCK “type II like” strains have been independently 
isolated on separate occasions (Dukes et al., 2011a); when previously published work 
is cited in this thesis, the nomenclature used is consistent with the source literature. 
The MDCKII cell line used in this study endogenously express ZO proteins, occludin 
and claudin-1, -2, -3, -4 and -7. The specific roles of these TJ proteins are discussed 
below. 
  
1.4.1 Zonula occludens (ZO) proteins 
Zonula occludens (ZO)-1 was the first TJ protein to be identified from a junction-
enriched membrane fraction (Stevenson et al., 1986). ZO-1 appears to be a ubiquitous 
component of all mammalian tight junctions, although it is at least partially redundant in 
function with other subsequently identified isoforms, ZO-2 and -3 (Jesaitis and 
Goodenough, 1994; Umeda et al., 2006). ZO proteins belong to the family of 
membrane-associated guanylate kinases (MAGUKs), which have a core structure 
consisting of PDZ, SH3 and GUK domains and mediate the interaction between 
transmembrane TJ proteins and the actin cytoskeleton (Shin et al., 2006). Additionally, 
the modular composition of ZO proteins allows them to act as scaffolds, which mediate 
the accumulation of a diverse array of plaque proteins (Balda and Matter, 2008; 
Traweger et al., 2013). ZO-1 is a peripheral membrane-associated protein that does 
not span the lipid bilayer, but specifically localises to the cytoplasmic face of TJ 
strands. Therefore, ZO proteins alone cannot account for the close association of 
neighbouring proteins at the TJ, but appear to be essential in organising a series of 
integral transmembrane proteins.  
 
Specifically, TJ formation is completely abrogated in cells lacking all three ZO protein 
isoforms, as claudins fail to oligomerise into functional strands (Umeda et al., 2006). 
This phenotype is rescued by the re-expression of ZO-1 or -2, but not -3, indicating that 
the individual isoforms have overlapping but distinct functions (Umeda et al., 2006). 
This is reinforced by observations of ZO protein knockout mice (Tsukita et al., 2001). 
ZO-1 knockout is embryonic lethal, due to defective yolk sac angiogenesis and 





apoptosis of embryonic cells (Katsuno et al., 2008). Embryos deficient for ZO-2 die 
shortly after implantation due to an arrest early in gastrulation (Xu et al., 2008), while 
ZO-3-/- mice lack an obvious phenotype (Xu et al., 2008). Therefore, while ZO-3 
appears to be dispensable for viability and TJ formation, ZO-1 and -2 have overlapping 
and essential roles in the generation of a functional paracellular barrier. 
 
Mouse mammary Eph4 cells lacking ZO proteins fail to form TJs, and monolayers 
exhibit negligible TER and high permeability to biotin (Umeda et al., 2006), indicating a 
crucial role for ZO-mediated TJ formation in determining pore and leak pathway 
permeability. However, these cells maintain functional segregation of apical and 
basolateral membrane proteins, suggesting that TJ strands are not necessarily 
required to provide a molecular fence to maintain the asymmetric distribution of 
membrane proteins (Umeda et al., 2006). Other mechanisms, involving external cues 
from the microenvironment, and the signalling of key polarity regulators such as the 
Par3/Par6/aPKC complex are thought to maintain overall apicobasal polarity in the 
absence of TJ strands, which may have a fine-tuning, rather than essential role (Shin et 
al., 2006; Tsukita et al., 2009).  
 
In MDCK cells, TALEN-mediated knockout of ZO-1, but not ZO-2/-3, induces dramatic 
changes in myosin organisation and disrupts the localisation, but not the expression, of 
TJ proteins; junctional levels of claudin-2 decrease, while those of claudin-1 and -7 
increase (Tokuda et al., 2014). ZO-1-/- clones tend towards increased TER values, 
decreased Na+ permeability, and increased permeability to Cl- and 4kDa dextran 
(Tokuda et al., 2014). The specific roles of each isoform will need to be fully addressed 
using knockout studies, as re-expression of trace amounts of ZO-1 was sufficient to 
rescue these diverse phenotypic changes (Tokuda et al., 2014). 
 
There are also emerging roles for ZO proteins in the regulation of transcription and cell 
proliferation (Bauer et al., 2010; McCrea et al., 2009; Traweger et al., 2013). ZO-1 is 
observed in the nuclei of sparse proliferating cells, while it is sequestered at the TJ 
once cultures become confluent (Gottardi et al., 1996). This suggests that ZO-1 may 
regulate cell growth and TJ formation in coordination with cell density and contact, 
possibly through the regulation of the Y-box transcription factor ZONAB, which 
promotes cell proliferation in a manner dependent on its nuclear localisation (Balda et 
al., 2003). Furthermore, ZO-1/ZONAB may influence the nuclear accumulation of Cdk4, 
a key regulator of the G1/S transition (Balda et al., 2003). 
 






Using monoclonal antibodies raised against the junctional fraction of the chick liver, 
occludin was the first identified transmembrane protein that localised exclusively to the 
tight junction of epithelial and endothelial cells (Furuse et al., 1993). Occludin is a 
65kDa tetraspan membrane protein, with cytoplasmic N- and C-termini and two 
extracellular loops. As occludin was predicted to seal the paracellular space, its name 
was derived from the Latin word “occlude” meaning “to shut or close” (Furuse et al., 
1993). The consequences of occludin knockout are complex; mice are born without any 
gross phenotype but exhibit postnatal growth retardation (Saitou et al., 2000). 
Surprisingly, TJ morphology is largely unaffected and intestinal barrier function appears 
to be uncompromised, but occludin-/- mice exhibit several abnormalities including 
chronic inflammation of the gastric epithelium, brain calcification and testicular atrophy 
(Saitou et al., 2000). These phenotypes may be manifestations of altered barrier 
functions in gastric and testicular epithelia and brain endothelia (Yu et al., 2005).  
 
Although occludin can form adhesions when expressed in fibroblasts that normally lack 
TJs (Van Itallie and Anderson, 1997), its expression alone is not sufficient to drive TJ 
strand formation (Furuse et al., 1998a). Furthermore, occludin is not strictly required for 
TJ formation or maintenance, as intact TJs were formed in the absence of occludin 
(Saitou et al., 1998). Taken together, these studies suggest that although occludin may 
be dispensable for TJ formation, it appears to have additional uncharacterised yet 
indispensable physiological functions. 
 
RNAi-mediated occludin knockdown also has diverse effects in MDCK cells (Yu et al., 
2005). Although TER is unaffected, permeability to mono- and divalent inorganic 
cations, and to larger molecular weight tracers, is increased, without affecting ion 
selectivity (Yu et al., 2005). Occludin-null cells also exhibit a reduced ability to extrude 
apoptosing cells from the monolayer. Occludin overexpression increases the TER of 
MDCK cells, which occurs with a concurrent increase in TJ strand number from 3 to 4, 
and an increase in mean TJ width (McCarthy et al., 1996). This suggests that occludin 
may regulate TJ strand organisation and resulting barrier properties (Balda et al., 
1996). Increased mannitol flux was also observed in cells overexpressing occludin, 
suggesting that occludin may serve to promote electrical barrier function while 
increasing permeability to larger, uncharged molecules through differential regulation of 
pore and leak pathway permeability (Shen et al., 2011).  
 
These observations were corroborated by studies involving the stable expression of 
either full-length or C-terminally truncated occludin in MDCKII cells (Balda et al., 1996). 





Expression of either increases TER and the paracellular flux of small molecular weight 
tracers (Balda et al., 1996). Cation selectivity is not affected, suggesting that occludin 
expression correlates with increased paracellular permeability to uncharged solutes, 
while an electrical seal is maintained. This study also identified an apparent fence 
function for occludin, as expression of C-terminally truncated occludin rendered 
MDCKII cells incapable of maintaining a fluorescent lipid in a specifically labelled 
domain. C-terminally truncated occludin localises to the TJ, but does not form a 
continuous band like full-length protein. However, the TJ strands themselves are 
complete, suggesting that the “gaps” in occludin staining are filled by other TJ 
components. The first members of the claudin family, claudin-1 and -2 were 
subsequently identified in 1998 (Furuse et al., 1998b). 
 
1.4.3 Claudins 
Two distinct peptides of ~22kDa were detected by silver-staining of the previously 
described junctional fraction of chicken liver (Furuse et al., 1998b). These proteins 
were named claudin-1 and claudin-2 from the Latin word “claudere” meaning “to close”. 
Claudin-1 and -2 are both tetraspan transmembrane proteins, although they bear no 
sequence similarity with occludin (Furuse et al., 1998b). Expression of claudin-1 or -2 is 
sufficient to drive the formation of TJ-like strands in fibroblasts that lack endogenous 
TJs, suggesting that claudins are the major protein component of TJ strands (Furuse et 
al., 1998b; Sasaki et al., 2003). Since the initial discovery of claudin-1 and -2, further 
family members have been identified. There are currently 24 identified mammalian 
claudin family members, which are all expressed in humans, with the exception of 
claudin-13 (Kwon, 2013). These claudins are expressed to different extents and ratios 
to tailor the function and properties of the TJ in a tissue-dependent manner. MDCKII 
cells express claudin-1, -2, -3, -4 and -7 and various studies have begun to elucidate 
the specific properties that they each confer to the TJ. For example, claudin-2, -10b 
and -16 form cation-selective channels (Hou et al., 2013; Li et al., 2013), whereas 
claudin-7, -10a and -17 form anion-selective channels (Hou et al., 2013). The recent 
solving of the crystal structure of the claudin-15 protomer has provided key insights into 
how ion selectivity may be regulated in different claudin species (Suzuki et al., 2014). 
 
The first claudin crystal structure 
Sequence analysis suggests that claudin family proteins have four transmembrane 
(TM) segments, a large extracellular loop (ECL1) joining TM1 and TM2 via a short 
extracellular helix (ECH), and a second shorter extracellular loop (ECL2) between TM3 
and TM4 (Figure 1.6) (Suzuki et al., 2014). The four transmembrane segments form a 
left-handed four-helix bundle while the extracellular loops form a β-sheet structure 





(Figure 1.6) (Suzuki et al., 2014). The length of the TM segments is consistent with the 
width of the lipid bilayer, and tight helical packing is possible due to the presence of 
residues with small side chains (Suzuki et al., 2014). The β-sheet is comprised of five 
β-strands, with four contributed from ECL1 and one from ECL2, and is stabilised by a 
disulphide bond formed between β3 and β4. The two cysteine residues involved are 
conserved amongst all claudins and may be necessary for proper claudin function 
(Suzuki et al., 2014). The sequences of ECL1 and ECL2 are relatively diverse and may 
be crucial for the ion selectivity of pores formed by different claudins. The β-sheet 
forms a “palm”, which is negatively charged in cation-selective claudins (claudin-2 and -
15) and positively charged in the anion-selective claudin-10a (Suzuki et al., 2014). 
Specific charged residues in ECL1 are thought regulate ion specificity of different 
claudins (Hou et al., 2013). For example, cation-selective, pore-forming claudins have 
an acidic residue at position 65  or 66, which is proposed to form part of an electrostatic 
cation-binding interface (Yu et al., 2009). Variable regions, V1 and V2 in ECL1 and 
ECL2 respectively, may be involved in subtype-specific compatibility of different 
claudins (Suzuki et al., 2014). The ECH between β5 and TM2 has a conserved 
hydrophobic residue that snugly fits into a hydrophobic pocket between TM3 and ECL2 
of adjacent claudin-15 protomers to form a linear polymer in the crystal lattice (Suzuki 
et al., 2014). These sites also have complementary electrostatic potentials and their 
relative positions on opposite sides of the protomer may permit claudin polymerisation 
into oligomeric pores and/or strands. FFEM revealed that mutation of the 
corresponding hydrophobic methionine residue prevented the formation of TJ strands 
in the plasma membrane, suggesting a molecular basis for the polymerisation of 
claudins into linear TJ strands (Suzuki et al., 2014). 
 
Additional structural features that are likely to be common to claudin family proteins 
have been identified independently of the crystal structure. For crystallisation studies, 
the C-terminal was truncated, but a conserved YV motif on the C-terminal tail of 
claudins is involved in their association with the PDZ domain of ZO-1, which may be 
essential for the polymerisation of claudins into functional TJ strands (Umeda et al., 
2006). Additionally, membrane proximal cysteine residues were mutated to avoid 
heterogeneous palmitoylation. Palmitoylation of these two additional cysteine residues 
at the cytoplasmic terminus of TM2 and TM3 increases the efficiency with which 
claudins are incorporated into the TJ (Van Itallie et al., 2005). The conserved 
disulphide bond immediately precedes residues involved in ion selectivity, suggesting it 
may function to orientate the relevant side group to protrude into the pore lumen (Yu et 
al., 2009). 
 





Figure 1.6: The overall secondary structure of the claudin-15 protomer. Claudin-15 has 4 
transmembrane helical segments (TM1 – 4) and an antiparallel β-sheet (β1 – 5), which forms 
two extracellular loops (ECL1 and 2) that protrude from the plasma membrane. β3 and β4 
strands are joined by a conserved disulphide bond, which may orientate residues required for 
ion selectivity. Dotted grey lines indicate suggested boundaries of the plasma membrane. 
Based on sequence conservation, the claudin-15 structure has provided key insights into the 
structural basis of membrane packing, TJ strand formation, claudin compatibility and ion 
selectivity that are likely to be common between claudin family proteins. (ECH) extracellular 
helix, (blue) α-helices, (red) β-strands. Image adapted from Suzuki et al (2014). 
 
The first claudin crystal structure has provided crucial insights into the structural basis 
for membrane insertion and packing, oligomeric strand formation via cis-interactions, 
subtype compatibility via trans-interactions and ion selectivity. The specific roles of 
different claudins have been further investigated using mouse knockout models, in 




CLDN1 knockout mice are viable, but die within one day of birth due to transepidermal 
water loss through the skin (Furuse et al., 2002). This was initially surprising as the TJ 
was thought to regulate the barrier function of simple epithelia, but not necessarily 
stratified epithelia like the epidermis. As with most TJ proteins, conditional or tissue-
specific knockout of claudin-1 has not been attempted. Claudin-1 expression increases 
TER in MDCKII cells by approximately 4-fold and decreases paracellular flux to dextran 
tracers of 4 – 40kDa, indicating that claudin-1 has a general barrier-promoting role 
when overexpressed (Inai et al., 1999). However, RNAi-mediated knockdown of 
claudin-1 has no discernible effect on MDCK TER or paracellular permeability (Hou et 
al., 2006). Considering the ability of claudin-1 to form recognisable TJ strands in 
fibroblasts and the functional consequences of overexpression, it appears that claudin-
1 is likely to have a genuine role in increasing epithelial barrier function, although this 
may be redundant with other expressed claudins or TJ proteins. 






In contrast to claudin-1, claudin-2 expression is associated with a decrease in TER and 
an increase in selective permeability to Na+ and water (Hou et al., 2006). Type I and II 
MDCK cells have contrasting barrier properties; MDCKI cells lack claudin-2 expression 
and have a high TER of ~4000Ω.cm2, while claudin-2-positive MDCKII cells have a low 
TER of <300 Ω.cm2 (Dukes et al., 2011a). The expression of claudin-2 in MDCKI cells 
mediates the conversion from a highly resistant to highly permeable phenotype (Furuse 
et al., 2001). RNAi-mediated knockdown of claudin-2 in MDCKII cells causes a three-
fold increase in TER and decrease in cation permeation (Hou et al., 2006). The 
TALEN-mediated knockout of claudin-2 has more severe effects, increasing TER by 
approximately fifty-fold to levels of 3000 – 4000Ω.cm2, comparable to the high-
resistance MDCKI strain (Tokuda and Furuse, 2015). Claudin-2 overexpression 
increases TER by increasing the number of cation pores, without increasing 
permeability to non-charged solutes larger than the pore (~ 6 – 7Å in radius) (Van Itallie 
et al., 2008). Claudin-2 knockout mice are viable and exhibit normal appearance, 
growth and behaviour (Muto et al., 2010). In the kidney, claudin-2 expression is 
confined to the areas of high epithelial permeability, such as the proximal tubule and 
descending limb of Henle (Hou et al., 2013). Although renal proximal tubules of 
CLDN2-/- mice appear normal, there is a significant decrease in the net reabsorption of 




Claudin-3 is expressed in a number of epithelia including skin, lung, kidney and 
intestine as well as in endothelia (Milatz et al., 2010). Claudin-3 is generally considered 
to be a barrier-forming protein as it seals the paracellular pathway to the passage of 
small cations, anions and uncharged solutes (Milatz et al., 2010) and is expressed in 
the “tighter” distal tubule in the kidney (Rahner et al., 2001). MDCKII cells only weakly 
express claudin-3 and its overexpression increases the TER of two MDCKII clones, 
expressing either high or low levels of claudin-2, indicating an intrinsic role for claudin-3 
in forming an electrical barrier (Milatz et al., 2010). The increase in TER was 
accompanied by decreased permeability to both positively and negatively charged ions 
as well as larger uncharged solutes (Milatz et al., 2010). Claudin-3 overexpression did 
not alter ion selectivity, indicating that ionic permeability was still governed by claudin-2 
based channels, although their number was reduced (Milatz et al., 2010). 
 






Claudin-3 and -4 resemble each other in many ways (Milatz et al., 2010). Both seal the 
TJ to the passage of ions and macromolecules and overexpression of either causes 
the formation of increasingly curved looping TJ strands (Milatz et al., 2010; Van Itallie 
et al., 2001). They have high sequence homology (67% of amino acids are identical, 
while ECL1 and 2 are 94% and 68% identical, respectively) and both are located on 
chromosome 7, suggesting possible gene duplication (Milatz et al., 2010). Claudin-3 
and -4 are commonly transcriptionally co-regulated (Milatz et al., 2010), although not by 
the RAF/MEK/ERK pathway (Doehn et al., 2009). Claudin-3 and -4 have non-
homologous C-termini, which are thought to be important for intracellular signalling, 
and vary in their ability to interact with other claudins. For example claudin-3, but not 
claudin-4, has been shown to interact in trans with claudin-1, -2 and -5 (Milatz et al., 
2010). In the kidney, claudin-4 is expressed in the high-resistance ascending limb of 
Henle and collecting duct, indicating that its expression correlates with low paracellular 
permeability (Hou et al., 2013). 
 
The functions of claudin-4 have been studied using RNAi in MDCKII and LLC-PK1 cells 
(Hou et al., 2006). Knockdown of claudin-4 decreases MDCKII TER by increasing 
permeability to Na+, but not Cl- ions (Hou et al., 2006). In contrast, claudin-4 
knockdown depresses paracellular permeability to Cl- ions in LLC-PK1 cells. Therefore, 
claudin-4 can act as either a Na+ barrier or Cl- channel depending on the cellular 
background. LLC-PK1 cells do not endogenously express claudin-2, and the observed 
increase in Na+ permeability following claudin-4 knockdown in MDCKII cells may 
potentially be explained by the ability of MDCKII, but not LLC-PK1 cells, to form 
claudin-2 based cation channels when claudin-4 is depleted (Hou et al., 2013). It has 
been proposed that differences in TJ protein composition, or pathways regulating its 
function, may explain why claudin-4 forms Cl- channels in LLC-PK1, but not in MDCKII 
cells (Hou et al., 2006). Consistent with these RNAi studies, overexpression of claudin-
4 in MDCKII cells increases TER by decreasing permeability to Na+, but not Cl- ions or 
mannitol. Therefore, in the MDCKII cell line relevant to this thesis, both knockdown and 
overexpression studies indicate that claudin-4 acts to seal the epithelial barrier by 
reducing Na+ permeability, although this function may be dependent on direct or 
indirect interactions with other TJ components. 
 
Claudin-7 
Claudin-7 is highly expressed in the high-resistance distal convoluted tubules and 
collecting duct of the kidney (Hou et al., 2013). Although, claudin-7 knockout mice are 
viable, they die within 12 days of birth, exhibiting severe salt wasting, chronic 





dehydration and growth retardation (Tatum et al., 2010). This study concluded that 
claudin-7 was essential for NaCl homeostasis in distal nephrons of the kidney. CLDN7-
/- mice also exhibit high levels of inflammation and defective architecture in the intestine 
(Ding et al., 2012). RNAi-mediated knockdown studies revealed that claudin-7 has 
similar functions to that of claudin-4 (Hou et al., 2006). Claudin-7 depletion significantly 
decreases MDCKII TER by increasing paracellular permeability to Na+ but not Cl- ions 
(Hou et al., 2006). Furthermore, knockdown of claudin-7 decreases paracellular Cl- 
permeability in LLC-PK1 cells, indicating that both claudin-4 and -7 can act as either 
Na+ barriers or Cl- channels depending on cell background (Alexandre et al., 2005). 
This effect is likely to be mediated by the difference in TJ composition between the cell 
types, and regulatory pathways, which may vary in different contexts. 
 
1.4.4 Additional TJ proteins 
The TAMP family of integral transmembrane TJ proteins includes tricellulin and 
MARVELD3 in addition to occludin. These proteins have distinct but overlapping 
functions (Raleigh et al., 2010).  In contrast to occludin, ZO and claudin family proteins, 
tricellulin appears to accumulate specifically at tricellular (rather than bicellular) cell-cell 
contacts, forming a peculiar tightly sealed tube that is aligned parallel with (rather than 
perpendicular to) the apicobasal axis (Ikenouchi et al., 2005). Stable suppression of 
tricellulin decreases the TER of Eph4 mouse mammary epithelial cells and increases 
paracellular permeability to small molecular weight dextran tracers (Ikenouchi et al., 
2005). Therefore, tricellulin appears to constitute a novel TJ subdomain, which 
specifically mediates paracellular permeability where multiple plasma membranes 
meet.  However, tricellulin can redistribute to bicellular membranes to compensate for 
the loss of occludin (Ikenouchi et al., 2008). Relatively little is known about the 
biological functions of MARVELD3. Although it appears to partially compensate for the 
loss of occludin or tricellulin, its expression alone is insufficient to restore barrier 
function (Raleigh et al., 2010). RNAi-based studies in Caco-2 intestinal epithelial cells 
indicate that MARVELD3 is not required for TJ formation, but that its depletion results 
in monolayers with increased TER (Steed et al., 2009). 
 
In contrast to the tetraspan TAMP and claudin family proteins, junction adhesion 
molecules (JAMs) are single-pass integral membrane proteins belonging to the 
immunoglobulin superfamily (Van Itallie and Anderson, 2014).  The JAM family 
includes JAM-A, -B, -C, -4, -L and the coxsackie adenovirus receptor (CAR) (Luissint et 
al., 2014). This family of proteins has not been studied as extensively as other TJ 
proteins. JAM-A concentrates to epithelial and endothelial TJs and lateral membranes, 
and is also expressed in immune cells. Therefore, JAM proteins may play a role in 





mediating the transmigration of immune cells across epithelial and endothelial 
monolayers (Martìn-Padura et al., 1998). JAMs do not appear to be essential for TJ 
formation, but do contribute to adhesion and signalling (Van Itallie and Anderson, 
2014).   
 
In summary, the TJ is an important subcellular structural feature that has key roles in 
determining paracellular permeability, apicobasal polarity and epithelial architecture. It 
also has emerging signalling functions, allowing it to regulate cell proliferation and 
migration. For these reasons, the study of TJ regulation is important in understanding 
how normal epithelia are generated during development and maintained in a 
physiological setting. Furthermore, the TJ and epithelial barrier properties are often 
deregulated in disease settings, such as inflammatory bowel disease and cancer. 
Therefore, understanding the mechanisms of TJ disruption has important therapeutic 
relevance. 
 
1.5 Regulation of the tight junction 
1.5.1 Transcriptional regulation of individual TJ proteins 
The overall properties of the TJ are regulated by its specific protein composition, which 
varies between different tissues and can be regulated by a variety of different 
extracellular signals. These compositional changes are often achieved through the 
transcriptional regulation of individual TJ proteins (Kwon, 2013). 
 
Colonic claudin-1 expression is regulated by Cdx1, Cdx2 and GATA4 transcription 
factors (Bhat et al., 2012). The E-box transcription family proteins, Slug and Snail, 
which are associated with epithelial-mesenchymal transition, have been show to bind 
to and inhibit the promoter activity of claudin-1, as well as occludin, claudin-3, -4 and -7 
(Ikenouchi et al., 2003; Martínez-Estrada et al., 2006). Claudin-1 expression is also 
regulated by RUNX3 in gastric epithelial cells (Chang et al., 2010) and the microRNA 
miR-155 in ovarian tissues (Qin et al., 2013). 
 
Molecular cloning of the 5’ flanking region of claudin-2 revealed a series of transcription 
factor binding sites that are conserved between mouse and human, suggesting that 
claudin-2 expression may be regulated by AP-1, NFκB, E-box, GATA, HNF-1 and Cdx 
transcription factors (Sakaguchi et al., 2002). Furthermore, LEF-1, a nuclear effector of 
the Wnt signalling pathway, directly binds to the claudin-2 promoter to enhance 
transcription, and also acts indirectly through the transactivation of Cdx2 (Mankertz et 
al., 2004). However, claudin-2 expression appears to be regulated in a highly tissue-
specific manner. HNF-1 is expressed in various tissues, including the liver, intestine, 





pancreas, stomach and kidneys, and is required for claudin-2 expression in the 
intestine and liver (Sakaguchi et al., 2002). However, renal claudin-2 expression is not 
affected in HNF-1α deficient mice (Sakaguchi et al., 2002). In addition, the expression 
of Cdx1 and Cdx2 is confined to the intestine, where they cooperate with GATA-4 and 
HNF-1α to regulate the regional expression of claudin-2 (Escaffit et al., 2005). In renal 
MDCKII cells, the expression of claudin-2, as well as claudin-3 and ZO-3, is regulated 
by GATA-4 (Guillemot et al., 2013) and the epidermal growth factor (EGF)-mediated 
downregulation of claudin-2 is mediated by STAT3 (García-Hernández et al., 2015). 
 
Although the expression of claudin-3 is decreased following GATA-4 knockdown, the 
claudin-3 promoter lacks the GATA consensus binding sequence. Therefore, this is 
likely to be an indirect consequence of transcriptional downregulation of claudin-2 and 
ZO-3  (Guillemot et al., 2013). The expression of claudin-3 and -4 is dependent on Sp1 
expression and specific epigenetic modifications (Honda et al., 2006). Furthermore, the 
EGF-mediated upregulation of claudin-4 is mediated through Sp1 (Ikari et al., 2009) 
and STAT3 (García-Hernández et al., 2015). In colonic crypts, claudin-7 expression is 
suppressed by TCF-4 and Sox9 (Darido et al., 2008). E74-like factor 3 (ELF3) is an 
ETS family transcription factor, which binds to and increases the activity of the claudin-
7 promoter (Kohno et al., 2006). In addition, hypermethylation of the claudin-7 promoter 
is associated with its reduced expression in breast cancer (Nakayama et al., 2008). 
 
Cloning of the occludin promoter from human genomic DNA revealed putative 
transcription factor binding sites for TCF, NF-IL6 and AP2, and occludin expression 
was downregulated by TNFα and IFNɣ (Mankertz et al., 2000). By computational 
analysis, the ZO-1 promoter contains several potential AP-1 and CREB sites, 
suggesting it may be a target of JunD. Consecutive promoter deletions revealed that 
JunD suppresses ZO-1 by binding CREB sites, but also inhibits translation, possibly by 
mediating interactions between the 3’UTR and RNA-binding proteins (Chen et al., 
2008). ZO-1 promoter activity is also regulated by E-box, MEIS, MOKF and TALE 
transcription factors (Cohen et al., 2006). 
 
Taken together, these studies illustrate that the transcriptional regulation of individual 
claudins is highly complex. Diverse transcription factors, epigenetic modifications and 
microRNA regulation act in concert to generate tissue-specific expression patterns. 
Additionally, the expression of individual claudins is differentially and diversely 
regulated in different cancer types (see Section 1.6.2). 
 





1.5.2 Dynamic regulation of tight junction proteins 
Due to the extensive interaction of different TJ proteins with each other and the actin 
cytoskeleton via ZO protein mediated interactions, the TJ was initially considered to be 
a stable heavily cross-linked complex (Shen et al., 2011). However, the molecular 
structure of the TJ exhibits a surprising degree of plasticity and undergoes constant 
remodelling (Turner et al., 2014). Individual TJ components are dynamic, both in terms 
of their movement within the plasma membrane and in exchange with cytoplasmic or 
vesicular protein pools (Shen et al., 2008). Functionally, constant TJ disassembly and 
reformation may provide a mechanism to regulate the probability of paracellular 
channels being found in an open state, and therefore form the molecular basis of 
experimental observations of paracellular permeability. Furthermore, the constant 
exchange of proteins between vesicular and junctional pools would allow rapid TJ 
remodelling. TJs require rapid assembly and disassembly in tissues that undergo 
continuous dynamic remodelling, for example, in the mammalian intestine where 
epithelial cells are replaced every 4 – 5 days (Chalmers and Whitley, 2012; Vereecke 
et al., 2011). These dynamic properties would also maintain barrier function during cell 
division or the extrusion of apoptosing cells from the monolayer. 
 
Although bulk internalisation of the TJ can be induced by non-physiological means, 
such as the depletion of extracellular calcium (Ivanov et al., 2004), individual TJ 
proteins exhibit distinct dynamic properties and are subject to differential modes of 
regulation (Shen et al., 2008). Protein dynamics within the TJ can be assessed by 
expressing fluorescently-tagged proteins and using time-lapse microscopy for 
fluorescence recovery after photobleaching (FRAP) experiments. The fluorescent 
signal is “bleached” by destroying the fluorophore with the beam of a laser scanning 
microscope. The fluorescent signal within the bleached region then recovers through 
the diffusion of intact fluorescently-tagged proteins from adjacent regions. The 
percentage and speed of fluorescence recovery reflects the overall mobility of the 
tagged-protein.  
 
The nature of recovery can be studied by photobleaching a length of plasma 
membrane and monitoring fluorescence recovery in the centre and edges of this 
region. Exchange with an intracellular pool is exhibited by uniform recovery across the 
length of the bleached region, whereas intramembrane diffusion is indicated by 
recovery at the edges prior to at the centre (Figure 1.7A and B) (Shen et al., 2011). 
Initial FRAP studies revealed that claudin-1, occludin and ZO-1 display distinct dynamic 
properties; claudin-1 is relatively stable at the TJ and exchange is mediated by 
diffusion within the plasma membrane, occludin is more mobile but still recovers via 





intramembrane diffusion, whereas junctional ZO-1 primarily exchanges with an 
intracellular pool (Shen et al., 2011). Furthermore, FRAP studies have been used to 
determine changes in TJ protein dynamics caused by different stimuli. For example, 
treatment of Caco-2 intestinal epithelial cells with PIK, a highly-specific peptide inhibitor 
of MLCK, increases TER by stabilising ZO-1 within the TJ, without affecting the 
dynamic behaviour of claudin-1, occludin or actin (Yu et al., 2010). 
 
Fluorescence loss in photobleaching (FLIP) involves photobleaching the cytoplasmic 
area. If claudin exchange is primarily through intramembrane diffusion, the 
fluorescence intensity of the junctional pool will remain constant, while exchange of 
junctional and cytoplasmic pools through endocytic exchange will lead to the depletion 
of junctional fluorescence (Figure 1.7C and D) (Shen et al., 2008). For example, 
continuous photobleaching of the intracellular region only slightly diminished the TJ-
associated fluorescence of occludin and claudin-1, suggesting minimal endocytic 
exchange (Shen et al., 2008). In contrast, photobleaching of cytoplasmic ZO-1 leads to 
the progressive decrease of junctional ZO-1 fluorescence (Shen et al., 2008). 
Photoactivatable tags allow fluorescence to be “switched on” in specific subcellular 
areas, allowing the movement of photoactivated proteins to be assessed independently 
of newly synthesised protein (Figure 1.7E and F) (Lippincott-Schwartz et al., 2003). 
Following photoactivation of occludin within the TJ, fluorescence within the area of 
activation progressively decreased but increased in adjacent regions of the TJ, 
indicating movement by intramembrane diffusion (Shen et al., 2008). The lack of 
fluorescent intracellular vesicles following junctional photoactivation suggests that, at 
steady-state, occludin does not exchange rapidly with an intracellular pool (Shen et al., 
2008).   
 
These reports indicate that dynamic regulation is a common regulatory feature of 
diverse TJ proteins. Furthermore, the combination of FRAP, FLIP and photoactivation 
studies indicate that individual proteins are characterised by distinct kinetics of 
endocytic exchange and intramembrane diffusion. This suggests that despite 
extensively characterised molecular interactions between ZO-1, occludin and claudin 
family proteins, the TJ is not a static cross-linked structure, but undergoes continuous 
dynamic remodelling. An important caveat of these studies is that the fusion of GFP to 
the C-terminal of different claudins is thought to interfere with the PDZ-domain 
mediated interaction with ZO-1/-2 (Sasaki et al., 2003). This is likely to affect the 
polymerisation of claudins into TJ strands (Umeda et al., 2006). Although these fusion 
proteins accurately target to the TJ, colocalise with their corresponding endogenous 
proteins and do not disrupt normal epithelial function, they may still display dynamic 





properties that are not truly reflective of endogenous claudins. The work in this thesis 
will instead focus on studying the endocytic trafficking of endogenous TJ proteins, 
which can be measured using alternative biochemical trafficking assays (Dukes et al., 
2011b; Dukes et al., 2012; Nishimura and Sasaki, 2008). 
 
  






Figure 1.7: Intramembrane diffusion and endocytic exchange can be distinguished using 
fluorescently tagged junction proteins in combination with photobleaching and photoactivation 
experiments. Predicted outcomes of protein dynamic experiments for intramembrane diffusion and 
endocytic trafficking models of claudin-1 and -4 redistribution. Various fluorescently tagged TJ proteins 
localise normally to areas of cell-cell contact (shown in red). (A and B) Fluorescence recovery after 
photobleaching (FRAP) involves localised fluorophore destruction by photobleaching (blue bolt). 
Fluorescence in the photobleached area is recovered by movement of fluorescently tagged proteins from 
adjacent regions. (A) Intramembrane diffusion would result in gradual recovery of fluorescence, initially at 
the periphery of the photobleached area. (B) Endocytic trafficking would result in uniform recovery of 
fluorescence across the photobleached area. (C and D) Fluorescence loss in photobleaching (FLIP) 
involves photobleaching the cytoplasmic area. (C) If claudin exchange is primarily through intramembrane 
diffusion, the fluorescence intensity of the junctional pool will remain constant. (D) Exchange of junctional 
and cytoplasmic pools through endocytic exchange will lead to the depletion of junctional fluorescence. (E 
and F) Photoactivatable tags allow fluorescence to be “switched on” in specific subcellular areas, allowing 
the movement of photoactivated proteins to be assessed. (E) Intramembrane diffusion would lead to 
increased fluorescence in the adjacent plasma membrane. (F) Endocytic exchange would result in an 
increase in cytoplasmic fluorescence. Image adapted from Shen et al (2011).  





1.5.3 Endocytic trafficking of TJ proteins 
Selective sorting of proteins through biosynthetic, internalisation, recycling and 
degradative pathways is a common feature of epithelial cells (Mostov et al., 2003). In 
MDCKII cells, 50% of the entire cell surface is endocytosed per hour and is largely 
replenished through recycling of internalised protein back to the cell surface (Mostov et 
al., 2003). Furthermore, mislocalised proteins can be endocytosed specifically from 
either the apical or basolateral plasma membrane domains into distinct endosomal 
compartments. From here, they can either be degraded or transported to the correct 
surface in a process called transcytosis (Mostov et al., 2003). Therefore, the polarised 
delivery of transmembrane proteins and their selective removal results in localised cell 
surface expression patterns, indicating a key role for endocytic sorting in maintaining 
steady-state polarity (Köhler and Zahraoui, 2005; Mostov et al., 2003; Zahraoui et al., 
2000).  
 
TJ proteins can undergo internalisation via clathrin-mediated endocytosis (Ikari et al., 
2011c) macropinocytosis (Bruewer et al., 2005) and caveolar endocytosis (Shen and 
Turner, 2005). They are initially trafficked into early endosomes, and from here they 
can either proceed along the degradative pathway, culminating in lysosomal 
degradation, or be recycled back to the plasma membrane (Figure 1.8A) (Chalmers 
and Whitley, 2012). This can proceed either directly via recycling endosomes or after 
additional sorting following retrograde transport to the trans-Golgi network (Figure 
1.8A) (De Matteis and Luini, 2008). 
 
 Surface-biotinylation techniques have been utilised to establish that constitutive 
endocytosis and recycling of endogenous TJ proteins is a common in various epithelial 
cell lines (Chalmers and Whitley, 2012; Dukes et al., 2011b; Dukes et al., 2012; 
Nishimura and Sasaki, 2008). These assays rely on the ability to label proteins 
specifically at the cell surface, using a membrane-impermeable and cleavable biotin 
moiety that forms a covalent bond with accessible lysine residue side chains (Figure 
1.8B). These biotin moieties can be cleaved from proteins remaining at the cell surface 
using membrane-impermeable reducing agents. Endocytosed protein is protected from 
this “surface strip” by an intact plasma membrane. Following cell lysis, biotinylated 
proteins can be retrieved using neutravidin beads, and the relative extent of protein 
internalisation can be assessed by SDS-PAGE and immunoblotting for proteins of 
interest. This assay can be extended to study endocytic recycling as, following the first 
surface strip, endocytosed protein is recycled back to the membrane and again 
becomes prone to stripping (Figure 1.8B). 
  






Figure 1.8: Tight junction proteins undergo constitutive endocytic recycling in epithelial cells. (A) 
Newly synthesised transmembrane TJ proteins are trafficked to the cell surface via the Golgi complex and 
trans-Golgi network (TGN), where they form extensive interactions with other proteins, both within the 
same and adjacent membranes. Despite these complex interactions, individual TJ proteins are highly 
dynamic in nature and are constitutively endocytosed from the plasma membrane into early endosomes. 
From here, they can either be trafficked through late endosomes towards the lysosome for degradation, or 
recycled back to the plasma membrane, either directly via recycling endosomes or after retrograde sorting 
in the Golgi/TGN. This allows rapid TJ remodelling in response during physiological processes that involve 
cell movement, but require epithelial barrier maintenance. (B) TJ protein trafficking can be assessed using 
a surface-biotinylation based biochemical trafficking assay. (I) Cell-surface proteins are labelled with a 
membrane-impermeant biotin moiety. Cooling cells effectively blocks endocytic trafficking as membranes 
become viscous at low temperatures. Surface biotin is effectively stripped with a membrane-impermeant 
reducing agent. (II) Endocytosed protein is protected from the surface strip by an intact plasma membrane. 
Biotinylated proteins are retrieved by neutravidin pulldown, allowing rates of internalisation to be 
established by SDS-PAGE and immunoblot. Recycled biotinylated protein again becomes amenable to 
surface-stripping. Lysing cells before and after the second surface-strip reveals the proportion of 
endocytosed protein that is degraded and recycled over the duration of the second incubation (III and IV).  





These biochemical trafficking assays have identified the constitutive endocytosis and 
recycling of occludin in MTD-1A mouse mammary epithelial cells (Morimoto et al., 
2005), claudin-2 in MDCKII cells (Dukes et al., 2012) and claudin-1 in MDCKII, Caco-2 
and 16-HBE human lung epithelial cells (summarised in Table 1.2) (Dukes et al., 
2011b), Therefore, the constitutive endocytosis and trafficking of TJ proteins is a 
common feature of diverse epithelial cell lines, although the specific trafficking rates of 
different components vary in a cell line-specific manner (Table 1.2). The ability to 
differentially regulate the trafficking of individual TJ components permits cells to alter 
the molecular composition of the TJ to fine-tune paracellular permeability properties 




MDCKII Caco-2 16-HBE MTD-1A 
Claudin-1 Recycled Recycled Recycled 
Not 
endocytosed 














Table 1.2: Continuous recycling of tight junction proteins is a common feature in diverse 
epithelial cell lines. Individual TJ proteins are constitutively endocytosed with distinct kinetics 
in epithelial cell lines derived from different tissues and species. (MDCKII) Madin-Darby canine 
kidney type II, (Caco-2) human colorectal carcinoma, (16-HBE) human bronchial epithelium, 
(MTD-1A) mouse mammary epithelium, (-) trafficking rates have not been determined. Table 
adapted from Chalmers and Whitley (2012). 
 
 
Various proteins have been implicated in regulating the internalisation and post-
endocytic trafficking of TJ proteins. The constitutive recycling of claudin-1 and -2 can 
be blocked by the expression of a dominant-negative CHMP3 ESCRT protein, which 
results in the internal accumulation of these claudins in discrete cytoplasmic 
compartments, potentially by mediating interactions with deubiquitination enzymes 
(Dukes et al., 2011b). YM201636 is an inhibitor of PIKfyve (FYVE finger-containing 
phosphoinositide kinase), which also blocks the constitutive recycling of claudin-1 and -
2. PIKfyve inhibition may alter the phospholipid composition of endosomes, influencing 
their interactions with the ESCRT trafficking machinery (Chalmers and Whitley, 2012; 
Dukes et al., 2012).  





The polarised targeting and recycling of TJ proteins is regulated by the Rab family of 
small GTPases, which act as molecular switches, alternating between GTP- and GDP-
bound states to mediate various aspects of vesicular trafficking (Bhuin and Roy, 2014; 
Kitt et al., 2008; Lu et al., 2015). For example, the endocytosis and recycling of E-
cadherin is regulated by Rab5 and Rab11, respectively (Desclozeaux et al., 2008; 
Kimura et al., 2006; Lock and Stow, 2005). Furthermore, the constitutive endocytic 
recycling of occludin is dependent on Rab13 function and its binding partner 
JRAB/MICAL-L2 (Morimoto et al., 2005; Yamamura et al., 2008). 
 
Rab14 is involved in the trafficking of molecules to the apical plasma membrane (Kitt et 
al., 2008) and colocalises with claudin-1, -2 and -4, but not occludin, mainly in 
intracellular punctae (Lu et al., 2014). Rab14 interacts with endotubin, a constituent 
apical endosome protein, to mediate junction formation and recycling of internalised TJ 
proteins back to the apical junction (McCarter et al., 2010). Rab14 knockdown results 
in increased TER, which coincides with the specific depletion of claudin-2 and altered 
endocytic trafficking of claudin-1 and occludin (Lu et al., 2014). Rab14 is proposed to 
sort claudin-2 out of the degradative pathway by regulating its trafficking out of the 
recycling endosome (Lu et al., 2014). Claudin-1 and occludin are also recycled 
significantly faster in Rab14-KD cells (Lu et al., 2014), suggesting that altered TJ 
protein trafficking may also play a role in mediating epithelial barrier changes (Lu et al., 
2014). 
 
As with Rab14, PKCι protects claudin-2 from lysosomal degradation and its depletion 
causes an increase in TER and decrease in dextran permeability (Lu et al., 2015). 
PKCι binds to Rab14, which mediates its apical distribution in MDCKII cells (Lu et al., 
2015). Therefore, PKCι and Rab14 appear to function in a coordinated manner to 
regulate tight junction composition through the regulation of claudin-2 trafficking (Lu et 
al., 2015). PKCι knockdown significantly deceases claudin-2, and increases claudin-4, 
protein levels, without altering levels of claudin-1, occludin, ZO-1 or E-cadherin (Lu et 
al., 2015). The current model involves the PKCι-mediated phosphorylation of claudin-2 
on S208, which functions to retain claudin-2 in a Rab14-mediated membrane recycling 
pathway. Taken together, these studies indicate that membrane trafficking and cell 
polarity pathways intersect at the endosomal compartment to regulate TJ protein 
trafficking through the interaction of Rab14 and PKCι (Lu et al., 2015).  
 
Interestingly, altered claudin-2 trafficking through depletion of Rab14 or PKCι is also 
associated with decreased claudin-2 transcription (Lu et al., 2014; Lu et al., 2015). A 
similar observation has been made regarding Rab25 knockdown and integrin 





transcription (Krishnan et al., 2013), suggesting that trafficking of adhesive proteins and 
receptors may provide signals that regulate their own transcription (Lu et al., 2015). In 
summary, various trafficking mediators, including ESCRT proteins, protein kinases and 
Rab GTPases, are required for TJ protein trafficking. However, the specific signalling 
pathways and post-translational modifications involved in specific cargo selection and 
the dynamic regulation of these processes during TJ remodelling are poorly 
understood. 
 
1.5.4 Post-translational modifications 
The C-terminal tail of claudins is recognised as an effector of claudin stability and a key 
site of post-translational modification. (Van Itallie et al., 2004). Yeast two-hybrid studies 
have been used to identify numerous interactions between TJ proteins and modifying 
enzymes and various modifications have been shown to occur in vitro. However, the 
majority of these reactions have not been demonstrated in vivo and how these 
modifications are dynamically regulated is poorly understood. 
 
Palmitoylation 
Palmitoylation is a lipid modification involving the acylation of cysteine residues with 
palmitic acid. These “lipid tethers” are thought to promote the association of proteins 
with lipid membranes (Conibear and Davis, 2010). Claudin family proteins contain 
conserved membrane-proximal cysteine residues after the second and fourth 
transmembrane domains (Suzuki et al., 2014; Van Itallie et al., 2005). Cysteine 
palmitoylation influences the behaviour of claudin-14; mutation of these residues to 
serine decreases junctional localisation and increases the amount of claudin-14 found 
in lysosomes (Van Itallie et al., 2005). Other than inefficiently targeting to the junction, 
palmitoylation-deficient claudin-14 appeared to behave normally, in terms of its ability 
to organise into TJ strands and regulate barrier function (Van Itallie et al., 2005). The 
reduced efficiency, rather than failure, in localising to the TJ suggests that 
palmitoylation is not a strict requirement for normal claudin distribution. 
 
In comparison to prenylation and myristoylation, which are considered to be essentially 
irreversible, palmitoylation is a reversible process (Conibear and Davis, 2010). Palmitic 
acid is added to His-Asp-Asp-Cys motifs by protein acyl-transferases (DHHC PATs). 
There are currently 23 identified mammalian DHHC PATs, which are antagonised by 
depalmitoylation enzymes called acyl-protein thioesterases (APT1, APT2 and APTL1) 
(Conibear and Davis, 2010).  For example, H-Ras and N-Ras are regulated by 
reversible palmitoylation allowing them to shuttle between a membrane-bound and 
cytoplasmic state (Conibear and Davis, 2010). Research into claudin palmitoylation is 





in its infancy; the specific enzymes involved in claudin palmitoylation have yet to be 
identified and it has not been established if claudins are dynamically regulated by 
rounds of palmitoylation and depalmitoylation. 
 
Ubiquitination 
Ubiquitin is a small 8.5kDa protein that is covalently conjugated to target lysine 
residues of other proteins (Cohen and Tcherpakov, 2010). Although initially associated 
with protein degradation, ubiquitination is increasingly recognised as a series of 
complex and diverse modifications that influence various protein properties (Cohen and 
Tcherpakov, 2010). A yeast two-hybrid screen identified the E3 ubiquitin ligase 
LNX1p80 as a novel binding partner of claudin-1. Overexpression of LNX1p80 
decreased the concentration of claudin-1, -2 and -4 at the TJ. Of note, the localisation 
of occludin, ZO-1 and E-cadherin were largely unaffected by LNX1p80 overexpression, 
suggesting claudins may be selectively targeted by specific ubiquitin ligases. LNX1p80 
promoted claudin-1 ubiquitination and colocalised with claudins in lysosomes, 
suggesting that LNX1p80-mediated ubiquitination may drive claudin endocytosis and 
lysosomal degradation (Takahashi et al., 2009). 
 
Another yeast two-hybrid study found that the HECT E3 ubiquitin ligase Itch could bind 
to and polyubiquitinate the N-terminal domain of occludin (Traweger et al., 2002). Itch 
overexpression increased the relative amount of occludin in the soluble fraction, 
suggesting that it may regulate the stability of occludin at the TJ, potentially by inducing 
its internalisation or by blocking its recycling (Traweger et al., 2002). 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
SUMOylation 
The addition SUMO-1 (small ubiquitin-like modifier 1) can regulate a number of protein 
functions including protein-protein interactions, subcellular localisation and trafficking 
(Van Itallie et al., 2012a). A yeast two-hybrid screen identified ubiquitin-conjugating 
enzyme E21 (SUMO ligase-1) and E3 SUMO-protein ligase PIAS (protein inhibitors of 
activated STATs) as binding partners of the C-terminal of claudin-2 (Van Itallie et al., 
2012a). Further study showed that claudin-2 is SUMOylated on K218. Interestingly, 
SUMO-1 overexpression selectively decreases claudin-2 levels along the lateral 
membrane, while TJ intensity is unaffected. This suggests that SUMOylation of claudin-
2 may selectively target lateral membrane-associated claudin-2 for degradation. 
However, modification of K218 was undetectable in basal conditions and physiological 
mechanisms that may induce claudin-2 SUMOylation have not been identified (Van 
Itallie et al., 2012a) 
 





The consensus peri-lysine sequence for SUMOylation is not conserved between all 
claudins (Van Itallie et al., 2012a). For example, claudin-4 lacks the sequence, 
suggesting SUMOylation is one potential mechanism for differentially regulating claudin 
proteins at the post-translational level. Claudin SUMOylation has yet to be 
demonstrated in vivo and the physiological relevance remains unclear. Claudin 
SUMOylation studies are at a very early stage and further work is required to establish 
if claudins are dynamically modified and how this may influence their function, 
localisation or stability. 
 
Phosphorylation 
Claudin phosphorylation by WNK kinases 
Mutations in the serine/threonine kinases WNK1 and 4 (with no lysine) are associated 
with pseudohypoaldosteronism type II, or Gordon’s syndrome, which is characterised 
by hypertension, hyperkalemia and hyperchloremic acidosis (Ohta et al., 2006). Large 
deletions of the first intron of WNK1 increase its mRNA expression levels, while 
missense mutations that cluster around a putative coiled-coil domain are observed in 
WNK4. There are two proposed pathogenesis models; a transcellular model where 
WNK kinases target thioazide-sensitive NaCl transporters and a paracellular model 
where claudin phosphorylation increases the chloride shunt (Ohta et al., 2006).   
 
Disease-causing WNK mutants have been shown to bind and phosphorylate claudin-1, 
-2, -3, -4 and -7 (Kahle et al., 2004; Ohta et al., 2006; Tatum et al., 2007; Yamauchi et 
al., 2004). WNK4 localises to the TJ, while WNK1 is mainly cytosolic (Ohta et al., 
2006). WNK kinases phosphorylate claudins on both serine (Tatum et al., 2007) and 
threonine residues (Ohta et al., 2006), with S206 of claudin-7 identified as a putative 
WNK phosphorylation site in mutagenesis studies (Tatum et al., 2007). 
Hyperphosphorylation of claudin C-terminal domains mediated by WNK overexpression 
or mutation is associated with increased paracellular Cl- permeability (Kahle et al., 
2004; Ohta et al., 2006; Tatum et al., 2007; Yamauchi et al., 2004). The mechanism by 
which these epithelial barrier changes proceed is not clear; WNK4 phosphorylation of 
claudin C-terminal residues may induce a conformational change to alter the ionic 
permeability of the extracellular claudin loops, or could affect claudin interactions with 
other proteins that bind via their cytoplasmic domains. Furthermore, although WNK 
kinases appear to be able to bind and phosphorylate many claudins, it is not clear 
which are the pathologically relevant targets, or how WNK kinases regulate 
physiological barrier function. 
 





S208 phosphorylation of claudin-2 
Phosphorylation of claudin-2 on S208 promotes its membrane retention and reduces its 
trafficking to lysosomes (Van Itallie et al., 2012b). This site is constitutively 
phosphorylated in MDCKII cells, with up to 50% of the total claudin-2 pool being 
phosphorylated at any given time (Van Itallie et al., 2012b). Various localisation-
deficient mutants that do not fully localise to the tight junction all show reduced 
phosphorylation at S208, suggesting that plasma membrane-associated kinases, for 
example PKCι (Lu et al., 2015), may phosphorylate claudin-2 to augment its function or 
enhance its retention at the cell surface. 
 
Both S208A and S208E mutants of claudin-2 are targeted to some extent to the plasma 
membrane, suggesting that a small amount of claudin-2 can localise to the TJ 
independently of S208 phosphorylation status. More recently, studies have implicated 
S208 phosphorylation of claudin-2 with its Rab14-mediated recycling (Lu et al., 2015). 
Claudin-2 is also phosphorylated at a number of other serine, threonine and tyrosine 
residues on the cytoplasmic C-terminal domain, suggesting that its regulation by 
phosphorylation is probably highly complex (Van Itallie et al., 2012b). 
 
CK2-mediated phosphorylation of occludin S408 
Barrier function can also be regulated through the phosphorylation of occludin. The C-
terminus of occludin appears to be heavily phosphorylated, although the functional 
consequences of phosphorylation of individual sites are highly variable. T403/404 
phosphorylation enhances trafficking of occludin to the TJ (Suzuki et al., 2009), 
whereas Y398/402 phosphorylation reduces trafficking to the TJ by interfering with 
occludin-ZO-1 interactions (Elias et al., 2009). Of note, occludin is phosphorylated on 
S408 by casein kinase 2 (CK2). Inhibition of CK2 increases TER and decreases 
paracellular cation permeability, in a claudin- and ZO-1-dependent manner (Raleigh et 
al., 2011). Phosphorylated occludin self-associates, allowing claudin-2 to form cation 
channels through homotypic trans-interactions (Raleigh et al., 2011). In its 
dephosphorylated state, occludin interacts with claudin-2 via ZO-1 to disrupt claudin-2 
pore formation (Raleigh et al., 2011). Thus, the phosphorylation states of several 
residues in the C-terminal of occludin appear to regulate its interaction with ZO-1, 
allowing it to modulate epithelial barrier properties by directly influencing claudin 
interactions. 
 
MAP kinase phosphorylation of claudin-1 T203 
The phosphorylation of claudin-1 on T203, a putative MAP kinase phosphorylation site, 
has been reported to be required for epithelial barrier formation (Fujibe et al., 2004). 





However, T203 is only conserved between mouse and rat, with an alanine present in 
this position in the corresponding chicken, cow, dog and human sequences. 
Furthermore, this threonine residue is not conserved in any other human claudin. The 
lack of conservation implies that phosphorylation of this site is not physiologically 
essential and unlikely to be relevant to studies in canine MDCKII cells. 
 
EphA2 phosphorylation of claudin-4 Y208 
Eph receptors and their ephrin ligands are widely expressed in epithelia and mediate 
cell-cell interaction. Upon cell contact, EphA2 is activated by binding of its cognate 
ephrin to modulate claudin-4 expression and localisation (Tanaka et al., 2005). EphA2 
expression increases phosphorylation of claudin-4 on Y208, part of the C-terminal YV 
motif involved in binding the PDZ domains of ZO-1/-2. Phosphorylation of this motif 
attenuates the interaction between claudin-4 and ZO-1 and decreases the 
incorporation of claudin-4 into the TJ. Furthermore, claudin-4 can restrain the 
oncogenic activity of EphA2, suggesting that they may reciprocally regulate one 
another (Shang et al., 2014). Given that the YV motif is highly conserved between 
claudins (Itoh et al., 1999) its phosphorylation by EphA2, other Eph receptors or other 
unrelated kinases, may represent a widely applicable mechanism that regulates the 
incorporation of claudins into TJ strands. 
 
Aldosterone-induced threonine phosphorylation of claudin-4 
RCCD2 (rat cortical collecting duct) cells exhibit a “tight” phenotype with basal TER of 
~5000Ω.cm2 (Le Moellic et al., 2005). Treatment of RCCD2 cells with aldosterone 
specifically increases threonine phosphorylation of claudin-4, without affecting its 
overall expression level or subcellular localisation (Le Moellic et al., 2005). This occurs 
concurrently with a decrease in TER and increase in paracellular permeability to iodine, 
but decreased permeability to mannitol. However, the kinase responsible and specific 
residues targeted were not identified. 
 
The C-terminal tails of claudins are heavily phosphorylated and the functional 
consequences of specific site modifications are beginning to be unravelled. 
Phosphorylation can alter protein stability, localisation, protein-protein interactions and 
incorporation into the TJ and possibly induce conformational changes to alter pore 
permeability. Therefore, direct phosphorylation of claudins, occludin or other TJ 
proteins is becoming increasingly recognised as a mechanism that will permit the 
dynamic regulation of TJ structure, composition and function. 
 





1.6 Emerging roles for tight junction proteins in cancer 
1.6.1 Epithelial-mesenchymal transition 
The epithelial-mesenchymal transition (EMT) is involved in developmental 
morphogenesis, regenerative processes like wound healing, and in diseases including 
fibrosis and carcinoma (Doehn et al., 2009; Kalluri and Weinberg, 2009). Although EMT 
exists as three distinct subtypes, these processes share common features: i) the loss 
of cell junctions, ii) the loss of apicobasal polarity, iii) the adoption of mesenchymal, or 
front-rear, polarity and iv) the increased ability to migrate and invade. TJs are 
implicated in all of these processes; they are intrinsic components of cell-cell junctions, 
regulate apicobasal polarity through fence and gate functions and by interacting with 
the Par3/aPKC complex, and also have pro- and antimigratory roles (see Section 1.2). 
 
Cells that have undergone EMT can revert to an epithelial state via a mesenchymal-
epithelial transition (MET). However  EMT and MET do not represent committed one-
way processes; cells exhibit high levels of plasticity to adopt increasingly epithelial or 
mesenchymal characteristics (Huang et al., 2012). The gradual progression of an 
epithelial cell into a motile mesenchymal state proceeds through the gradual 
disassembly of epithelial junctions, from the apical to basal side of the cell. Early 
stages of TJ breakdown and the accompanying disruption of apicobasal polarity 
(Figure 1.9A) are followed by early intermediate stage AJ and desmosome 
disassembly, initially through post-translational mechanisms (Figure 1.9B) (Huang et 
al., 2012). Late intermediate stages are characterised by the transcriptional 
downregulation of junction proteins by master transcriptional regulators (Figure 1.9C). 
EMT is only “complete” when TJ, AJ and desmosomes proteins are fully 
transcriptionally downregulated and the cell has adopted mesenchymal traits, which 
promote an invasive phenotype to favour metastasis (Figure 1.9D) (Huang et al., 
2012). These discrete stages of EMT serve only to highlight that the transition is 
gradual, but do not necessarily reflect the degree of phenotypic plasticity and 
reversibility that actually exists. However, TJ disruption and the loss of polarity is 
considered a relatively early event in the transformation of growth-arrested and 
organised epithelial cells into mesenchymal-like cells with increased capacity for 
migration, invasion and metastasis (Huang et al., 2012) (Martin 2014).  
 
EMT is governed by a set of master regulators including Snail, Twist and Zeb 
transcription factors (Savagner, 2010). Snail binds to E-box elements in the promoter 
regions of E-cadherin, occludin and claudin-3, -4 and -7 to repress their activity 
(Ikenouchi et al., 2003). In contrast, Snail does not affect the mRNA or protein levels of 
ZO-1, although it is lost from areas of cell-cell contact and accumulates in the 





cytoplasm (Ikenouchi et al., 2003). This suggests that TJs are disassembled during 
EMT through the transcriptional downregulation of specific TJ components. 
 
In a similar fashion, Snail and Slug repress claudin-1 expression in MDCK cells by 
binding to E-box promoter elements, causing a complete loss of TER (Martínez-
Estrada et al., 2006). Furthermore, Snail/Slug levels are inversely correlated with 
claudin-1 expression in invasive human breast tumours (Martínez-Estrada et al., 2006). 
Snail expression also induces the loss of MDCKII TER and increases paracellular 
permeability to Na+ and Cl- through the downregulation of claudin-4 and -7, and to a 
lesser extent claudin-2 (Carrozzino et al., 2005). These studies suggest that during 
EMT, TJs are disassembled through the direct transcriptional repression of occludin 
and claudin family proteins. Additionally, altered endocytosis and recycling of E-
cadherin have emerged as alternative mechanisms allowing cells to undergo dynamic 
morphological changes (Bryant and Stow, 2004; Palacios et al., 2001; Palacios et al., 
2005). Endocytic circuitries are frequently “rewired” in physiological transition states to 
impart phenotypic plasticity by modulating adhesive junctions, the distribution of 
polarity regulators and actomyosin dynamics, allowing rapid adaption to dynamically 
changing microenvironments (Corallino et al., 2015). Although structural alterations to 
TJs and increased epithelial leakiness have been observed in preneoplastic growths 
and in adenocarcinoma (Mullin et al., 2005), little is known about the role of TJ protein 
trafficking during tumourigenesis, possibly due to the paucity of in vitro cell lines that 
form functional TJs (Huang et al., 2012). 
  



















Figure 1.9: Alterations in adhesive cell-cell junctions and cell polarity during epithelial-
mesenchymal transition. (A) Epithelial cells are characterised by a highly polarised structure 
and a series of cell-cell junctions, including the TJ (red), AJ (blue) and desmosomes (grey). 
During the epithelial-mesenchymal transition, these cell-cell contacts loosen and “unzip” through 
the sequential loss of the TJ (B), AJ (C) and desmosomes (D). This transition proceeds via 
intermediate stages with a high degree of plasticity and reversibility. Dynamic regulation of 
junction protein trafficking may be involved in TJ and AJ remodelling during these transitions. 
Image adapted from Huang (2012). 
 
  





1.6.2 Differential claudin expression in cancer 
Although there is no systematic sequence data on claudin mutations in any tumour 
type (Turksen and Troy, 2011), their expression is differentially regulated in a huge 
number of tumours (Table 1.3) (Ding et al., 2013; Kwon, 2013). However, there is no 
overriding pattern, with the specific claudins being either up or downregulated 
depending on tumour type and stage (Turksen and Troy, 2011). Therefore, it would be 
an oversimplification to state that epithelial barrier function is simply “lost” during 
tumourigenesis, when more complex changes in the expression and localisation of 
individual TJ components are clearly evident in diverse tumour types. 
 
Although many studies implicate TJ proteins in tumour suppression by providing a 
barrier to uncontrolled tumour growth and increased migration (Royer and Lu, 2011), 
various TJ components are actually upregulated in some tumour types. For example, 
claudin-4 is not normally expressed in ovarian epithelia, but was found to be highly 
expressed in pancreatic, ovarian and primary breast tumours (Boylan et al., 2011; Jiwa 
et al., 2014; Neesse et al., 2012). Increased claudin-4 expression generally favours 
prognosis, but is also associated with cancer progression in some contexts (Neesse et 
al., 2012). Claudin-4 expression may inhibit primary tumour growth but promote the 
cohesion of established metastases, conferring a survival advantage in the host tissue 
(Jiwa et al., 2014; Lin et al., 2013; Shang et al., 2012; Shang et al., 2014). 
 
Furthermore, claudin-2 expression is significantly upregulated in colorectal cancer and 
correlates with cancer progression (Dhawan et al., 2011). Claudin-2 expression 
increases colorectal cancer cell proliferation, anchorage-independent growth and 
tumour growth in vivo. Mechanistically, this may be mediated through increased 
paracellular permeability to luminal carcinogens, as well as growth factors, which would 
gain increased access to activate basolateral receptors and promote neoplastic 
transformation and growth (Dhawan et al., 2011). 
 
Taken together, these studies indicate that the regulation of claudins in cancer is highly 
complex, with context-dependent consequences. Claudin expression can correlate 
positively or negatively with prognosis, depending on whether they are expressed in 
primary or metastatic tumours. Furthermore, the effect of specific changes in TJ 
composition on paracellular permeability may gain functional significance depending on 
the tissue microenvironment in which they are situated. 
 
While complex and differential claudin expression is widely observed in cancers of 
many origins, there is currently a lack of data regarding relevant claudin mutations 





(Turksen and Troy, 2011). Claudin-1 mutations cause neonatal sclerosing cholangitis 
associated with ichthyosis, claudin-14 mutations are associated with nonsyndromic 
recessive deafness (Wilcox et al., 2001) and mutations to either claudin-16 or -19 
underlie hereditary hypomagnesia (Kang et al., 2005). While these specific disease-
causing claudin mutations have been identified, no corresponding mutations have been 
observed in cancer. Future studies will be required to determine whether and how 
claudins or other TJ-associated proteins are mutated in cancer, as well as how claudin 
expression is regulated by epigenetic mechanisms, EMT-associated transcription 
factors, specific oncogenes and related signalling pathways. 
 
 
Tissue Claudin-1 Claudin-2 Claudin-3 Claudin-4 Claudin-7 
Breast ↓ ↓ ↓ ↑↓ ↓ 
Cervical ↑ ↑ - ↑ ↑ 
Colorectal ↑ - ↑ ↑ 
 
Oesophageal - - ↑ ↑ ↓ 
Kidney ↑↓ - ↑ ↑↓ ↑ 
Gastric - - - - - 
Liver ↓ - - - - 
Melanoma ↑ - - - - 
Ovarian - - ↑↓ ↑↓ - 
Prostate ↓ ↓ ↑ ↑ ↓ 
Pancreatic - - - ↑ - 
Uterine - - ↑ ↑ - 
Table 1.3: Differential regulation of claudin expression levels is frequently observed in 
cancers of diverse origins. (↑) Upregulated, (↓) Downregulated, (↑↓) Up- or downregulated, (-) 




1.6.3 Paracellular permeability in tumourigenesis 
Many growth factor receptors are largely confined to the basolateral surface of 
epithelial cells, where they are functionally segregated from relatively high luminal 
ligand concentrations by an intact TJ. This has been demonstrated in vitro, where 
apical heregulin-α only activates basolateral erbB2 receptors following epithelial 
damage or when TJs are disassembled by depleting extracellular calcium (Vermeer et 
al., 2003). This suggests that the loss of epithelial barrier function may result in the 
constitutive exposure of growth factor receptors to ligands, driving aberrant 
downstream signalling and proliferation. It has also been suggested that changes in 





intercellular pH and electrical cues influence cell proliferation, although these 
suggestions are largely speculative in nature (Tsukita et al., 2008). 
 
1.6.4 Cell Migration 
Increased junctional levels of claudins generally impair cell migration in MDCKII cells 
(Ikari et al., 2011a; Ikari et al., 2012b). In addition to increasing TER, claudin-2 
knockdown increases the rate of recovery in an MDCKII scratch wound migration 
assay (Ikari et al., 2011a). This proceeds without any significant increase in cell 
proliferation, and is dependent on the increased expression of matrix metalloproteinase 
(MMP9), at both the mRNA and protein level (Ikari et al., 2011a). Furthermore, the 
forced expression of claudin-2 effectively blocks the induction of MMP9 and reduces 
cell migration to basal levels (Ikari et al., 2011a). This suggests that the loss of claudin-
2 expression leads to the transcriptional upregulation of proteinases that enhance cell 
migration through the degradation and remodelling of the extracellular matrix (Ikari et 
al., 2011a). Claudin-4 overexpression decreases cell migration in an MDCKII scratch-
wound assay and also increases the extent of cell-cell contact and adhesion, by 
increasing the proportion of claudin-1, -3 and -4 associated with ZO-1 at the apical 
junction (Ikari et al., 2012b). 
 
The expression of individual claudin proteins is frequently deregulated in various 
cancers. While EMT is generally associated with TJ loss and the transcriptional 
downregulation of its components, individual TJ proteins can be up- or downregulated 
in different tissues and cancers. TJ deregulation may contribute to tumourigenesis 
through changes in paracellular permeability and apicobasal polarity in addition to 
emerging roles in regulating cell migration. However, the specific impact of different 
oncogenes and their associated signalling pathways on individual TJ proteins is poorly 
understood.  





1.7 The RAF/MEK/ERK pathway 
Mitogen-activated protein kinases form functional signalling modules that relay 
messages from the cell surface to nuclear and cytoplasmic effectors, which determine 
a cell’s response to diverse stimuli (Figure 1.10A) (Santarpia et al., 2012). Growth 
factor receptors expressed at the cell surface, including the receptor tyrosine kinases 
(RTKs) epidermal growth factor receptor (EGFR) and Met, are activated upon binding 
of their cognate growth factor ligands (Wortzel and Seger, 2011). Ligand-binding 
normally induces RTK dimerisation and autophosphorylation of the corresponding 
dimer partner through the intrinsic tyrosine kinase activity of each RTK (Roskoski, 
2012). Various phosphotyrosine residues on the cytosolic RTK domain then serve as 
docking sites for adaptor proteins that contain SH2 or PTB domains (Roskoski, 2012). 
GRB2 is an adaptor protein that binds to activated receptors and recruits Sos, a 
guanine exchange factor (GEF), which converts GDP-bound Ras into its active GTP-
bound form (Sturm et al., 2010). Active Ras activates a plethora of downstream 
signalling pathways including PI3 kinase, Rac, Rho and RAF/MEK/ERK pathways 
(Santarpia et al., 2012). 
 
In its inactive state, RAF protein exists in a closed conformation, where the N-terminal 
region sterically inhibits the catalytic region of the C-terminal kinase domain 
(Matallanas et al., 2011). The RAF activation mechanism is complex and proceeds via 
the following steps: i) the dephosphorylation of CRAF to unmask the RBD and CRD 
domains, enabling Ras interaction and membrane recruitment, ii) direct molecular 
interaction of CRAF with Ras, iii) phosphorylation of the CRAF activation segment in 
the CR3 domain and N-region, by proteins including Src and JAK family kinases, iv) 
homo- and heterodimerisation of RAF monomers, which enhances the kinase activity 
and signalling of RAF and v) deactivation initiated by binding of protein phosphatases 
that return CRAF to its inactive state (Matallanas et al., 2011). 
 
In their active phosphorylated state, RAF proteins specifically bind and phosphorylate 
MEK1/2 kinases on neighbouring serine residues, leading to their catalytic activation 
(Figure 1.10A) (McMahon, 2001). MEK1/2 are dual specificity kinases that activate 
ERK1/2 by phosphorylating threonine and tyrosine residues in a conserved TEY motif 
(Figure 1.10A) (Butch and Guan, 1996). This facilitates the translocation of ERK1/2 to 
the nucleus, where they interact with a huge number of transcriptional activators and 
repressors to modulate gene expression (Figure 1.10A). ERK1/2 also have a large 
number of substrates in the cytoplasm and other subcellular organelles (Wortzel and 
Seger, 2011), allowing the RAF/MEK/ERK pathway to mediate a diverse range of 





cellular processes, including proliferation, differentiation and apoptosis, in a stimulus-
dependent manner (O’Neill and Kolch, 2004). 
 
 
Figure 1.10: Physiological and pathological RAF/MEK/ERK pathway signalling. The 
RAF/MEK/ERK pathway is involved in the transduction of extracellular signals from cell surface 
receptors, including receptor tyrosine kinases (RTKs), to the cell interior, and participates in the 
regulation of diverse responses to a number of stimuli. (A) In a physiological setting, RTK 
activation leads to activation of the GTPase, Ras, which recruits RAF kinase for activation at the 
plasma membrane. RAF is activated in a complex process involving phosphorylation, 
dephosphorylation, dimerisation and transactivation. RAF is the first member of a three-tiered 
kinase cascade and phosphorylates MEK, which in turn phosphorylates and activates ERK. 
ERK has many substrates in the nucleus and throughout the cell and can regulate various 
processes in stimulus-dependent manner. Activated ERK also provides negative feedback at 
various levels of the cascade to inhibit its own activation. (B) BRAF is frequently mutated in 
cancer, with an activating V600E mutation being particularly prevalent. Activating mutations 
generate a constitutively active BRAF kinase, the activity of which is independent of upstream 
activation by RTKs or Ras. BRAF
V600E
 is also insensitive to ERK-mediated negative feedback, 
resulting in elevated pathway output and ERK-dependent transformation. Experimentally, this 
can be mimicked by expression of oncogenic BRAF variants or non-physiological inducible-
activity RAF constructs, for example ΔCRAF:ER. 
 
Stimuli that activate the RAF/MEK/ERK pathway through the activation of RTKs and 
Ras will also lead to the simultaneous activation of other parallel signalling pathways. 
Various studies have implicated the RAF/MEK/ERK pathway in the regulation of TJ 
permeability, and have involved the use of growth factors in combination with small 
molecule inhibitors to independently block downstream pathways. As a result, it is 
difficult to elucidate the exact contribution of the RAF/MEK/ERK signalling pathway, 
when other pathways will inevitably be activated. By contrast, a limited number of 
studies have activated the pathway at the level of RAF or MEK. The expression of 
oncogenic or non-physiological constitutively active RAF proteins provides the ability to 





specifically activate the RAF/MEK/ERK pathway due to the highly specific nature of 
RAF/MEK and MEK/ERK interactions (Figure 1.10B). 
 
1.7.1 RAF, MEK and ERK kinases 
ERK kinases appear to be the only physiological substrates of MEK (Roberts and Der, 
2007; Shaul and Seger, 2007). In contrast ERK has more than 150 identified nuclear 
and cytoplasmic substrates (Yoon and Seger, 2006). The ability of a common pathway 
to mediate different outcomes is thought to be achieved through a combination of 
differential signal strength and duration, crosstalk with other signalling cascades and 
scaffolding complexes that connect activators and effectors and target them to different 
subcellular locations (O’Neill and Kolch, 2004; Shaul and Seger, 2007). Although the 
effects of RAF/MEK/ERK activation are often due to changes in gene expression, ERK 
has numerous cytoplasmic substrates and has been implicated in regulating clathrin-
independent membrane trafficking at the apical recycling endosome by interacting with 
the GTPase Arf6 (Robertson et al., 2006). 
 
MEK kinases are the only widely accepted RAF substrates (Matallanas et al., 2011). 
However, MAP kinase-independent roles of RAF kinases have also emerged 
(Ehrenreiter et al., 2005; Hindley and Kolch, 2002; Matallanas et al., 2011). These 
include the suppression of proapoptotic kinases, ASK1 and MST2, the regulation of cell 
motility by modulating Rho activity (Ehrenreiter et al., 2005) and the induction of 
aneuploidy (Kamata et al., 2010). Notwithstanding, activation at the level of RAF still 
permits activation of the pathway in a far more specific manner than through growth 
factor stimulation, which will simultaneously activate other RTK- and Ras-dependent 
pathways. MEK-dependent and -independent effects can be further distinguished 
through the use of small molecule inhibitors of RAF, MEK and ERK.  
 
The first raf gene (rapidly accelerated fibrosarcoma) identified was a retroviral 
oncogene, v-raf, which is transduced by the murine sarcoma virus (Bonner et al., 1985; 
Matallanas et al., 2011). Raf-1, or CRAF, the protein encoded by the corresponding 
cellular proto-oncogene c-raf, was shown to mediate the cellular effects of growth 
factors by acting as an effector of Ras, and an activator of MEK (Matallanas et al., 
2011). Two additional RAF isoforms, ARAF and BRAF, were subsequently identified 
(Beck et al., 1987; Ikawa et al., 1988). The three RAF isoforms, encoded by 
independent genes, share MEK1/2 kinases as substrates, but can elicit distinct 
biological outcomes (Matallanas et al., 2011). BRAF, CRAF and ARAF have similar 
structures with three conserved regions (CR1 – 3) (Figure 1.11A) (Matallanas et al., 
2011). CR1 contains a Ras-binding domain (RBD) and cysteine-rich domain (CRD), 





which mediate the interaction with Ras at the plasma membrane. CR2 contains 
inhibitory phosphorylation sites that participate in the negative regulation of Ras-
binding and RAF activation. CR3 features the kinase domain, including the activation 
loop, the phosphorylation of which is crucial for kinase activation (Matallanas et al., 
2011). Functionally, the RAF structure can be considered as a regulatory N-terminal 
domain consisting of the RBD, CRD and inhibitory phosphorylation sites, and a C-
terminal catalytic domain, which includes the active site and phosphorylation sites that 
are necessary for kinase activation (Matallanas et al., 2011). The regulatory domain 
acts to restrain the activity of the catalytic domain, and its removal generates truncated 
and constitutively active kinases, referred to as ΔARAF, ΔBRAF and ΔCRAF (Figure 
1.11) (Stanton et al., 1989). 
 
The three RAF isoforms exhibit distinct biochemical properties; BRAF exhibits greater 
kinase activity than CRAF, and in turn ARAF. This is explained by differences in their 
modes of activation. RAF activation requires phosphorylation of at least two sites, the 
N-terminal acidic motif (NtA) and the activation loop (Hu et al., 2013). In ARAF and 
CRAF, the NtA motif is comprised of SSYY residues (S = serine, Y =tyrosine) (Figure 
1.11). For full activation, all four sites must be negatively charged (Emuss et al., 2005). 
At the plasma membrane, tyrosine residues are phosphorylated by Src and serine 
residues by PAK or PKC family kinases (Hu et al., 2013). Following NtA 
phosphorylation, RAF monomers form asymmetric dimers, with one partner acting as 
the activator, and the other as a receiver (Hu et al., 2013). NtA phosphorylation is 
required for the activator to allosterically induce cis-autophosphorylation of the receiver 
kinase, which is required for its full activation (Hu et al., 2013). In contrast to ARAF and 
CRAF, the NtA motif of BRAF is comprised of SSDD residues (S = serine, D = aspartic 
acid) (Figure 1.11). Therefore, the N-region is exhibits a constitutive negative charge 
due to the presence of the two aspartic acid residues combined with constitutive serine 
phosphorylation (Emuss et al., 2005). As a result, activation of BRAF is relatively 
simple, requiring activation loop phosphorylation induced by Ras activation, while 
ARAF and CRAF require additional tyrosine and serine phosphorylation events (Marais 
et al., 1997). Figure 1.11 illustrates the structural similarities and differences between 
RAF isoforms. 
  








Figure 1.11: Similarities and differences of RAF kinase isoforms. RAF kinases share 
conserved structural features. All RAF isoforms have three conserved regions (CR1 – 3). CR1 
contains a Ras-binding domain (RBD) and cysteine-rich domain (CRD), which are involved in 
Ras-binding. CR2 contains inhibitory phosphorylation sites that act to restrain the kinase 
activity. CR3 contains the active site and other features including the N-terminal acidic (NtA) 
motif and activation segment, which must be phosphorylated to achieve full kinase activity. (B) 
The regulatory N-domain (CR1 and CR2) of A, B or CRAF inhibits the kinase activity of the 
catalytic C-domain. Removal of CR1 and CR2 generates truncated and constitutively active 
ΔRAF kinases. (C) During activation, the NtA of ARAF and CRAF, which is comprised of serine 
(S) and tyrosine (Y) residues, must be phosphorylated to allow asymmetric RAF dimerisation, 
allosteric transactivation and cis-autophosphorylation of the activation segment. The presence 
of aspartic acid (D) residues and constitutive serine phosphorylation confers a constitutive 
negative charge to the BRAF NtA, “priming” it for single-step activation through phosphorylation 
of the activation segment. As a result, BRAF exhibits relatively high endogenous kinase activity 
and is particularly prone to activating mutations that mimic activation segment phosphorylation, 
for example the oncogenic V600E mutation. Image adapted from Matallanas (2011). 
  





1.7.2 RAF/MEK/ERK signalling in cancer 
The RAF/MEK/ERK signalling pathway is frequently activated in cancer through 
oncogenic mutations to RTKs, Ras, and RAF proteins (Table 1.4). The “priming” 
negative charge of the N-region not only underlies the high endogenous activity of 
BRAF, but also results in its frequent mutation in cancer; BRAF can be activated by 
single point mutations that mimic activation loop phosphorylation, while ARAF and 
CRAF activation is a multistep process (Emuss et al., 2005). There is a particularly high 
incidence of BRAF mutations in thyroid, colorectal and biliary tract carcinoma as well 
as in melanoma (Table 1.4) (Kamata and Pritchard, 2011), with more than 40 different 
mutations in the braf gene identified in human cancer (Cantwell-Dorris et al., 2011). 
Activating mutations cluster in the glycine-rich loop and activation segments and target 
residues involved in the stabilisation of interactions between these regions. Mutations 
frequently disrupt this hydrophobic interaction, destabilising the inactive conformation 
to render BRAF constitutively active (Cantwell-Dorris et al., 2011). 
 
Over 90% of braf mutations are accounted for by a single point mutation at position 
1799 (Cantwell-Dorris et al., 2011; Davies et al., 2002). This mutation causes the 
substitution of valine for glutamic acid at codon 600 (V600E). The negatively charged 
glutamic acid mimics phosphorylation of the activation segment, and disrupts its self-
inactivating interaction with the P-loop (Röring et al., 2012). The V600E mutation 
increases BRAF activity 500-fold and also renders BRAF insensitive to ERK-mediated 
negative feedback, leading to increased transcriptional output and ERK-dependent 
transformation (Pratilas et al., 2009). BRAFV600E activity does not appear to require RAF 
dimerisation (Röring et al., 2012). and is independent of upstream stimuli, allowing cells 
to become self-sufficient in growth signals that rely on the RAF/MEK/ERK pathway 
(Cantwell-Dorris et al., 2011). BRAFV600E mutation alone is insufficient for cell 
transformation (Tsao et al., 2012) and coincident mutations, for example to p53, may 
be required for tumourigenesis (Patton et al., 5AD). However, cells exhibit BRAFV600E 
oncogene addiction, where they depend on sustained ERK signalling to maintain 
growth factor-independent survival (Wickenden et al., 2008). For these reasons 
therapeutic targeting of the RAF/MEK/ERK pathway has proved to be relatively 
successful for certain cancer types (Roberts and Der, 2007). 
  






Percentage of cases with point mutations (%) 
KRAS  NRAS  HRAS  BRAF  CRAF  ARAF  MEK1  
Adrenal gland  0.2 2.4 1.2 1 0 0 0 
Autonomic ganglia  0.2 1.3 0.3 0.3 0.3 0 0.2 
Biliary tract  23.4 2.5 0.5 5.5 0.8 1.6 0 
Bone  1.7 1.8 1.3 7.8 0 0 0 
Breast  1.6 0.7 0.3 1.2 0.3 0.4 0.4 
Central nervous system  0.9 0.7 0.3 7.9 0.1 0 0 
Cervix  5.8 0.5 4.5 0.8 0 0 0 
Endometrium  14.1 2.1 0.5 1.4 2 2.3 0.9 
Eye  1.6 2.3 0 9.5 0 0 0 
Genital tract  8.8 2.7 1.1 2 0 0 0 
Haematopoietic/lymphoid  4.4 8.7 0.2 10.2 0.1 0.1 1.5 
Kidney  0.5 0.3 0.1 2.1 0.3 0.2 0.1 
Large intestine  34.4 4.1 0.5 12.5 2.9 2.2 2.6 
Liver  2.1 0.4 0.1 1.5 0.8 0.6 0.1 
Lung  16.5 0.6 0.5 2.2 0.7 0.8 0.6 
Meninges  0 6.6 0 0.7 0 0 0 
Oesophagus  1.8 0 0.4 0.4 0.2 0.3 0 
Ovary  11.6 0.8 0.1 7.1 0.1 0.4 0.1 
Pancreas  57 0.8 0 1.5 0.3 0.1 0.1 
Peritoneum  45.2 0 0 0 0 0 0 
Pituitary  0 0 3.2 17.8 0 0 0 
Pleura  3.4 3.6 0 2.3 0 0 0 
Prostate  4.5 0.7 2.6 1.5 0.5 0 0.1 
Salivary gland  2.5 0.7 8.7 0.6 0 0 0 
Skin  2.3 15.6 11.5 41.3 2.1 1 4.8 
Small intestine  22.9 0.8 0 4.4 0 0 0 
Soft tissue  3.9 3.4 3.2 1.8 0.3 0 0.2 
Stomach  6 1 1.2 1.1 2 2 1.8 
Testis  3.8 2.4 3.9 2.6 0 0 0 
Thyroid  1.8 6.7 3.8 41.3 0.2 0.2 0 
Upper aerodigestive tract  2 1.5 5.9 1 0.5 0 0.2 
Urinary tract  4.3 1.2 9.1 2.2 0.4 0.4 0 
 
Table 1.4: A summary of RAS/RAF/MEK/ERK pathway mutations in primary human 
cancer samples. Mutations that activate the RAS/RAF/MEK/ERK pathway are common in 
cancer.  There is particular high incidence of KRAS mutations in pancreatic, colorectal and 
biliary tract cancers, although Ras will simultaneously activate other signalling pathways in 
addition to the RAF/MEK/ERK pathway. Specific activating mutations at the level of RAF are 
also common, with BRAF more frequently mutated than CRAF or ARAF. BRAF mutations are 
particularly prevalent in thyroid, colorectal and biliary tract carcinoma, as well as in melanoma. 
(ND) not determined. Rare point mutations to CRAF and ARAF are indicated by the number of 
cases in brackets. Data obtained from the Catalogue of Somatic Mutations in Cancer (COSMIC) 
database (Forbes et al., 2014). 
 
  





1.7.3 Experimental modulation of RAF/MEK/ERK signalling 
Specific activation of the RAF/MEK/ERK pathway has been achieved through the 
expression of variously modified versions of kinases at each tier of the cascade. MEK 
can be rendered constitutively active by introducing a double S218/222D mutation, 
mimicking RAF-dependent regulatory site phosphorylation (Lemieux et al., 2011). 
Constitutively active ERK constructs have recently been generated by introducing 
L84P/S162D mutations in the active site and an additional D330N mutation to inhibit 
the binding of inhibitory phosphatases to the CD site (Rian et al., 2013). Conversely 
MEKK97M and ERKK52R mutations generate catalytically inactive kinases (Khoo et al., 
2003; Mansour et al., 1994). Deletion of the conserved N-terminal CR1 and CR2 
regions of all three RAF isoforms yield constitutively active forms (ΔARAF, ΔBRAF 
ΔCRAF) that can elicit cell transformation (Figure 1.11B) (Stanton et al., 1989). 
 
Although useful in an experimental setting, the expression of bona fide oncogenic 
variants, such as BRAFV600E, presents a more pathologically relevant approach. The 
different transcriptional outputs of cells transformed by RTK or BRAFV600E mutation 
indicate that although various mutations activate the RAF/MEK/ERK pathway, 
differences in regulatory and feedback mechanisms can result in distinct biological 
outcomes (Pratilas et al., 2009). In addition, fusion of the N-terminally truncated ΔRAF 
proteins to the ligand-binding domain of the estrogen receptor generates inducible-
activity constructs – the activity of which is dependent on the presence of an activating 
ligand hormone (McMahon, 2001). This approach has recently been extended to 
generate conditionally active versions of BRAFV600E, providing a method of rapidly and 
reversibly activating the RAF/MEK/ERK pathway. These tools offer increased control of 
signal strength and duration and the ability to study temporal or dynamic effects on cell 
phenotype and behaviour. 
 
In addition to catalytically inactive MEK and ERK kinase constructs, the RAF/MEK/ERK 
pathway can be effectively inhibited using small molecule inhibitors of MEK. 
PD0325901 is a second generation selective and non ATP-competitive inhibitor of 
MEK1 and 2, with IC50 values of approximately 1nM (Thompson and Lyons, 2005). 
PD0325901 is one of a series of benzhydroxamate MEK inhibitors that bind to an 
interior hydrophobic pocket adjacent to the ATP binding site. As a result, the MEK 
catalytic site is partially blocked, preventing entry of the ERK activation loop and its 
subsequent phosphorylation (Thompson and Lyons, 2005). PD0325901 exhibits 
greater potency than commonly used MEK inhibitors such as U0126, effectively 
blocking phosphorylation of ERK1 and 2 at 25nM compared to 10µM U0126 (Bain et 
al., 2007). Only a small number of other kinases are marginally inhibited by 





PD0325901, even at higher concentrations of 10µM (Bain et al., 2007). Therefore, 
although clinically limited by concerns over neurological toxicity (Pratilas and Solit, 
2010), the use of PD0325901 in an experimental setting provides the ability to inhibit 
RAF/MEK/ERK pathway signalling in a highly specific manner. Specific small molecule 
inhibitors in combination with oncogenic and inducible activity RAF kinase constructs 
provide a set of molecular tools for probing the specific contribution of the 
RAF/MEK/ERK signalling pathway to TJ regulation. 
 
1.8 Tight junction regulation by the RAF/MEK/ERK pathway 
1.8.1 ERK activity correlates with renal epithelial permeability 
In the kidney, blood is forced into the Bowman’s capsule under high pressure, and the 
resulting filtrate passes along the nephron, through the proximal tubule, loop of Henle, 
distal tubule and collecting duct, and accumulates in the bladder (Figure 1.12). As the 
tubule contents pass along the nephron, the selective reabsorption of salts and water 
through transcellular and paracellular pathways produces an increasingly concentrated 
filtrate. The epithelial barrier gradually increases, from a “leaky” permeable epithelium 
in the proximal tubule, to a “tighter” resistant epithelium in the distal tubule and 
collecting duct (Figure 1.12). This increase in epithelial sealing is required to effectively 
contain the concentrated filtrate and prevent diffusion into the surrounding tissue via 
the paracellular pathway (Flores-Benítez et al., 2007). Epithelial tightness correlates 
with ERK activity in vivo (Masaki et al., 2004). Differential claudin expression is 
observed in different renal nephron segments (Hou et al., 2013). For example, the 
cation-pore forming claudin-2 is confined to the highly permeable proximal tubule and 
descending limb of Henle (Figure 1.12) (Hou et al., 2013). Renal epithelial permeability 
is inversely correlated with the expression of EGF/EGFR (Ikari 2011). Furthermore, in 
normal human and rat kidney, phosphorylated ERK is largely confined to the cytoplasm 
of cells in the high resistance collecting duct (Masaki et al., 2004). These observations 
suggest that EGFR signalling may influence the composition or properties of the TJ, at 
least partially through the RAF/MEK/ERK pathway (Figure 1.2). 
 
Consistent with in vivo observations, ERK activity correlates with the TER of renal cell 
lines in vitro (summarised in Table 1.5). MDCKI cells exhibit high endogenous levels of 
active ERK and a high TER of ~4000Ω.cm2, whereas MDCKII cells exhibit low active 
ERK levels and have much lower TER values of <300Ω.cm2 (Dukes et al., 2011a). 94D 
mouse renal collecting duct cells also exhibit high TER values of ~4000Ω.cm2 and have 
high baseline levels of phosphorylated ERK (Lipschutz et al., 2005). Crucially, leaky 
and tight renal cell lines can be interconverted by the activation or inhibiton of 
RAF/MEK/ERK signalling. The TER of leaky MDCKII cells can be increased through 





treatment with EGF or HGF, or the expression of hormone-inducible RAF kinase or 
constitutively active MEK kinase constructs, in a MEK-dependent manner (Lipschutz 
2005, Hansen 2000). This correlates with the specific downregulation of the pore-
forming claudin-2, at both the mRNA and protein level (Ikari 2011, Doehn 2009, 
Lipschutz 2005, Singh and Harris 2004). Furthermore, inhibition of ERK activity in 
MDCKI or 94D cells decreases their TER to levels comparable with those observed in 
MDCKII cells (Table 1.5) (Lipschutz et al., 2005). Further evidence for TJ regulation by 
the RAF/MEK/ERK pathway has come from studies utilising the expression of RAF and 
MEK kinases, as well as treatment with various growth factors and hormones that 
regulate epithelial barrier properties in a MEK-dependent manner. 
  






Figure 1.12: TJ permeability correlates positively with claudin-2 expression, and 
negatively with EGF/EGFR expression along the renal nephron. Epithelial permeability 
varies in a segment-specific manner in the renal nephron (Hou et al., 2013). Downstream 
activation of the RAF/MEK/ERK pathway by EGFR activation has been implicated in mediating 
the transcriptional downregulation, as well as internalisation and degradation of claudin-2 (Ikari 
et al., 2011c). EGFR may also exert effects on the TJ independently of RAF/MEK/ERK 
signalling. Representative TER values of different renal segments and the effect of 
RAF/MEK/ERK activation or inhibition are summarised in Table 1.5. 
 
 
Cell line 94D MDCKI MDCKII 
Representative of tissue type Collecting duct Distal tubule Proximal tubule* 
TER (Ω.cm2) ~4000 ~4000 <300 
Basal ERK activity High High Low 
Effect of ERK activation on TER No change No change Transient increase 
Effect of MEK inhibitors on TER Decrease Decrease No change 
 
Table 1.5: Correlation between basal ERK activity and transepithelial resistance of renal 
cell lines derived from different nephron segments. Transepithelial resistance (TER), a 
measure of TJ permeability, is correlated with basal ERK activity in various renal cell lines. 
MDCKII cells are representative of the proximal tubule of the kidney nephron, and exhibit low 
TER, while MDCKI and 94D cell lines represent more distal nephron segments, have high basal 
ERK activity and low epithelial permeability to effectively contain increasingly concentrated 
nephron contents. Importantly, high and low resistance cell lines can be interconverted by the 
activation or inhibiton of the RAF/MEK/ERK pathway, highlighting a key role for this signalling 
pathway in regulating the TJ and epithelial permeability. (MDCK) Madin-Darby canine kidney 
cells, strain I and II, (94D) mouse renal collecting duct cells.  *The parental MDCK-NBL2 cell 
line was derived from the distal tubule, but the MDCKII strain exhibits properties of the proximal 
tubule, including low TER and abundant claudin-2 expression. Data obtained from Lipschutz et 
al (2005) and Dukes et al (2011). 





1.8.2 Tight junction regulation by RAF kinases 
Specific activation of the RAF/MEK/ERK pathway using constitutively active or 
hormone-dependent RAF or MEK kinase constructs is associated with transcriptional 
changes that affect a number of TJ proteins in a tissue-specific manner. A recent 
genome-wide microarray in MDCKII cells utilised an inducible activity ΔCRAF:ER 
kinase construct to identify 1089 genes whose expression was regulated by increased 
ERK activity, and a further subset of 228 genes which were also dependent on RSK 
kinase activity (Doehn et al., 2009). This study identified RSK kinase as a key effector 
that coordinates multiple transcription-dependent mechanisms to stimulate motility and 
invasion. Several TJ proteins were identified, with differential dependencies on ERK 
and RSK kinase activity (summarised in Table 1.6). RAF/MEK/ERK activity is sufficient 
to drive the complete loss of claudin-2 mRNA expression, with a relative increase in 
mRNA expression of claudins -4, -6, -7 and -18. Interestingly, increased mRNA 
expression of these claudins is Rsk-dependent, while the decrease in claudin-2 mRNA 
is Rsk-independent (Table 1.6). Another study identifying Rnd3/RhoE as key regulator 
of RAF/MEK/ERK-mediated MDCK transformation observed a transient 3-fold increase 
in MDCK TER, which peaked at 18 hours following ΔCRAF:ER activation (Hansen et 
al., 2000). Although limited in number, these studies indicate that activation of the ERK 
pathway is sufficient to drive changes in TJ protein expression and epithelial 
permeability properties, but have mainly focussed on transcriptional changes to 
individual TJ components. 
 
Protein Fold change(ΔCRAF:ER +4HT) MEK-dependent? Rsk-dependent? 
Claudin-2 ↓ 150x (complete loss) Yes No 
Claudin-4 ↑ 2x Yes Yes 
Claudin-6 ↑ 30x (not normally expressed) Yes Yes 
Claudin-7 ↑ 2x Yes Yes 
Claudin-18 ↑ 3x Yes Yes 
E-cadherin ↑ 2x Yes No 
β-catenin ↓ 2x Yes No 
ZO-2 ↑ 5x Yes No 
ZONAB ↑ 5x Yes No 
Occludin Not identified in study 
Claudin-1 Not identified in study 
ZO-1 Not identified in study 
Table 1.6: Transcriptional changes to genes encoding junction proteins associated with 
ΔCRAF:ER activation. A genome-wide microarray utilised a hormone-dependent RAF kinase 
fusion protein (ΔCRAF:ER) in combination with small molecule inhibitors of MEK and RSK 
kinases to determine genes that are transcriptionally regulated by the RAF/MEK/ERK/Rsk 
pathway. In MDCKII cells, specific activation of the RAF/MEK/ERK pathway caused the 
downregulation of claudin-2, the upregulation of claudin-4, -6, -7 and -18 and altered expression 
other TJ/AJ-associated genes. Specificity of the response to RAF/MEK/ERK pathway activation 
was confirmed with a MEK inhibitor, and individual genes exhibited differential requirements for 
downstream Rsk activity. Data obtained from Doehn et al (2009). 





CRAF activity is associated with the transcriptional downregulation of occludin in rat 
salivary gland Pa-1 cells, via activation of the transcription factor, Slug (Li and Mrsny, 
2000; Wang et al., 2007). However, the majority of studies have failed to report a link 
between RAF/MEK/ERK activity and the altered transcription of occludin in renal cell 
lines. Post-translational phosphorylation and membrane recruitment of occludin is 
observed following inhibition of MEK in Ras-transformed MDCK cells, although no 
change in mRNA level is observed (Chen et al., 2000). This highlights the tissue- and 
cell line-specific effects of RAF/MEK/ERK activation on TJ protein regulation. As 
previously discussed, these complex effects are likely to be, at least in part, due to 
tissue-variable expression of relevant transcription factors. Although RAF/MEK/ERK 
activity induces changes in the transcription and expression of individual TJ 
components, its impact on the trafficking and distribution of the existing protein pools 
has not been studied in great detail. Studies involving growth factors and small 
molecule inhibitors implicate the RAF/MEK/ERK pathway in the modulation of TJ 
protein endocytosis and stability, but may be complicated by the simultaneous 
activation of additional signalling pathways. 
 
1.8.3 Tight junction regulation by Ras 
Early observations in MDCKII cells indicated that KRas-transformation caused cell 
multilayering and the diminished localisation of apical, but not basolateral plasma 
membrane proteins (Schoenenberger et al., 1991). Although ZO-1 appeared to localise 
correctly to the apex of the lateral membrane, Ras-transformed monolayers exhibited 
increased transepithelial resistance (Schoenenberger et al., 1991). More recent studies 
show that epithelial permeability is regulated by specific regulation of individual TJ 
components (Chen et al., 2000; Mullin et al., 2005). Ras-transformed MDCK cells 
exhibit a fibroblastic phenotype and express low levels of E-cadherin. In contrast, the 
TJ proteins claudin-1, occludin and ZO-1 are expressed but sequestered in the 
cytoplasm (Chen et al., 2000). These TJ proteins are rapidly recruited to areas of cell-
to-cell contact following the addition of an inhibitor of MEK, but not of PI3K. This 
membrane recruitment appears to be a post-translational process, as respective mRNA 
levels are unaffected by MEK inhibition. MEK inhibition causes a concomitant four-fold 
increase in TER and and increase in TJ strand formation onfirmed by electron 
microscopy. MEK inhibition increased both the tyrosine phosphorylation and half-lives 
of ZO-1 and occludin, but not of claudin-1, suggesting that MEK-dependent post-
translational modification of TJ proteins may influence TJ barrier formation. 
 
Another study carried out in LLC-PK1 cells, a low-resistance porcine renal epithelial 
cell line with similar characteristics to MDCKII cells, observed a similar increase in TER 





of approximately 40% following oncogenic KRasG12V expression (Mullin et al., 2005). 
This proceeded with the concurrent loss of claudin-2 protein and increased expression 
of claudin-1, -4 and -7 (Mullin et al., 2005). Interestingly Ras-transformation also 
increased the flux of mannitol tracers up to 10Kda, indicating increased leak pathway 
permeability (Mullin et al., 2005). Rather than reflecting a complete loss of epithelial 
integrity, the selective nature of the permeability changes suggests that they proceed 
through the modulation of individual TJ components that determine its specific 
properties (Mullin et al., 2005). Although these studies implicate the RAF/MEK/ERK 
pathway in TJ regulation, Ras will simultaneously activate additional signalling 
pathways. The exact contribution of the RAF/MEK/ERK pathway and the mechanisms 
through which it exerts its effects on TJ permeability remain unclear. 
 
1.8.4 Tight junction regulation by epidermal growth factor 
EGF regulates epithelial barrier properties in various tissues. In MDCKII cells, EGF 
treatment is associated with the transcriptional downregulation of claudin-2, 
upregulation of claudin-4 and a concurrent increase in TER. EGFR-mediated increases 
in TER have variously been reported to be blocked by independent inhibition of MEK 
(Ikari et al., 2011c; Singh and Harris, 2004), Src (García-Hernández et al., 2015), PKC 
(protein kinase C) (Singh and Harris, 2004), PI3K (phosphatidylinositol 3-kinase) 
(Singh et al., 2007), STAT3 (García-Hernández et al., 2015) or blocking antibodies 
against β1-integrin (Singh et al., 2007) or the accessory protein, CD9 (Singh et al., 
2007). 
 
Treatment of MDCKII cells with EGF causes the downregulation of claudin-2, at both 
the mRNA and protein levels and this is blocked by co-treatment with either U0126 or 
PD98059, small molecule inhibitors of MEK1/2, but not by inhibitors of PI3K, JNK or 
p38 MAP kinases (Ikari et al., 2011c). Furthermore, claudin-2 protein levels are 
decreased by CA-MEK, but not DN-MEK (Ikari et al., 2011c). This suggests that ERK 
activity alone is sufficient to drive the depletion of claudin-2 protein. Elsewhere, the 
EGF-mediated downregulation of claudin-2 was shown to be blocked by inhibitors of 
MEK, Src or the transcription factor STAT3 (García-Hernández et al., 2015). It is 
unclear from this study alone whether, MEK, Src and STAT3 function in a linear 
pathway downstream of EGFR activation. 
 
In addition to transcriptionally downregulating claudin-2, EGF was reported to increase 
its clathrin-dependent endocytosis and lysosomal degradation.  This conclusion was 
drawn as claudin-2 protein depletion could be blocked by clathrin siRNA, or 
monodansylcadaverine, an inhibitor of endocytosis (Ikari et al., 2011c). Furthermore, 





EGF treatment appeared to increase the association between claudin-2 and the 
clathrin adaptor, adaptin α. Treatment of MDCKII cells with EGF and chloroquine, an 
inhibitor of lysosomal degradation, resulted in the accumulation of claudin-2 in a late 
endosomal/lysosomal compartment. Although EGF increased the rate of claudin-2 
degradation when protein neosynthesis was blocked by cycloheximide, rates of 
internalisation and endocytic recycling were not actually measured. EGF also increases 
claudin-4 mRNA and protein expression in a MEK-dependent manner (Ikari et al., 
2009). This is recapitulated by the expression of CA-MEK and is dependent on the 
transcription factor Sp1. EGF-mediated increases in claudin-4 expression are also 
sensitive to inhibition of MEK, Src and STAT3, in a similar fashion to the 
downregulation of claudin-2 (García-Hernández et al., 2015).  
 
EGF treatment is associated with an increase in MDCKII TER, which is consistent with 
claudin-2 downregulation. However, this process is also associated with increased 
junctional localisation of the barrier-promoting claudins -1, -3 and -4 (Singh and Harris, 
2004). Although total claudin-1 protein levels are increased, translocation into the TJ 
still occurs in the presence of cycloheximide. In contrast, incorporation of claudin-3/-4 
into the TJ is largely dependent on protein neosynthesis (Singh and Harris, 2004). EGF 
has no effect on the expression level or localisation of ZO-1, occludin, E-cadherin or β-
catenin, suggesting that the effects are at least somewhat specific to claudins (Singh 
and Harris, 2004). The increase in TER is also blocked by inhibitors or EGFR 
(PD153035), MEK (PD98059) or PKC (staurosporine) (Singh and Harris, 2004). 
However, this study did not address the specific pathways responsible for the diverse 
effects on specific claudin species. 
 
Expression of a non-cleavable membrane-bound heparin-binding EGF-like growth 
factor (HB-EGF) had similar effects to exogenous EGF treatment on claudin-2 
expression and claudin-1/-3/-4 localisation (Singh et al., 2007). However, stable 
expression of a secretable HB-EGF led to MDCK dedifferentiation and transformation, 
exhibited by loss of cell-cell contact and complete loss of TER. This suggests that 
either the duration or magnitude of EGFR activation may influence the effects on 
MDCK barrier function. Alternatively, the mode of EGFR activation, i.e. juxtacrine as 
opposed to auto- or paracrine, may affect the TJ response (Singh et al., 2007). 
 
In intestinal Caco-2 cells, hydrogen peroxide drives TJ disruption through the tyrosine 
phosphorylation, threonine-dephosphorylation and cellular redistribution of occludin 
and ZO-1 from the TJ to the cytoplasm (Basuroy et al., 2006). This disruption can be 
prevented by the treatment with EGF, and this protection is dependent on MEK/ERK 





signalling. Phosphorylated ERK colocalised and coimmunoprecipitated with occludin, 
demonstrating an interaction between ERK and a TJ component. However, the 
conservation and potential consequences of this interaction in different tissues are 
unclear, especially as the permeability of intestinal and renal cells is differentially 
regulated by the RAF/MEK/ERK pathway 
 
1.8.5 Tight junction regulation by ouabain 
Ouabain, or g-strophanthin, is a cardiac glycoside that exhibits high toxicity due to 
inhibition of the basolateral Na+/K+ ATPase transporter. At high concentrations 
(>300nM), ouabain induces cell detachment through the internalisation of claudin-2, 
claudin-4, occludin and ZO-1 by an EGFR-Src-ERK1/2 signalling pathway. These 
proteins are differentially regulated at the protein and mRNA level and are also 
differentially sensitive to MEK inhibiton. Increased expression of occludin and claudin-4 
is MEK-dependent, as is the induced decrease in expression of ZO-1, but not claudin-2 
(Rincon-Heredia et al., 2014). These observations suggest that ouabain may engage 
multiple signalling pathways to modulate TJ protein expression. 
 
Ouabain is also thought to be produced at low concentrations by the human 
hippocampus and adrenal glands to function as a hormone, which regulates sodium 
homeostasis in the kidney (Larre et al., 2010). Low concentrations of ouabain (10nM), 
which do not affect Na+/K+ pumping, cell detachment or apoptosis, are sufficient to 
increase MDCK TER, which occurs concurrently with an increase in claudin-1, -2 and -
4 protein levels (Larre et al., 2010). This is at least partially due to increased levels of 
their respective mRNA transcripts (Larre et al., 2010). This increase in TER is blocked 
by inhibition of Src, but only partially by inhibition of MEK (Larre et al., 2010). Studies 
involving both EGF and ouabain implicate an EGFR-Src-ERK1/2 signalling axis in 
regulating the expression and localisation of individual claudin species. However, these 
effects appear to be differentially blocked by inhibitors of EGFR, Src and MEK. 
Furthermore, the duration, magnitude and mode of activation determine the specific 
changes for TJ protein expression. Therefore, the RAF/MEK/ERK signalling pathway is 
implicated in mediating the altered expression and distribution of various TJ proteins in 
a stimulus-dependent manner (Table 1.7) Although informative, these studies reinforce 
the need for specific tools and methods that allow the exact contribution of individual 
signalling pathways to be examined. 
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Table 1.7: Stimuli that activate the RAF/MEK/ERK pathway have differential effects on the 
expression and distribution of individual tight junction components. The RAF/MEK/ERK 
pathway is implicated in regulating the expression and distribution of TJ proteins downstream of 
various growth factor receptors and Ras. However, differential TJ regulation by these different 
stimuli suggests that there are important contributions from other signalling pathways. Specific 
activation of the RAF/MEK/ERK pathway using constitutively active RAF or MEK constructs 
indicate a role in transcriptional regulation of the TJ, but its specific role in post-translationally 
regulating TJ protein distribution and trafficking rates is not known.  (-) not affected, (↑) 
increased, (↓) decreased. Data obtained from (a) Lipschutz et al (2005), (b) Chen et al (2000), 
(c) Ikari et al (2011), (d) Ikari et al (2009), (e) Singh and Harris (2004), (f) Balkovetz et al (2004), 
(g) Mullin et al (2005), (h) Twiss et al (2013), (i) Hansen et al (2000) and (j) Doehn et al (2009). 
Summary data from MDCKII or (*)LLC-PK1 cells. Table 1.7 is presented on the previous page. 
 
1.9 Introduction summary 
 
 TJs are essential organising features of epithelia, regulating paracellular 
permeability, apicobasal polarity, intracellular signalling and cell migration.  
 
 Individual TJ proteins are diversely regulated by various stimuli at the 
transcriptional level, as well as through altered rates of internalisation and post-
endocytic trafficking to recycling or degradative pathways. 
 
 The exact contribution of different signalling pathways to TJ protein trafficking 
and function is poorly understood in both physiological and pathological 
settings. 
 
 The RAF/MEK/ERK pathway appears to regulate ionic homeostasis in the 
kidney and has been implicated in mediating TJ disruption in response to 
diverse stimuli, in inflammatory diseases and during tumourigenesis. 
 
 This is partially achieved through the transcriptional downregulation of claudin-
2, but post-transcriptional changes involving altered distribution and/or 
trafficking of claudins -1, -2, -3 and -4 have been reported in growth factor 
based studies. 
 
 The exact role that the RAF/MEK/ERK pathway plays in regulating these post-
translational changes is unclear. 
 
 The effects of RAF/MEK/ERK activity on the rates of TJ protein internalisation, 
degradation and recycling have not been determined. This may represent a 
novel regulatory mechanism that modulates TJ composition and epithelial 
permeability in health and disease. 
 






1.10 Aims and objectives 
The key aims of this thesis are to: 
 
1. Determine how specific activation of the RAF/MEK/ERK pathway influences the 
TJ and associated barrier properties. 
 
2. Assess RAF/MEK/ERK-mediated changes in TJ protein expression and 
localisation. 
 
3. Define how rates of TJ protein internalisation, degradation and recycling are 
specifically regulated by the RAF/MEK/ERK pathway. 
 
These aims will be achieved by completing following objectives:  
 
 Generate recombinant adenoviruses to efficiently express BRAFWT and 
BRAFV600E transgenes in MDCKII cells. 
 
 Characterise the downstream activation of MEK and ERK by immunoblot and 
high-content microscopy. 
 
 Evaluate epithelial barrier function by measuring transepithelial resistance in 
BRAFWT/V600E-expressing monolayers. 
 
 Determine the effects of specific RAF/MEK/ERK pathway activation on TJ 
protein level by immunoblot. 
 
 Assess the role of RAF/MEK/ERK activity on TJ protein localisation using 
confocal microscopy. 
 
 Measure rates of TJ protein internalisation, degradation and endocytic recycling 
using inducible-activity RAF:ER fusion proteins and surface-biotinylation based 
biochemical trafficking assays. 
















Chapter 2: Materials and Methods 
  






All general laboratory chemicals were of analytical grade and purchased from Sigma-
Aldrich (Poole, Dorset, UK) or Fisher Scientific (Loughborough, UK) unless otherwise 
stated. Treated tissue culture grade flasks and plates were purchased from Corning, 
(Arlington UK), unless otherwise stated. 
 
2.1.1 Buffers 
Phosphate-buffered saline (PBS) 
154mM NaCl, 12.5mM Na2HPO4.12H2O, pH7.2. 
 
PBS/CM 
154mM NaCl, 12.5mM Na2HPO4.12H2O, 0.9mM CaCl2, 0.33mM MgCl2, pH7.2. 
 
Tris-buffered saline (TBS) 
10mM Tris.Cl, pH7.4, 154mM NaCl. 
 
TBS-Tween 
10mM Tris.Cl, pH7.4, 154mM NaCl, 0.1% Tween-20. 
 
TBS/C (for dilution of 2-mercaptoethanesulphonate) 
50mM Tris.Cl, pH8.6, 100mM NaCl, 2.5mM CaCl2. 
 
Lysogeny broth (LB) 
1% (w/v) Bacto-tryptone, 0.5% (w/v) Yeast extract, 1% (w/v) NaCl, pH7.5. 
 
Agar plates (with ampicillin) 
1% (w/v) Bacto-tryptone, 0.5% (w/v) Yeast extract, 1% (w/v) NaCl, 1.5% (w/v) 
Agar, 50µg/ml ampicillin, pH7.5. 
 
5X Tris-Borate-EDTA (TBE) buffer 
1.1M Tris.Cl, pH8.3, 900mM Borate, 25mM EDTA. 
Diluted 1/10 in ddH2O to a working 0.5X solution. 
 
2X Hank’s buffered salt solution (HBSS) 
280mM NaCl, 10mM KCl, 1.5mM Na2HPO4.12H2O, 12mM D+glucose, 50mM 4-
(2-hydroxyethyl)-1-piperazineethanesulphonic acid  (HEPES). 
 
  





Standard lysis buffer 
10mM Tris.Cl, pH7.6, 5mM EDTA, 1mM EGTA, 50mM NaCl, 30mM sodium 
pyrophosphate, 50mM NaF, 1mM DTT, 100µM sodium orthovanadate, 1% (v/v) 
Triton X-100, SigmaFAST protease inhibitors (Sigma-Aldrich). 
 
Non-reducing lysis buffer for biotinylation assays and neutravidin pulldowns 
50mM Tris.Cl, pH 8.0, 1.25% (v/v) Triton X-100, 0.25% (w/v) SDS, 150mM 
NaCl, 5mM EDTA, 5mg/ml iodoacetamide, 10ug/ml 4-
Amidinophenylmethanesulphonyl Fluoride Hydrochloride (APMSF). 
 
Neutravidin bead wash buffer 
50mM Tris.Cl, pH 8.0, 0.5% (v/v) Triton X-100, 0.1% (w/v) SDS, 150mM NaCl, 
5mM EDTA. 
 
Reducing sample buffer 
30mM Tris.Cl, pH6.8, 1% SDS, 5% glycerol, 100mM DTT, 0.05% bromophenol 
blue. 
 
Resolving gel buffer 
1.5M Tris.Cl, pH8.8. 
 
Stacking gel buffer 
0.5M Tris.Cl, pH6.8 
 
SDS-PAGE running buffer 
25mM Tris.Cl, pH6.3, 0.2M glycine, 0.1% (w/v) SDS. 
 
Semi-dry transfer buffer 
25mM Tris.Cl, 0.2M glycine. 
 
Membrane blocking buffer 
5% milk powder (w/v) in TBS-Tween. 
 
Enhanced chemiluminescence reagent 
Solution A – 100mM glycine in NaOH, pH10.0, 0.4mM luminol, 8mM 4-
iodophenol. 
Solution B – 0.12% (w/w) hydrogen peroxide in ddH2O. 
Solutions A and B were mixed in 1:1 ratio immediately prior to use. 






Antibody suppliers, product information and dilutions for different applications are 
summarised in Table 2.1. For immunoblotting, primary and secondary antibodies were 
diluted in TBS-Tween. For immunostaining, primary and secondary antibodies were 
diluted in PBS containing 2% (v/v) normal goat serum (NGS) (Invitrogen, Paisley, UK). 
 
Antibody (Clone) Species Supplier Code Dilution MW (kDa) 
α-claudin-1 Rabbit pAb Thermo Fisher 59-9000 




Mouse mAb Thermo Fisher 32-5600 
WB - 1:2000 
~22 - 23  
 (12H12) IF 1:200 
α-claudin-4 
Mouse mAb Thermo Fisher 32-9400 
WB - 1:2000 
~22 
(3E2C1) IF 1:50 
α-ZO-1 
Mouse mAb Thermo Fisher 33-1900 
WB - 1:2000 
195 
 (1A12) IF 1:50 
α-occludin 
Mouse mAb Thermo Fisher 33-1500 
WB - 1:2000 
65 
(OC-3F10) IF 1:100 
α-E-cadherin 
Mouse mAb Thermo Fisher 33-4000 
WB - 1:2000 
120 
(4AC7) IF 1:100 
α-ppERK1/2 
Mouse mAb Sigma-Aldrich M9292 
WB - 1:2000 ERK1 44 






WB - 1:2000 ERK1 44 

























WB - 1:2000 0.2 






WB - 1:1000 1.1 




Mouse mAb Thermo Fisher 13-6800 WB - 1:1000 95 
α-mouse Alexa® 
Fluor 546 
Goat pAb Thermo Fisher A-11030 IF - 1:500 - 
α-rabbit Alexa®     
Fluor 647 
Goat pAb Thermo Fisher A-21245 IF - 1:500 - 
α-mouse-HRP Goat pAb Sigma-Aldrich A4416 WB - 1:5000 - 
α-rabbit-HRP Goat pAb Pierce 31210 WB - 1:5000 - 
Table 2.1: Antibodies used for immunostaining and immunoblotting. Antibody clones are 
provided where available. Dilutions are of original supplied stocks in appropriate buffer. (WB) 
Western blot, (IF) immunofluorescence, (pAb) polyclonal antibody, (mAb) monoclonal antibody, 
(HRP) horseradish peroxidase Antibodies were sourced from Cell Signaling Technology 
(Hitchin, UK), Sigma-Aldrich (Poole, Dorset, UK), Fisher Scientific (Loughborough, UK) or 
Pierce (Loughborough, UK). 
  






2.2.1 Cell culture 
MDCKII cells (Madin-Darby canine kidney cells #00062107, European Collection of 
Cell Cultures, Salisbury, UK) were maintained at 37°C and 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM) without phenol red (Lonza, Slough, UK) 
supplemented with 10% (v/v) fetal bovine serum (FBS) (Invitrogen) and 2mM L-
glutamine (Invitrogen). Cells were passaged twice weekly at a dilution of 1/10 and 
maintained in culture for a maximum of 15 passages (approximately 2 months). Cells 
were washed once in PBS and once with trypsin-EDTA (Invitrogen), prior to incubation 
in fresh trypsin-EDTA for 10 minutes at 37°C, 5% CO2. Trypsin was neutralised by 
resuspending cells in DMEM containing serum and pelleting at 200 x g for 2 minutes. 
The pellet was resuspended in 10ml of complete DMEM and passaged at a 1/10 
dilution. For freezing MDCKII cell stocks, one T75 tissue culture flask was trypsinised 
and pelleted as outlined above. The resulting pellet was resuspended in 2ml of 10% 
(v/v) DMSO in FBS and split into four 0.5ml aliquots in sterile cryogenic storage vials 
(Invitrogen). Vials were frozen at a controlled rate by placing in an isopropanol 
chamber at -80°C overnight before transferring to liquid nitrogen. To thaw cells, a 
single vial was thawed at 37°C, resuspended in 20ml of complete DMEM in a T75 
tissue culture flask and incubated at 37°C overnight. Media was refreshed after 24 
hours to remove excess cell debris and DMSO. 
 
Prior to plating cells for experiments, a sample of resuspended cells was 
counterstained with trypan blue to assess viability. Cells were counted using a 
haemocytometer and diluted to a plating concentration of 2x105cells/ml. MDCKII cells 
were grown until fully confluent, as assessed by stable TER readings, for a minimum of 
8 days, with media changes every 2 days prior to experimental use. Cells were 
transduced and maintained in serum- and phenol red-free DMEM to minimise 
ΔCRAF:ER activation in the absence of hormone. ΔCRAF:ER activity was induced 
through the addition of 1µM 4-hydroxytamoxifen (4HT) (Sigma-Aldrich) to the culture 
medium. 
 
HEK293 cells (a kind gift from Professor James Uney, University of Bristol, UK) were 
maintained between passages 30 and 40 at 37°C, 5% CO2 in DMEM (Invitrogen) 
supplemented with 10% (v/v) FBS. Cells were passaged twice weekly by briefly 
washing in PBS and incubating with trypsin-EDTA for 5 minutes at 37°C, 5% CO2. Cells 
were resuspended in 12ml of complete DMEM and passaged at a dilution of 1/12. 
HEK293 cells were frozen for storage and thawed as outlined above. All cell lines were 





routinely tested for mycoplasma using the MycoAlert detection kit (Lonza), according to 
the manufacturer’s instructions. 
 
2.2.2 Calcium phosphate transfection 
HEK293 cells were transfected using a calcium phosphate based method for 
generating recombinant adenovirus. HEK293 cells were plated at a density of 2x105 
cells/ml in a T25 tissue culture flask and incubated at 37°C, 5% CO2 for two days, until 
50 – 80% confluent. A total of 6µg of plasmid DNA was diluted to a final volume of 
140µl in DNase/RNase-free ddH2O. 19.8µl of 2M CaCl2 was added dropwise to the 
DNA solution. 159.8µl of 2x HBSS was added dropwise to form a precipitate. The 
solution was incubated at room temperature for 20 minutes, mixed thoroughly by 
pipetting and added dropwise to the cell culture medium. Cells were incubated at 37°C, 
5% CO2 for 4 hours. The media was removed and cells were rinsed with PBS. Cells 




MDCKII cells were plated at a density of 2x105cells/ml on 8-well µ-slides (Ibidi, 
Glasgow, UK). 24 hours after adenoviral transduction, cells were treated as described. 
Cells were fixed and permeabilised in ice-cold methanol at -20°C for 10 minutes and 
rinsed three times in PBS. Non-specific binding sites were blocked using 10% (v/v) 
normal goat serum (NGS) in PBS for 30 minutes. Primary antibodies were diluted as 
previously described in 2% (v/v) NGS/PBS. Appropriate species-specific fluorophore-
conjugated secondary antibodies were also diluted in 2% (v/v) NGS/PBS. Primary 
antibody incubations were performed overnight at 4°C and secondary antibody 
incubations at room temperature for 2 hours. Cells were washed five times in PBS 
between antibody incubations. For phalloidin staining of the actin cytoskeleton, 1µg/ml 
TRITC-phalloidin/PBS (Invitrogen) was added to cells for 40 minutes at room 
temperature. Cells were washed three times with PBS prior to nuclear counterstaining. 
Nuclei were counterstained with 300nM DAPI in PBS and stored at 4°C until required. 
Slides were imaged using a Zeiss LSM510META laser-scanning confocal microscope 
(Plan-ApoChromat 63x/1.4 Oil Phase objective). Confocal images are presented as 
overhead composite projections of multiple 1µM Z-slices through the MDCKII 
monolayer, accompanied by an orthogonal cross-section view. All images were 
processed using ImageJ software (National Institutes of Health). Images from different 
experimental conditions were processed in an identical fashion. Presented images are 
representative of three independent experiments.  
 





High-content microscopy and analysis 
MDCKII cells were plated at 2x105 cells/ml in 96-well plates. Cells were fixed and 
permeabilised with methanol and stained as outlined above. Plates were imaged using 
an INCell Analyzer 2000 (GE Healthcare, Buckinghamshire, UK). Images were 
analysed using INCell Developer Toolbox software. For claudin expression analysis, 
the average immunofluorescence intensity was measured across each image and 
therefore provides population averages, rather than single cell data. Data are 
normalised to the average intensity at t=0 and presented as mean values ±s.e.m. from 
three biological repeats, each consisting of 8 fields of view from wells treated in 
duplicate.  
 
For single cell measurements of ERK1/2 and ppERK1/2 immunostaining intensity, 
images were segmented based on the nuclear DAPI stain. The imaged was then 
“declumped” to ensure that each nuclear object referred to a single cell. This nuclear 
mask was dilated to generate a mask encompassing the cytoplasm and nucleus. A 
cytoplasmic mask was generated by subtracting the initial nuclear mask from the whole 
cell mask. Individual nuclear, cell and cytoplasmic targets were linked based on 
overlap. Integrated (Intensity x Area) immunostaining intensity was then measured in 
each compartment. Nuclear:cytoplasmic ratios were calculated by dividing the 
integrated immunostaining intensity in the nuclear objects by those measured in the 
cytoplasmic objects. For data presentation, cell values were divided into 
subpopulations based on their level of transgene expression, which was determined by 
cytoplasmic GFP fluorescence intensity, unless otherwise stated. A schematic of the 
segmentation strategy is provided in Section 3.3.1 (Figure 3.2). 
 
2.2.4 Protein biochemistry 
Endocytosis, recycling and degradation biotin assays 
Biotinylation assays to assess endocytosis, recycling and degradation of integral cell-
surface proteins were performed as previously described (Dukes et al., 2011b; 
Nishimura and Sasaki, 2008). A schematic of the biotinylation assay is provided in 
Section 1.5.3 (Figure 1.8). 
 
Confluent MDCKII cells were rinsed in ice-cold PBS/CM to block membrane trafficking. 
Cells were surface-labelled on ice for 30 minutes with 1ml of 0.25mg/ml EZ-link sulpho-
NHS-SS-biotin (Pierce, Loughborough, UK), a membrane-impermeable and cleavable 
biotin moiety that forms peptide bonds with accessible lysine side chains. EZ-link 
sulpho-NHS-SS-biotin was diluted in ice-cold PBS/CM. Free biotin was quenched using 
50mM NH4Cl in PBS/CM for 15 minutes, followed by three PBS/CM washes to remove 





residual NH4Cl. For endocytosis assays, prewarmed DMEM was added and cells were 
returned to 37°C for 1 hour. Cells were transferred to ice and rinsed with ice-cold 
PBS/CM to halt membrane trafficking. Remaining surface biotin was removed by four 
10 minute washes in 2-mercaptoethanesulphonate (MESNA) (Sigma-Aldrich) in 
TBS/CM. Internalised biotinylated proteins were protected from the MESNA strip by the 
intact plasma membrane. Free –SH groups were quenched by three 5 minute 
incubations in ice-cold 0.5mg/ml iodoacetamide in PBS/CM. 
 
For the recycling assay, MESNA-stripped cells were returned to 37°C for 20 minutes. 
Biotinylated proteins that had been recycled to the cell surface were again prone to 
surface-stripping. Cells were lysed both before a second MESNA strip, to control for 
degradation of protein during this incubation, and after to assess the relative amount of 
biotinylated cargo that had been returned to the cell surface. The amount of recycled 
cargo is indicated by the decrease in pulldown signal between the “degradation” and 
“recycling” stages of the assay. Cells were lysed in 800µl of non-reducing lysis buffer, 
incubated for 20 minutes on ice with regular vortexing, briefly sonicated and centrifuged 
at 16,000 x g to remove large cell debris. 100µl of the lysate was kept to assess total 
protein levels, while the remaining lysate was used for neutravidin pulldown of 
biotinylated protein. 30µl of neutravidin beads (Pierce) were added to the remaining 
lysate and incubated overnight with constant rotation at 4°C.  
 
Neutravidin beads were collected by centrifugation at 1000 x g for 3 minutes. Bead 
pellets were washed 3 times in neutravidin bead wash buffer (see Section 2.2.1) and 
neutravidin-bound protein was eluted by heating to 95°C for 10 minutes in 150µl 
reducing sample buffer (see Section 2.2.1). Neutravidin beads were separated by 
centrifugation at 1000 x g for 3 minutes. The eluted protein and whole cell lysate 
samples were subjected to SDS-PAGE and immunoblotting for the protein(s) of 
interest. For biotinylation assay experiments, immunoblots are presented for both 
neutravidin pulldowns and whole cell lysate inputs. Quantified band intensity data are 
presented for either pulldown or lysate alone, or pulldown/lysate, where pulldown 
values were normalised to lysate values, as indicated in the text. All immunoblots are 
representative of three biological repeats unless otherwise stated.  
 
A “no biotin” control ensured that the neutravidin pulldown was specific for biotinylated 
protein. The “surface label” control represents a sample that has been lysed 
immediately after surface-labelling, without surface-stripping. This indicates the 
maximum amount of surface protein initially biotinylated at the cell surface. A “surface 
strip” control involved the surface-stripping of biotin immediately after the initial label. 





This revealed the strip efficiency, which was consistent for each protein studied but 
varied between 80 – 95%, depending on the protein of interest. 
 
Cumulative degradation and internalisation assays 
For biotinylation-based degradation assays, the endocytosis stage of the biotinylation 
assay was performed, but the duration of the 37°C incubation was varied as described. 
A similar protocol was used to measure cumulative degradation of surface-biotinylated 
claudins. In this case, cells were not surface-stripped following incubation, so any 
decrease in the level of biotinylated protein can be attributed to protein degradation. 
For cycloheximide chase assays, cells were treated with 30µM cycloheximide (Sigma-
Aldrich) in the presence or absence of 1µM 4HT. Cell lysates were subjected to SDS-
PAGE and claudin levels were determined by immunoblot. Band intensities were 
quantified using ImageJ and are normalised to either t=0 or the surface label control as 
described. Data are presented as mean values ±s.e.m. from three biological repeats. 
Data were analysed using a two-way ANOVA with Bonferroni post-test to compare 
relative levels in control and 4HT-treated conditions at each time point. 
 
Protein assays 
The bicinchoninic acid (BCA) protein assay (Pierce) was used to determine lysate 
protein concentrations prior to neutravidin pulldown and/or SDS-PAGE. A standard 
curve was generated using 0 – 5mg/ml bovine serum albumin (BSA) diluted in the 
appropriate lysis buffer. A BCA working solution was prepared by mixing Reagent A 
and B together in a ratio of 50:1. 200µl of working solution was added to 10µl of each 
lysate or standard in each well of clear-bottomed 96-well plates (Corning). The plate 
was incubated at 37°C for 30 minutes and absorbance readings at 565nm were taken 
using a Spectra Rainbow microplate spectrophotometer (Thermo Fisher). Protein 
concentrations were determined from the BSA standard curve in Microsoft Excel. 




Proteins were separated according to molecular weight by sodium dodecyl sulphate – 
polyacrylamide gel electrophoresis (SDS-PAGE) using the Laemmli discontinuous 
buffer system (Laemmli, 1970) and the Mini-PROTEAN® Tetra Cell Electrophoresis 
Chamber (BioRad, Hemel Hempstead, UK). 1mm thick mini-gels were prepared with 
resolving and stacking gels of different compositions, depending on the molecular 
weight of the markers being assessed (Table 2.2). Low molecular weight claudin 
proteins (~20kDa) were effectively separated on 15% gels, while others markers were 





generally resolved on 10 – 12.5% gels. Resolving gels were topped with a lower 
percentage stacking gel (pH6.8). Gel recipes are presented in Tables 2.2 and 2.3. Cell 
lysates were solubilised by heating to 95°C in reducing sample buffer for 10 minutes. 
10µl of each sample was loaded onto gels alongside 5µl of Novex Sharp Pre-stained 
Protein Standards (3.5 – 160kDa) (Invitrogen). Electrophoresis was carried out at a 




Volume required for 2X 1mm gels 
10% 12.5% 15% 
1.5M Tris.Cl, pH8.8 2.5ml 2.5ml 2.5ml 
30% (w/v) 37:1 acrylamide:bisacrylamide 3.3ml 4.2ml 5.0ml 
ddH2O 4.0ml 3.1ml 2.3ml 
10% SDS 200µl 200µl 200µl 
10% APS 67µl 67µl 67µl 
TEMED 4µl 4µl 4µl 
 
Table 2.2 Recipes for SDS-PAGE resolving gels. Different percentage gels were used 





Reagent Volume required for 2X 1mm gels 
0.5M Tris.Cl, pH6.8 1.26ml 
30% (w/v) 37:1 acrylamide:bisacrylamide 0.8ml 
ddH2O 2.9ml 
10% SDS 100µl 
10% ammonium persulphate 33µl 
N,N,N',N-tetramethylethylenediamine (TEMED) 5µl 
 
Table 2.3: Recipe for SDS-PAGE stacking gels. Volumes provided are sufficient for two mini-
gels. 
 
Semi-dry protein transfer 
PVDF membranes (Millipore) were cut to the size of each SDS-PAGE gel, pre-soaked 
in methanol for 1 minute and equilibrated in semi-dry transfer buffer for 10 minutes. 
The PVDF membrane and SDS-PAGE gel were sandwiched between 3 layers of 
transfer buffer-saturated filter paper in the Trans-Blot SD Semi-Dry Transfer Cell 
(Biorad). Air bubbles were removed by rolling each layer with 10ml pipette. Semi-dry 
transfer was carried out at a constant voltage of 15V for 30 minutes. 
 
Immunoblotting 
PVDF membranes were blocked in membrane blocking buffer for 1 hour at room 
temperature. Excess membrane blocking buffer was removed by rinsing in TBS-





Tween. Primary antibodies were diluted in TBS-Tween as described in Table 2.1. 
Membranes were incubated in primary antibody overnight at 4°C. Membranes were 
subjected to three 5 minute washes in TBS-Tween and incubated in the appropriate 
species-specific horseradish-peroxidase (HRP)-conjugated secondary antibody, diluted 
in TBS-Tween, for 2 hours at room temperature. Membranes were washed in TBS-
Tween as before and twice quickly with ddH2O to remove residual Tween. Membranes 
were incubated for 1 minute in ECL reagent. Images were developed using the Fusion-
SL Chemiluminescence System (Vilber Lourmat, Marne-la-Vallée, France). Band 
intensities were quantified using ImageJ. The bands detected by each antibody, and 
their approximate molecular weight in comparison to molecular weight markers, are 
described in results chapters 1 – 3 upon their first use. All immunoblots are 
representative of three biological repeats unless otherwise stated.  
 
2.2.5 Transepithelial resistance (TER) measurements 
MDCKII cells were grown on transwell polyethylene terephthalate (PET) filters with a 
pore size of 0.4µm (Millipore, Nottingham, UK). Filters were placed in a 24-well plate, 
with 1ml of media in the basolateral compartment, and 200µl of a 2x105 MDCKII cell 
suspension added to the apical compartment. Cells were grown past confluence for 8 
days, with media changes every 2 days, until resistance measurements had plateaued. 
Resistance measurements were taken using an EVOMX epithelial voltohmmeter and 
Endohm-6 chamber (World Precision Instruments, Hitchin, UK). Resistance values 
were normalised by subtracting the raw resistance value of a blank filter from those of 
each experimental sample. TER was calculated by multiplying the blank-corrected 
resistance reading by the filter surface area (0.33cm2). TER readings were then 
normalised to the average TER reading at t=0 across all repeats. Relative TER 
readings are presented as mean values ±s.e.m. from three independent experiments. 
Data were analysed using a repeated measures two-way ANOVA with Bonferroni post-
test, comparing replicate means against the control treatment at each time point. 
 
2.2.6 Molecular biology 
Restriction digests 
Restriction enzymes were used to digest DNA plasmids, both for subcloning and 
analytical DNA gels. Restriction enzymes used are presented in Table 2.4. Digests 
were performed according to the manufacturers’ instructions. Analytical digests were 
performed for 1 hour at 37°C, while digests performed for the purpose of subcloning 
were performed overnight at 37°C to achieve more complete digestion. 
  





Restriction enzyme Supplier Product Code Restriction Site 
AvrII Fermentas FD1564 C^CTAGG 
BamHI Fermentas FD0054 G^GATCC 
Kpn2I (BspEI) Fermentas FD0534 T^CCGGA 
KpnI Fermentas FD0524 GGTAC^C 
NotI New England Biolabs RO547 TTAAT^TAA 
PacI Fermentas FD1253 A^CTAGT 
SpeI Fermentas FD0694 C^TCGAG 
XhoI Fermentas FD0593 GC^GGCCGC 
Table 2.4: Restriction enzymes used for DNA digestion. The relevant restriction sites and 
supplier information for restriction enzymes used in construct generation and cloning. 
Restriction enzymes were sourced from New England Biolabs (Hitchin, UK) or Fermentas 
Thermo Scientific (Loughborough, UK). 
 
DNA agarose gel electrophoresis 
PCR products or digested DNA samples were combined with bromophenol blue 
loading buffer and loaded onto 0.6 – 1 % (w/v) agarose TBE gels containing SYBR® 
Safe DNA Gel Stain (Thermo Fisher) alongside 5µl of 1kB DNA Ladder (Promega, 
Southampton, UK). DNA gels were run at approximately 10V/cm of gel until the gel 
front approached the end of the gel. DNA was visualised using a non-UV Dark Reader 
Transilluminator (Clare Chemical Research, CO, US). Where necessary, gel extraction 
was performed using the Wizard SV Gel and PCR Clean-Up System (Promega) 
according to the manufacturer’s instructions. 
 
Transformation of competent E.coli 
5-alpha competent E. coli (High Efficiency) cells (New England Biolabs) were thawed 
on ice and dispensed into 25µl aliquots. 2.5µl of plasmid solution was added to each 
aliquot and incubated on ice for 30 minutes. Negative “no DNA” and positive pUC19 
vector control transformations were included according to the manufacturer’s 
instructions. Samples were heat-shocked at 42°C for 30s and placed on ice for 2 
minutes. 250µl of prewarmed SOC medium (New England Biolabs) was added and 
samples were incubated at 37°C for 1 hour with vigorous shaking. Bacteria were 
pelleted by brief centrifugation at 10,000 x g and resuspended in 100µl SOC medium. 
The bacterial solution was then spread onto LB agar plates containing 50µg/ml 
ampicillin. Spread plates were incubated at 37°C overnight to allow colony formation. 
 
Bacterial culture 
Successful transformation was indicated by successful colony formation of pUC19 
positive control, vector-transformed samples. Colonies corresponding to the desired 
plasmid product were expanded by picking a single colony with a pipette tip and adding 





to prewarmed LB containing 50µg/ml ampicillin (5ml for miniprep, and 250ml for 
maxiprep cultures). Cultures were grown overnight at 37°C with vigorous shaking. 
 
Plasmid purification 
Plasmids were purified from overnight cultures using either the Wizard Plus SV 
Minipreps DNA Purification System (Promega) or the GenElute™ HP Maxiprep Kit 
(Sigma-Aldrich) according to the manufacturers’ instructions. Prior to adenoviral 
generation, pacAd5 9.2 – 110 sub360 backbone and pAd5CMV K-NpA shuttle vectors 
were purified by ethanol precipitation. 0.1 volumes of 3M sodium acetate solution and 
0.7 volumes of isopropanol were added to each plasmid preparation. Samples were 
mixed by inversion and centrifuged at 16,000 x g for 30 minutes. The supernatant was 
decanted with a fine glass pipette and the DNA pellet was rinsed with 70% ethanol and 
centrifuged as before for >10 minutes. The supernatant was decanted as before and 
the pellet was air-dried to remove residual ethanol. The DNA pellet was resuspended in 
100µl of DNase/RNase-free ddH2O and stored at -20°C. 
 
Adenoviral shuttle vector production 
In order to generate recombinant adenoviruses, desired transgenes were initially 
subcloned into the pAd5CMV K-NpA adenoviral shuttle vector (a kind gift from Beverly 
Davidson, University of Iowa, IA). Plasmid maps and analytical digests are presented in 
the Appendix (Figures A1 – A8). Successful subcloning was confirmed by sequencing 
provided by Source Biosciences (Nottingham, UK). 
 
pAd5CMV GFP-myc-BRAFWT and pAd5CMV GFP-myc-BRAFV600E 
pJET1.2 GFP-myc-BRAFWT and pJET1.2 GFP-myc-BRAFV600E (kind gifts from 
Professor Catrin Pritchard, University of Leicester, UK) were digested with SpeI and 
NotI and cloned into the multiple cloning site of pAd5CMV K-NpA. The SpeI/NotI-
digested pAd5CMV K-NpA vector was treated with Antarctic Phosphatase (New 
England Biolabs) according to the manufacturer’s instructions to remove 5’ phosphates 
and minimise recircularisation by self-ligation. Antarctic Phosphatase was heat 
inactivated at 70°C for 5 minutes. Digested vectors and inserts were ligated using T4 
DNA ligase (Promega) according to the manufacturer’s instructions. A “no insert” 
reaction was included to control for the efficiency of target vector digestion and self-
ligation. A vector:insert molar ratio of 1:3 was used to optimise ligation efficiency, and 
was calculated using the following equation: 
  







                     
                  
                  
                    
 
 
Ligation reactions were used to transform competent E. coli and prepare spread plates 
as previously described. Successful ligation was indicated by colony growth on the LB 
plates containing ampicillin – circularisation due to successful ligation permitted 
expression of the AmpR cassette, allowing colony growth under ampicillin-restricted 
conditions. 
 
pAd5CMV GFP-myc-BRAFWT:ERT2 and pAd5CMV GFP-mycBRAFV600E:ERT2 
pJET1.2 BRAFWT:ERT2 and pJET1.2 BRAFV600E:ERT2 (kind gifts from Dr. Martin 
McMahon, UCSC, CA, USA) were subcloned into the existing pAd5CMV GFP-myc-
BRAF constructs using a BspEI/NotI digest. These constructs retained the GFP and 
myc epitope tags and 5’ end of the existing BRAF constructs. The C-terminal was 




pCMVNeoMyc1ΔRaf-1ER* (a kind gift from Dr. Simon Cook, Babraham Institute, UK) 
was digested with BamHI and subcloned into BamHI-digested pAd5CMVeGFP 
(provided by Dr. Jim Caunt and Dr. Paul Whitley). 
 
pAd5CMVmycΔCRAF:ER and pAd5CMVHAΔCRAF:ER 
Myc- and HA-tagged versions of ΔCRAF:ER were generated from the parent 
pCMVNeoMyc1ΔRaf-1ER* vector using the polymerase chain reaction (PCR) with 
primers designed to incorporate the epitope tags, as well as terminal SpeI and NotI 
restriction sites (Table 2.5). PCR was carried out using Phusion® High-Fidelity DNA 
Polymerase (New England Biolabs) and Techne Genius PCR Thermal Cycler. PCR 
conditions are presented in Tables 2.6 and 2.7. Resulting PCR products were digested 
with SpeI and NotI and ligated into SpeI/NotI-digested pAd5CMV GFP-myc-BRAFWT. 
  






















Table 2.5: Primers used for cloning. Primer sequences used in the generation of 
pAd5CMVmycΔCRAF:ER and pAd5CMVHAΔCRAF:ER. Restriction sites are highlighted in 
bold. Myc and HA epitope tag sequences are underlined. Primers were sourced from Invitrogen. 
 
 
Reagent Stock Concentration Final concentration Volume (µl) 
5x HiFi buffer 5X 1X 5 
Forward primer 10µM 0.3µM 0.75 
Reverse primer 10µM 0.3µM 0.75 
dNTPs 10mM 0.3mM each 0.75 
Template DNA 
(pCMVNeoMyc1ΔRaf-1:ER*) 
10ng/µl 10 - 100ng 1 - 10 
ddH2O N/A N/A 16.25 
HiFi DNA polymerase 1U/µl 1U 0.5 
Total N/A N/A 25 
Table 2.6: PCR reaction setup. PCR reactions used in the generation of mycΔCRAF:ER and 
HAΔCRAF:ER. Reaction conditions are summarised in Table 2.7. 
 
 
Cycles Stages Temperature (°C) Time 
1 Initial denaturation 95 3 minutes 
30 
Denaturation 98 20 seconds 
Annealing 67 15 seconds 
Extension 72 2 minutes (15 - 60seconds/kb) 
1 Final extension 72 5 minutes 
∞ Hold 10 Hold 
Table 2.7: PCR reaction conditions. PCR cycles used in the generation of mycΔCRAF:ER 
and HAΔCRAF:ER. An elongation time of 2 minutes was used for the predicted PCR product of 
~2kb. 





Generation of recombinant adenovirus 
Recombinant adenoviruses were generated and purified to a high titre using a RapAd 
system developed by the University of Iowa Gene Transfer Vector Core (Anderson et 
al., 2000). The desired transgene is initially subcloned into the pAd5 K-NpA shuttle 
vector, which is cotransfected with the pacAd5 9.2 – 100 sub360 backbone vector into 
a HEK293 helper cell line. Homologous recombination of PacI-digested vectors 
generates a continuous sequence for viral particle production. However, the pacAd5 
9.2 – 100 sub360 backbone vector is devoid of packaging signals and the E1 gene, 
which encodes an ATP-dependent helicase that is required for DNA unwinding and 
polymerase recruitment. The generated recombinant adenovirus is therefore 
replication-deficient and requires endogenous E1 expression in the host cell line to 
replicate itself. E1-expressing HEK293 cells are therefore a suitable helper cell line for 
adenovirus production. The adenoviral-mediated delivery of genetic information to 
HEK293 cells initiates an infectious cycle. Genetic material is therefore delivered by 
adenoviral “infection”. In contrast, the generated adenoviruses cannot replicate in E1-
deficient MDCKII cells. Therefore, transgenes are transiently expressed in MDCKII 
cells following adenoviral “transduction”. 
 
Individual shuttle vectors and the pacAd5 9.2 – 100 sub360 backbone vector were 
digested with PacI (New England Biolabs, Hitchin, UK), mixed and cotransfected into 
HEK293 cells by calcium phosphate transfection (4.5µg of pacAd5 9.2 – 100 sub360 
backbone vector combined with 1.5µg of pAd5 shuttle vector). Transfected cells were 
incubated at 37°C to allow recombination and for a visible cytopathic effect to become 
evident. Cytopathic plaques were evident by localised areas of cell death with rounded 
cells at the periphery (Figure 2.A and B). In the case of GFP-tagged transgenes, high 
fluorescence levels were visible at the plaque periphery (Figure 2A and B). Lysates 
were collected and used for further virus bulking. 10x T175 tissue culture flasks of 
HEK293 cells were infected and incubated at 37°C, 5% CO2 for 1 – 3 days until cells 
easily detached from the flask surface. Cells were carefully collected and pelleted at 
200g for 10 minutes. The cell pellet was resuspended in 3ml of 100mM Tris.Cl, pH7.5, 
snap-frozen in liquid nitrogen and stored at -80°C. Cells were lysed by three freeze-
thaw cycles. Cell debris was removed by centrifugation at 1500 x g for 10 minutes. The 
viral supernatant was combined with 0.6 volumes of CsCl-saturated 100mM Tris.Cl, 
pH7.5 and transferred to an ultracentrifuge tube (Beckman Coulter, High Wycombe, 
UK). The supernatant was topped up with a solution of 1 volume 100mM Tris.Cl:0.6 
volumes CsCl-saturated 100mM Tris.Cl. The tubes were heat-sealed and subjected to 
ultracentrifugation at 65000rpm in a VTi65 rotor (Beckman Coulter) for 6 – 8 hours. The 
tubes were depressurised by inserting 3 needles into the neck of each tube. The white 





band of adenovirus particles (Figure 2.1C) was removed using a 21G needle and 
syringe and added to a fresh ultracentrifuge tube, which was filled with a solution of 1 
volume 100mM Tris.Cl:0.6 volumes CsCl-saturated 100mM Tris.Cl. Samples were 
ultracentrifuged as before for 12 hours. The adenoviral band was removed and inserted 
into a 10kDa cut-off Slide-A-Lyzer™ dialysis cassette (Pierce). To remove residual 
CsCl, the purified adenovirus was dialysed in 1L of 3% (w/v) sucrose in PBS for 3 
hours, with hourly changes of dialysis solution. The virus was removed from the 
dialysis cassette, snap-frozen in single-use 20µl aliquots and stored at -80°C. All 
adenoviral waste was sterilised in Virkon (Fisher Scientific). 
 
 
Figure 2.1: Generation and purification of recombinant adenovirus. (A) HEK293 cells 10 
days after cotransfection with PacI-digested pacAd5 9.2 – 100 sub360 backbone and 
pAd5CMVeGFPΔCRAF:ER shuttle vectors. Cells maintain low levels of fluorescence due to 
expression of eGFPΔCRAF:ER from the shuttle vector. (B) Following homologous 
recombination between the backbone and shuttle vector, cell lysis causes the formation of viral 
plaques, which appear as areas of localised cell death with rounded cells expressing high levels 
of transgene at the periphery. Scale bar = 200µm. (C) CsCl-gradient ultracentrifugation 
generates a distinct adenoviral band at the interface between two CsCl solutions (white 
arrowhead). Images acquired with the EVOS® FL Cell Imaging System (Life Technologies). 
 
 
2.2.7 Real time quantitative PCR (RT-qPCR) 
RNA was isolated from confluent MDCKII cells using the Reliaprep RNA Cell Miniprep 
System (Promega) according to the manufacturer’s instructions. RNA samples were 
treated with Turbo DNaseI (Ambion, Warrington, UK) at 37°C for 30 minutes. DNaseI 
was heat-inactivated at 75°C for 10 minutes. Reverse transcription was performed with 
the Cloned AMV First Strand Synthesis Kit (Invitrogen) using 1.2µg of extracted RNA 






















90ng of single-strand cDNA was amplified using SYBR Green PCR Mastermix (Applied 
Biosystems, Paisley, UK) according to the manufacturer’s instructions. Primers used in 
PCR were previously described by Ikari et al (2011b) are presented in Table 2.8. PCR 
reactions were carried out using the StepOnePlus RealTime PCR System (Applied 
Biosystems) and threshold cycles (CT) were calculated using the instrument software. 
Primers were validated by PCR reactions with serial dilutions of template cDNA, which 
generated linear standard curves of CT plotted against log[cDNA] (see Appendix, 
Figure A9). Control reactions without reverse transcriptase confirmed the absence of 
contaminating genomic DNA. Amplification efficiency (E) was calculated from the 
standard curve of each primer pair using the formula:              (Table 2.8) using 
the Pfaffl method (Pfaffl, 2001). CT values for each gene were normalised to those 
obtained for GAPDH. These ΔCT values were used to calculate the relative change in 
mRNA expression as the ratio (R) of mRNA expression in treated cells/mRNA 
expression of control cells using the equation,                                . Data 
are presented as mean ratio values ±s.e.m. from three biological repeats. Treatments 
were compared using a one-way ANOVA with Dunnett’s post-test.  
 
Target Forward primer Reverse primer 
Primer 
efficiency 
CLDN1 5'-ATCTACTCGTACGCCGGCGACAAC-3' 5'-AGCAGCGAGTCGAAGACCTTGCAC-3' 1.96 
CLDN2 5'-GCACAGGCATAACCCAGTGT-3' 5'-GACAATGCAGGCCAACGAAG-3' 2.07 
CLDN4 5'-TGCACCAACTGCGTGGAGGATGAG-3'  5'-ACCACCAGCGGGTTGTAGAAGTCC-3'  2.15 
GAPDH 5'-ACGGCACAGTCAAGGCTGAG-3' 5'-CAGCATCACCCCATTTGATGTTGG-3'  2.03 
Table 2.8: Primers used for RT-qPCR. Forward and reverse primer sequences used in RT-
qPCR to determine mRNA levels of CLDN1, CLDN2, CLDN4 and GAPDH. Primer sequences 
were previously reported by Ikari et al (2009 and 2011). Primers were sourced from Invitrogen. 
 
 
2.2.8 Statistical Analysis 
Mean and standard error values were calculated using GraphPad software (Prism, La 
Jolla, CA, USA). All statistical analyses were performed using GraphPad for 
experiments with at least three independent experiments. Statistical analysis was 
carried out using either a one-way ANOVA with Dunnett’s post-test when comparing a 
series of treatments to a single control condition, or two-way ANOVA with Bonferroni 
post-test when comparing mean differences between groups divided on two 
independent variables (for example, adenovirus type and adenoviral titre). 
Transepithelial electrical resistance values were compared using a two-way ANOVA 
with Bonferroni post-test and were corrected for repeated measures, as multiple 
readings were consecutively taken of the same treated filters. Relevant p-values are 
indicated where relevant, * p < 0.05, ** p < 0.01 and *** p < 0.001. 


















Chapter 3: Tight junction regulation by BRAFWT and BRAFV600E 








The RAF/MEK/ERK pathway has been implicated in mediating alterations in TJ protein 
expression and localisation downstream of diverse stimuli. However, the simultaneous 
activation of multiple downstream pathways, by EGFR for example, makes it difficult to 
determine the unique contribution of individual pathways. Phosphorylation of MEK by 
RAF, and subsequently of ERK by MEK, is highly specific (Matallanas et al., 2011; 
Roskoski, 2012). The pathologically relevant activation at the level of RAF allows the 
specific activation of the RAF/MEK/ERK pathway, independently of upstream input or 
parallel signalling pathways.  
 
Activating mutations in RAF are frequently observed in cancer, with particularly high 
incidence in melanoma and ovarian, thyroid and colorectal carcinomas (Davies et al., 
2002; Dhomen and Marais, 2007). While the activity of ARAF and CRAF isoforms is 
tightly regulated by  phosphorylation of the N-region, the presence of negatively 
charged aspartic acid residues and constitutive phosphorylation within this region of 
BRAF essentially primes it for activation (Brummer et al., 2006; Emuss et al., 2005). 
Consequently, single point mutations can generate constitutively active oncogenic 
versions of BRAF, with the V600E mutation being the most frequent BRAF mutation 
found in human cancer (Roberts and Der, 2007). BRAFV600E is independent of upstream 
signalling from Ras and insensitive to ERK-mediated negative feedback (Pratilas et al., 
2009). Furthermore, overexpression of wild-type BRAF, possibly as a result of gene 
amplification, can drive constitutive activation of the RAF/MEK/ERK pathway in 
malignant melanoma (Tanami et al., 2004). Therefore, expression of BRAFWT or 
BRAFV600E is a powerful experimental technique to achieve specific activation of 
RAF/MEK/ERK pathway, and is highly relevant for understanding how TJ structure and 
epithelial barrier properties are regulated in BRAF-driven cancers.  
 
Madin-Darby Canine Kidney (MDCK) II cells are a widely used and well-characterised 
model cell line for studying polarised epithelia in culture. In contrast to the vast majority 
of immortalised and cancer cell lines, they readily form functional TJs when grown in 
simple 2D culture, either on plastic or semi-permeable membrane supports. This has 
permitted their wide use as a model system for studying TJs and membrane trafficking 
as well as additional roles in modelling viral infection (Dukes et al., 2011a). MDCKII 
cells do not harbour any known mutations that affect the RAF/MEK/ERK pathway, 
permitting their use for studying the impact of growth factors and oncogenes in an 
unperturbed background. This makes MDCKII cells an ideal model for studying 
RAF/MEK/ERK signalling in vitro and a logical choice for studying downstream effects 
on TJ trafficking in this thesis. 







Several MDCK strains have been developed from a single parental MDCK-NBL-2 
strain that was isolated from the distal tubule of the kidney of a healthy female cocker 
spaniel in the 1950s (Dukes et al., 2011a; Ikari et al., 2011c). MDCK cells lack 
endogenous p16INK4a expression and are therefore immortalised due to the lack of a 
functional senescence program (Plath et al., 2000). Two clonal strains are frequently 
used, MDCKI and MDCKII, which differ in the repertoire of TJ proteins expressed and 
their paracellular permeability. While MDCKI cells are a high-resistance cell line that  
does not endogenously express claudin-2 and exhibits typical TER values of 
~4000Ω.cm2, MDCKII cells display characteristics of the more “leaky” proximal tubule 
(Dukes et al., 2011a; Ikari et al., 2011c). This phenotype is manifested by low TER 
values of <300Ω.cm2 (Dukes et al., 2011a) and the abundant expression of claudin-2, 
which confers junctional permeability to small cations and water (Amasheh et al., 
2002). MDCKII cells also endogenously express claudin-1, -2, -3, -4 and -7, the TAMP 
family member occludin and the peripheral proteins zonula occludens (ZO)-1/-2 (Dukes 
et al., 2011a; Hou et al., 2006).  
 
One potential difficulty with working with MDCKII cells is that they are typically difficult 
to transfect with traditional lipid- or calcium phosphate-based approaches. Transfection 
efficiency is typically too low for transient expression experiments. Stable transfection 
of MDCKII cells can be achieved using retroviral or lentiviral vectors. However, these 
approaches require a selection procedure, typically using antibiotics. In addition to 
being time-consuming, clonal selection has been reported to generate MDCK 
subclones with varying properties (Milatz et al., 2010). Furthermore, various MDCK 
strains exhibit significant genetic drift when maintained in culture, which may generate 
unpredictable clonal artefacts (Cassio, 2013). It is therefore important to maintain 
working MDCKII cultures at a low passage to minimise the divergence of cell lines used 
within and between different laboratories (Cassio, 2013). 
 
The use of adenoviral vectors overcomes these issues and provides a more flexible 
experimental setup. Recombinant adenoviruses can be rapidly generated to deliver 
transgenes of up to approximately 7kb (Anderson et al., 2000). Viral uptake is 
extremely efficient in any cell line that expresses the coxsackie adenovirus receptor 
(CAR), which is itself an integral TJ protein (Coyne and Bergelson, 2005). For this 
reason, control adenoviruses will be used to control for the effect of transduction on TJ 
integrity and composition. Following transduction, transgene expression is typically 
detectable within 24 hours. Furthermore, the relative level of transgene expression can 
be regulated by titrating the concentration of adenoviral particles used for transduction. 
This easily permits the study of transgene “dose” responses and also allows the 







expression of different mutants to be closely matched, revealing the intrinsic properties 
that point mutations, for example BRAFV600E, have on protein function and downstream 
signalling.  
 
Importantly, adenoviruses have successfully been used as transgene vectors in 
MDCKII cells, with no reported effects of using control AdGFP viruses (Dukes et al., 
2011b). Therefore, adenoviral vectors provide the ability to express desired transgenes 
in a highly efficient, reproducible and controllable manner, while avoiding the necessity 
for time-consuming and potentially problematic selection procedures. 
 
3.2 Aims and objectives 
The aims of this chapter are to establish how specific activation of the RAF/MEK/ERK 
pathway affects the expression levels and subcellular distribution of individual TJ 
components and the impact that this has on epithelial permeability. This will be 
achieved by completing the following objectives: 
 
1. Generate recombinant adenoviruses to express BRAFWT and oncogenic 
BRAFV600E in MDCKII cells. 
 
2. Characterise BRAFWT and BRAFV600E-mediated downstream activation of MEK 
and ERK by immunoblot and high-content microscopy. 
 
3. Evaluate changes in epithelial barrier function through transepithelial electrical 
resistance measurements. 
 
4. Determine changes in TJ protein expression by immunoblot. 
 












3.3.1 Characterisation of BRAFWT and BRAFV600E fusion proteins 
Adenoviruses were generated to express N-terminally GFP- and myc-tagged full-length 
BRAFWT and oncogenic BRAFV600E in MDCKII cells (AdBRAFWT and AdBRAFV600E, 
respectively). To assess their ability to activate the RAF/MEK/ERK pathway, 
transduced cell lysates were subjected to SDS-PAGE and immunoblot to determine 
levels of phosphorylated MEK1/2 (ppMEK1/2) and ERK1/2 (ppERK1/2).  Antibodies for 
ERK1/2 and ppERK1/2 each detected a specific pair of bands, migrating marginally 
below a 50kDa molecular weight marker. This is consistent with the predicted 
molecular weights of 44 and 42kDa for ERK1 and ERK2, respectively. Antibodies for 
MEK1/2 and ppMEK1/2 each detected a single band that migrated marginally below 
the 50kDa molecular weight marker, consistent with their predicted molecular weight of 
45kDa. Nontransduced lysates exhibited low levels of ppERK1/2 and ppMEK1/2, which 
were barely detectable by immunoblot (Figure 3.1A).  
 
Transgene expression level can be regulated by varying the adenoviral titre used for 
transduction. Approximate viral titres of 3, 10 and 30 pfu/nl achieved a range of 
transgene expression levels, which were detected using an antibody raised against 
GFP (Figure 3.1A). Both BRAFWT and BRAFV600E transgenes have a predicted 
molecular weight of approximately 122kDa (BRAF ~95kDa, GFP ~27kDa and myc 
epitope ~0.2kDa) and were detectable as single bands migrating close to a 110kDa 
molecular weight marker (Figure 3.1A). Expression levels were closely matched 
between BRAFWT and BRAFV600E (Figure 3.1B). Increasing BRAFWT expression 
positively correlated with downstream ppMEK1/2 and ppERK1/2 (Figure 3.1C,D), which 
is consistent with the relatively high basal kinase activity of wild-type BRAF (Pritchard 
et al., 1995). Oncogenic BRAFV600E exhibited greater specific activity, strongly inducing 
downstream phosphorylation of MEK1/2 and ERK1/2 even at low expression levels 
(Figure 3.1C and D). Total MEK1/2 and ERK1/2 levels controls and were not affected 
by expression of BRAFWT or BRAFV600E, indicating that they are regulated by 
phosphorylation and not at the total protein level (Figure 3.1E and F). 
 
Downstream activation of MEK and ERK by the generated BRAF constructs was 
further characterised using high-content microscopy. This permits the high-throughput 
quantification of RAF/MEK/ERK pathway activation at the single cell level, allowing the 
relationship between transgene expression levels and pathway activation to be 
established. Stimulation of the RAF/MEK/ERK pathway results in phosphorylation and 
translocation of ERK into the nucleus, where it is rapidly dephosphorylated by nuclear 
phosphatases (Caunt and Keyse, 2013; Lenormand et al., 1993). As a result, ERK 







accumulates in the nucleus in a dephosphorylated state (Cagnol and Rivard, 2012; 
Pouysségur et al., 2002; Rushworth et al., 2014). In contrast, cytoplasmic ppERK is a 
more durable and sustained signal (Cagnol and Rivard, 2012). Transduced cells were 
fixed and immunostained to determine downstream ERK pathway activation by 
quantifying relative cytoplasmic ppERK1/2 levels, as well as the nuclear to cytoplasmic 
ratio of total ERK1/2. Each image was segmented to identify individual cells based on a 
nuclear DAPI stain (Figure 3.2A). This nuclear mask was dilated to generate an 
approximate whole cell mask. A cytoplasmic mask was generated by subtracting the 
nuclear mask from the whole cell mask. RAF/MEK/ERK pathway activation was 
determined by measuring the integrated intensity of ERK1/2 and ppERK1/2 in each 
compartment (Figure 3.2B). As both BRAFWT and BRAFV600E are cytoplasmic kinases, 
relative transgene expression was determined by measuring cytoplasmic GFP 
intensity. 
 
Confluent MDCKII cells were transduced with GFP, BRAFWT or BRAFV600E and 
RAF/MEK/ERK pathway activation was assessed by immunostaining for total and 
phosphorylated ERK1/2 (Figure 3.3A). Expression of GFP did not increase nuclear 
ERK1/2 or cytoplasmic ppERK1/2 above the basal levels observed in nontransduced 
cells (Figure 3.3B and C), indicating that adenoviral transduction alone does not 
activate the ERK pathway (Figure 3.3B). Increasing BRAFWT expression caused an 
increase in levels of total ERK1/2 in the nucleus (Figure 3.3B) and phosphorylated 
ppERK1/2 in the cytoplasm (Figure 3.3C). BRAFV600E expression resulted in near 
maximal levels of nuclear ERK1/2 and cytoplasmic ppERK1/2, even at the lowest 
detectable expression levels (Figure 3.3A, B and C). Rare nontransduced cells within 
the BRAFV600E-expressing population exhibited low levels of cytoplasmic ppERK1/2 and 
excluded total ERK1/2 from the nucleus (Figure 3.3A), indicating that BRAFV600E 
activates the ERK pathway in a cell-autonomous manner. Although the cell population 
exhibits heterogeneous transgene expression levels, the vast majority of cells exhibit 
elevated ERK pathway activity due to high adenoviral transduction efficiency in 
combination with the constitutive and feedback-insensitive activity of BRAFV600E, which 
leads to unrestrained signal amplification. 
  


















or 24 hours. (A) Cell lysates were subjected to 
SDS-PAGE and immunoblot to determine downstream phosphorylation of MEK1/2 and ERK1/2. 
Transgene expression was regulated by varying the viral titre used for transduction and 
quantified by immunoblotting for GFP. Immunoblots are representative of three biological 
repeats. (B) Quantification of immunoblots revealed that transgene expression levels were 
closely matched, and highlight the functional consequence of V600E mutation. BRAF
V600E
 
expression dramatically increased downstream phosphorylation of ERK1/2 (C) and MEK1/2 (D), 
while higher levels of BRAF
WT 
expression were required to elicit the same response. Total levels 
of ERK1/2 (E) and MEK1/2(F) were not affected under the same conditions. Molecular weight 
markers are superimposed on the left-hand side of each immunoblot. Each antibody generated 
bands consistent with the predicted molecular weight provided by the manufacturer. The same 
lysates were used to asses TJ protein levels in figure 3.4. Data are presented as mean values 




 treatments were compared to controls 
using a two-way ANOVA with Bonferroni post-test, *** p<0.001.  




















Figure 3.2: The segmentation strategy for quantifying immunostaining intensity in 
nuclear and cytoplasmic compartments. (A) A nuclear mask was generated by setting a 
threshold intensity value across each DAPI-stained image. Nuclei were “declumped”, ensuring 
each nucleus corresponded to a single object. This nuclear mask was dilated to obtain a cell 
mask. A cytoplasmic mask was subsequently generated by subtracting the nuclear mask from 
the cell mask. Each image represents 1/16
th
 of one field of view. Each experimental condition is 
quantified from 12 fields of view over 3 separate wells and therefore involves the measurement 
of thousands of cells. (B) The generated masks are then applied to each fluorescence channel, 
allowing the quantification of immunostaining intensity for different markers in each subcellular 
compartment. Nuclear, cell and cytoplasmic targets are linked together based on their overlap. 
Images were processed using INCell Developer Toolbox software (GE Healthcare Life 
Sciences). Example images are of MDCKII cells transduced with AdBRAF
WT
. Scale bar = 50µm. 
  



















for 24 hours. Cells were fixed and immunostained to determine 
downstream phosphorylation of ERK1/2 using high-content microscopy. (A) Representative 
images of MDCKII cells expressing the indicated transgene that have been fixed and 
immunostained for total and phosphorylated ERK1/2. Scale bar = 40µm. (B) Cytoplasmic and 
nuclear ERK1/2 intensities were quantified using the segmentation strategy outlined in figure 
3.2. Nuclear translocation of ERK1/2 was exhibited by an increase in the ratio of 
nuclear:cytoplasmic ERK1/2. (C) Downstream phosphorylation of ERK1/2 was assessed by 
quantifying the intensity of ppERK1/2 immunostaining in the cytoplasm. Accumulation of total 
ERK1/2 in the nucleus and phosphorylated ERK1/2 in the cytoplasm indicate that BRAF
V600E
 
expression potently activates the RAF/MEK/ERK pathway, whereas high levels of BRAF
WT
 
expression are required to stimulate a similar response. Data are representative of three 
biological repeats. 







3.3.2 BRAFV600E activity differentially regulates junction protein levels 
To determine if specific activation of the RAF/MEK/ERK pathway induced changes in 
junction protein levels after 24 hours, transduced cell lysates were subjected to SDS-
PAGE and immunoblot for a variety of TJ- and AJ-associated proteins. Occludin and E-
cadherin each migrated as single bands corresponding to their predicted molecular 
weights of 65 and 120kDa, respectively (Figure 3.4A). Levels of occludin and E-
cadherin were unaffected by the expression of BRAFWT or BRAFV600E in this time frame 
(Figure 3.4A – C). Claudin-1, -2 and -4 each migrated as single bands of approximately 
20kDa, consistent with their respective predicted molecular weights of ~22kDa, ~22 – 
23kDa and ~22kDa. Levels of claudin-1, and to a greater extent, claudin-2, were 
decreased following expression of BRAFV600E, but not BRAFWT (Figure 3.4D and E). 
Under the same experimental conditions, total levels of claudin-4 were not affected 
(Figure 3.4E), indicating that individual claudin protein levels are differentially regulated 
by RAF/MEK/ERK pathway activation. 
 
To confirm that the observed downregulation of claudin-1 and -2 was not an indirect 
effect of adenoviral transduction, confluent MDCKII cells were transduced with 
AdBRAFWT or AdBRAFV600E, alongside a control AdGFP adenovirus, and lysed after 24 
hours (Figure3.5A). Transduction with AdGFP did not increase ppERK1/2 levels 
(Figure 3.5C) or affect the levels of claudin-1 or -2 (Figure 3.5E and F), confirming that 
the observed RAF/MEK/ERK pathway activation and claudin-1/-2 downregulation are 
specific to BRAF-mediated signalling  and not a more general effect of adenoviral 
transduction. Although BRAFWT expression marginally increased ppERK1/2 levels 
(Figure 3.5C), claudin-1 and -2 levels were not significantly affected (Figure 3.5E and 
F). Expression of BRAFV600E induced a significant decrease in claudin-2 (Figure 3.5F), 
and to a lesser extent, claudin-1 levels, which were not statistically significant in this 
particular series of experiments (Figure 3.5E). 
  










 differentially regulates junction protein levels. Confluent MDCKII 





hours. (A) Cell lysates were subjected to SDS-PAGE and immunoblot to determine levels of 
occludin, E-cadherin, claudin-1, -2 and -4. Immunoblots are representative of three biological 
repeats. BRAF
V600E
 expression did not alter total levels of occludin (B) or E-cadherin (C), but 
differentially regulated claudin protein levels. Claudin-1 (D), and to a greater extent, claudin-2 
(E) levels were decreased following the expression of BRAF
V600E
, but not BRAF
WT
. By contrast, 
total levels of claudin-4 were not affected (F). Molecular weight markers are superimposed on 
the left-hand side of each immunoblot. Each antibody generated bands consistent with the 
predicted molecular weight provided by the manufacturer. Immunoblots from figure 3.1 were 
obtained using the same cell lysates. The following pairs of immunoblots were obtained from 
the same gel: ERK1/2 and claudin-1, ppERK1/2 and claudin-2, E-cadherin and occludin. Data 





treatments were compared to control treatments using a two-way ANOVA with Bonferroni post-
test, * p<0.05 *** p<0.001.   








Figure 3.5: Claudin-1 and -2 levels are not influenced by transduction with a control GFP 





for 24 hours. (A) Cell lysates were subjected to SDS-PAGE 
and immunoblot to determine levels of claudin-1 and -2, as well as downstream ERK 
phosphorylation. (B) Transgene expression was confirmed by immunoblotting for GFP, which 
generated bands of ~30kDa and ~120kDa, corresponding to monomeric GFP and BRAF fusion 
proteins, respectively. Expression of GFP did not affect levels of ppERK1/2 (C), ERK1/2 (D), 
claudin-1 (E) or claudin-2 (F). Expression of BRAF
V600E
, but not BRAF
WT
 caused a significant 
decrease in claudin-2, and a marginal, yet statistically insignificant decrease in claudin-1 levels 





 were compared at each viral titre using a two-way ANOVA with Bonferroni post-test, * 
p<0.05, ** p<0.01.  







3.3.3 BRAFV600E transiently increases MDCKII transepithelial resistance 
As claudins are major determinants of paracellular ionic permeability (Balkovetz, 2009; 
Günzel and Fromm, 2012), transepithelial resistance (TER) was determined in MDCKII 
cells expressing GFP, BRAFWT or BRAFV600E. MDCKII cells were grown until confluent 
on semi-permeable transwell filters. TER readings of approximately 150Ω.cm2 were 
stable in nontransduced control monolayers over 48 hours of measurement (Figure 
3.6A). Following transduction, TER readings were normalised to the nontransduced 
control readings at each time point (Figure 3.6, bottom row). Expression of GFP or 
BRAFWT did not significantly affect TER at any time point (Figure 3.6B and C). In 
contrast, 24 – 32 hours after transduction, BRAFV600E expression caused a transient 
increase in TER of approximately 1.8-fold. At later time points, TER readings had 
decreased to approximately baseline levels (Figure 3.6D), indicating epithelial barrier 





expression transiently increases MDCKII transepithelial resistance. 







TER readings were taken 6, 24, 32 and 48 hours after transduction. (A) 
Nontransduced control monolayers exhibited stable TER readings of approximately 150Ω.cm
2
 
over the course of the experiment.  Expression of GFP (B) or BRAF
WT 
(C) did not affect MDCKII 
transepithelial resistance (TER). (D) BRAF
V600E
 expression caused a transient increase of 
approximately 1.8-fold in TER at 24 – 32 hours post-transduction. Actual TER values (top row) 
and those normalised to the nontransduced control treatment at each time point (bottom row) 
are presented as mean values ±s.e.m from 3 biological repeats. Data were compared to the 
nontransduced control are each time point using a repeated measures two-way ANOVA with 
Bonferroni post-test, * p<0.05, ** p<0.01, *** p<0.005.  







3.3.4 BRAF activity differentially regulates junction protein distribution 
To determine if RAF/MEK/ERK activity affected the subcellular distribution of TJ 
markers, MDCKII monolayers were immunostained and examined using confocal 
microscopy. Confluent MDCKII cells expressing BRAFWT or BRAFV600E were fixed and 
costained for claudin-1 and -2. Figure 3.7 shows overhead projections of MDCKII 
monolayers accompanied by an orthogonal cross-section taken through the monolayer. 
 
Under nontransduced control conditions, claudin-2 localises to the most apical-tip of 
the lateral membrane, with claudin-1 predominantly associated with the lateral 
membrane (Figure 3.7A). Junctional claudin-2 staining was dramatically decreased in 
cells expressing BRAFWT (Figure 3.7B and C) and almost completely lost in those 
expressing BRAFV600E (Figure 3.7D and E). In contrast, claudin-1 staining appears 
throughout the cytoplasm following BRAFWT or BRAFV600E expression (Figure 3.7C – E). 
Although junctional staining initially appears to be lost, the orthogonal views reveal that 
claudin-1 persists at the apical side of the plasma membrane even as cells begin to 
overlap and form multi-layered structures (Figure 3.7E). Cells transduced with the 
control AdGFP virus maintained claudin-1 at the lateral membrane (Figure 3.8A and B) 
and claudin-2 at the apical junction (Figure 3.8C and D), indicating the observed effects 
are not a consequence of adenoviral transduction. Control cells and those expressing 
either GFP or BRAFWT exhibited perinuclear and lateral membrane-associated claudin-
4 (Figure 3.9A – C). Cells expressing BRAFV600E exhibit higher overall levels of claudin-
4, which localises to areas of cell-cell contact and throughout the cytoplasm (Figure 
3.9D). 
 
Under control conditions, E-cadherin extensively localises along the lateral membrane 
(Figure 3.10A). Lateral membrane staining was consistently observed in cells 
expressing GFP (Figure 3.10B), BRAFWT (Figure 3.10C) or BRAFV600E (Figure 3.10D), 
with minimal cytoplasmic staining detectable under any experimental condition. 
Occludin is predominantly concentrated at the apical junction (Figure 3.11A). Although 
high levels of BRAFV600E expression generates a diffuse cytoplasmic occludin signal 
(Figure 3.11D), strong junctional occludin staining is maintained in cells expressing 
GFP, BRAFWT or BRAFV600E (Figure 3.11B – D). The peripheral TJ protein ZO-1 is also 
precisely targeted to the apical junction in nontransduced cells (Figure 3.12A), and is 
unaffected in cells expressing either GFP (Figure 3.12B) or BRAFWT (Figure 3.12C). 
BRAFV600E-expressing cells maintained strong junctional staining of ZO-1, but also 
exhibited a diffuse signal across the cytoplasm, in manner similar to that of occludin. 
Cells expressing BRAFV600E also exhibited nuclear ZO-1 staining, with 1 – 2 discrete 
structures per nuclei (Figure 3.12D). Data are summarised in Table 3.1  












 activity causes the downregulation of 
claudin-2 and the altered distribution of claudin-1. Confluent MDCKII cells were transduced 




for 24 hours prior to fixation and immunostaining for 
claudin-1 or -2. (A) Claudin-2 normally localises to the apical junction. Junctional claudin-2 was 
dramatically decreased in cells expressing BRAF
WT
 (B and C) and almost completely lost in 
those expressing BRAF
V600E
 (D and E). Claudin-1 normally localises more laterally than claudin-




 leads to diffuse cytoplasmic staining of claudin-1, but 
orthogonal views taken in the indicated plane (white dashed line) show that claudin-1 is 
maintained at cell-cell contacts towards the apical side of the monolayer in each condition (C – 
E) . Images are representative of three biological repeats. Orthogonal views were taken in the 
indicated plane (dashed line). Scale bar = 20µm. 
 
 














Figure 3.8: The distribution and levels of claudin-1 and –2 are not affected by 
transduction with a control GFP adenovirus. To control for the effects of adenoviral 
transduction on the distribution of claudin-1 and -2, confluent MDCKII cells were transduced 
with a control adenovirus to express GFP. Claudin-1 is maintained at the lateral membrane (A 
and B), and claudin-2 at the apical junction (C and D), in control AdGFP-transduced cells. 
Images are representative of three biological repeats. Orthogonal views were taken in the 
indicated plane (dashed line). Scale bar = 20µm.  
















expression increases junctional levels of claudin-4. Confluent 




for 24 hours prior to 
fixation and immunostaining for claudin-4. (A) Nontransduced control cells stain relatively 
weakly for claudin-4, which exhibits perinuclear and partial plasma membrane localisation. This 





expressing cells exhibit higher overall levels of claudin-4, with strong staining evident at areas of 
cell-cell contact as well as throughout the cytoplasm. Images are representative of three 
biological repeats. Orthogonal views were taken in the indicated plane (dashed line). Scale bar 
= 20µm. 
  
















expression does not influence the distribution of E-cadherin. 




for 24 hours 
prior to fixation and immunostaining for E-cadherin. (A) E-cadherin normally localises to the 





 (D). Images are representative of three biological repeats. Orthogonal views 
were taken in the indicated plane (dashed line). Scale bar = 20µm.  













Figure 3.11: Junctional occludin is maintained following BRAF
V600E 
expression. Confluent 




for 24 hours prior to 
fixation and immunostaining for occludin. (A) Occludin normally localises to the apical junction 
and this expression pattern is largely preserved in cells expressing GFP (B), BRAF
WT
 (C) and 
expressing BRAF
V600E
 (D). (D) BRAF
V600E 
expression also causes a slight increase in diffuse 
occludin staining throughout the cytoplasm. Images are representative of two biological repeats. 
Orthogonal views were taken in the indicated plane (dashed line). Scale bar = 20µm.  















 expression has diverse effects on the subcellular distribution of 




 for 24 
hours. (A) Immunostaining of fixed cells revealed that ZO-1 precisely localises to the apical 
junction under control conditions, and in cells expressing either GFP (B) or BRAF
WT
 (C).  
BRAF
V600E
-expressing cells maintain continuous junctional staining, with ZO-1 also diffusely 
distributed across the cytoplasm and is present in discrete structures within the nucleus (white 
arrowheads) (D). Images are representative of three biological repeats. Orthogonal views were 
taken in the indicated plane (dashed line). Scale bar = 20µm. 
  







3.3.5 BRAFWT and BRAFV600E expression is lost following MEK inhibition 
To confirm that the diverse effects on TJ remodelling were mediated by RAF/MEK/ERK 
pathway activation, MDCKII cells were transduced in media containing DMSO or the 
MEK inhibitor PD0325901. Treatment with PD0325901 alone did not affect total 
claudin-2 levels, indicating that inhibiton of RAF/MEK/ERK signalling does not further 
increase claudin-2 expression. BRAFWT and BRAFV600E-mediated increases in 
ppERK1/2 levels were successfully blocked by PD0325901 treatment (Figure 3.13A 
and B). As expected, BRAFV600E expression dramatically decreased claudin-2 levels, 
and this was completely blocked by PD0325901 treatment (Figure 3.13D). Surprisingly, 
BRAFWT and BRAFV600E expression, as assessed by immunoblotting for the associated 
myc tag, was completely lost in PD0325901-treated conditions (Figure 3.13E). 
 
To determine if the presence of PD0325901 in the transduction media affected 
adenovirus integrity or uptake, cells were transduced in the absence of PD0325901. 24 
hours after transduction, DMSO or PD0325901 was added to the culture medium for a 
further 24 hours prior to cell lysis (Figure 3.14A). PD0325901 successfully inhibited 
BRAF-mediated ERK phosphorylation (Figure 3.14B and C). The BRAFV600E-driven 
decrease in claudin-2 levels were also restored by PD0325901 treatment, indicating 
that the loss of claudin-2 is a reversible process when elevated ERK signalling is 
subsequently blocked (Figure 3.14D). However, BRAF transgene expression was still 
suppressed following the delayed addition of PD0325901 to the culture medium, 
indicating that PD0325901 did not suppress BRAF transgene expression by inhibiting 
adenoviral transduction. Decreased levels of BRAFWT and BRAFV600E were evident in 
immunoblots using antibodies against either myc (Figure 3.14E) or GFP tags (Figure 
3.14F). Of note, PD0325901 did not affect the expression level of GFP alone (Figure 
3.14F), suggesting some degree of specificity of PD0325901 to the suppression of 
BRAF construct levels. Taken together, these data suggest that PD0325901 may 
specifically affect either the synthesis or stability of the generated BRAFWT and 
BRAFV600E constructs. Therefore, it could not definitively be stated that claudin-2 
protein depletion was dependent on ERK signalling, as the apparent “rescue” of 
claudin-2 levels by PD0325901 may have been mediated through the unexpected loss 




























expression. MDCKII cells were transduced in media containing DMSO or the MEK inhibitor, 
PD0325901. (A) Cell lysates were subjected to SDS-PAGE and immunoblot. MEK inhibition 
successfully blocked BRAF-mediated increases in ERK phosphorylation (B and C) and 
decreases in claudin-2 (D). However, BRAF transgene expression was completely lost in 
PD0325901-treated conditions (E), making it impossible to determine if the apparent claudin-2 
rescue is due to the blockade of downstream signalling or the loss of BRAF expression. 
Immunoblots are representative of three biological repeats. The following pairs of immunoblots 
were obtained from the same gel: myc and ERK1/2, ppERK1/2 and claudin-2. Data are 
presented as mean values ±s.e.m from three biological repeats. Data were compared to the 


















 transgene expression. MDCKII cells were transduced in media lacking 
PD0325901. After 24 hours, 5µM PD0325901 was added to the culture medium for a further 24 
hours prior to cells lysis and immunoblot (A). MEK inhibition successfully blocked BRAF-
mediated increases in ERK phosphorylation (B and C) and reversed the downregulation of 
claudin-2 (D). BRAF transgene expression was completely lost in PD0325901-treated 
conditions, as assessed by immunoblotting for myc (E) or GFP tags (F). Immunoblots for 
ppERK1/2 and claudin-2 were obtained from the same gel. Data is presented from a single 
biological repeat. 







3.3.6 BRAFV600E induces a transformation-associated phenotype 
In addition to distinct regulation of TJ protein expression levels and localisation, 
expression of BRAFWT and BRAFV600E had wider ranging effects on MDCKII cell 
morphology and proliferation associated with cell transformation. Confluent MDCKII 
cells are characterised by an extensive network of actin stress fibres that line the basal 
membrane and cortical actin fibres that are associated with the lateral and apical 
membrane domains (Figure 3.15A). Expression of BRAFWT or BRAFV600E leads to loss 
of basal stress fibres and increased levels of cortical actin at the apical surface (Figure 
3.15C and D). This remodelling of the actin cytoskeleton is accompanied by dramatic 
changes in the morphology of individual MDCKII cells and the organisation of the 
monolayer. MDCKII cells typically adopt a compact polygonal shape as cells tightly 
pack into a multicellular monolayer. Expression of BRAFV600E leads to cells adopting an 
elongated morphology, with protrusions that overlap with one another (Figure 3.16D). 
In some instances, cells stack on top of each other to form disorganised multi-layered 
structures (Figure 3.16E). 
 
To determine if expression of BRAFWT or BRAFV600E increased the rate of cell 
proliferation, transduced cells were fixed and costained for the proliferation marker, 
Ki67, and the mitotic marker, phospho-histone H3 (pHH3) (Figure 3.17). Expression of 
BRAFV600E, and BRAFWT at high levels, increased the mean Ki67 immunostaining 
intensity (Figure 3.17E), suggesting that their expression increases MDCKII cell 
proliferation. The mitotic index was calculated in each condition by calculating the 
percentage of total cells that stained positively for both markers. Control samples 
exhibited a mean mitotic index of approximately 0.5% (Figure 3.17A and F), indicating 
that at any one time, 1 out of 200 cells is undergoing mitosis. This was not affected by 
the expression of GFP (Figure 3.17B and F), but high levels of BRAFWT expression 
doubled the mitotic index to approximately 1.0% (Figure 3.17C and F). At the same 
viral titre, expression of BRAFV600E increased the mitotic index to approximately 2.0%, 
with partial increases observed at lower levels of expression (Figure 3.17D and F). 
Taken together, these data indicate that expression of BRAFWT or BRAFV600E has wide-
ranging effects on MDCKII cells inducing cytoskeleton remodelling and changes in cell 
shape, the loss of cellular organisation and increased proliferation rates, which are all 
consistent with a transformed phenotype (Huang et al., 2012) 
 
  


















causes remodelling of the actin 





for 24 hours prior to fixation. The actin cytoskeleton was stained with TRITC-phalloidin. (A) 
Successive optical slices proceeding from the apical to basal surfaces revealed that control 
cells exhibit cortical plasma membrane associated staining at the apical surface and midline, as 
well as an extensive meshwork of basal stress fibres. This pattern is maintained in GFP-




 lose basal stress 
fibres and exhibit increased levels of cortical actin (D and C, respectively).  Images are 
representative of three biological repeats. Orthogonal views were taken in the indicated plane 
(dashed line). Scale bar = 20µm. 
  










 expression disrupts MDCKII monolayer organisation. Confluent 





Fixed cells were examined by confocal microscopy. Control cells (A), and those expressing 
GFP (B) or BRAF
WT 
(C), adopt a highly organised structure where cells are tightly packed 
together to form a monolayer. Expression of BRAF
V600E
 leads to cells adopting an elongated 
mesenchymal-like shape, with protrusions that reach below neighbouring cells (D). Groups of 
cells expressing high levels of BRAF
V600E
 overlap with one another, forming a highly 
disorganised multi-layered structure (E). Images are representative of three biological repeats. 
Orthogonal views were taken in the indicated plane (dashed line). Scale bar = 20µm. 
  











 increases measures of MDCKII cell 





for 24 hours. Fixed cells were immunostained for the mitotic marker phospho-histone H3 
(pHH3) and the proliferation marker Ki67. (A – D) Images of MDCKII cells expressing the 
indicated transgenes are representative of three biological repeats. Scale bar = 50µm. (E) 
Expression of BRAF
V600E
, and high levels of BRAF
WT
, increased the mean immunostaining 
intensity of the proliferation marker Ki67 (E). Mitotic cells were identified as those exhibiting 
pHH3 and Ki67 intensities above set threshold values. The mitotic index was calculated by 
dividing the number of mitotic cells by the total number of cells identified. (F) Expression of 
BRAF
V600E
, and high levels of BRAF
WT
, increased the mitotic index of MDCKII cells. Data are 
presented as mean values ±s.e.m from three independent experiments. Data were compared to 
the nontransduced control treatments using a two-way ANOVA with Bonferroni post-test, * 
p<0.05, ** p<0.01, *** p<0.005.  








Specific activation of the RAF/MEK/ERK pathway through the expression of BRAFWT 
and BRAFV600E alters the composition of the TJ through surprisingly diverse 
mechanisms, where individual TJ proteins are differentially regulated in terms of their 






Claudin-1 ↓ - 
Punctate cytoplasmic staining 
Retained at the apical junction 
Claudin-2 ↓↓↓ ↓↓↓ Staining is lost 
Claudin-4 - ↑ 
Increased levels at areas of cell-cell 
contact 
Occludin - - 
Diffuse cytoplasmic staining 
Retained at the apical junction 
ZO-1 ND ND 
Diffuse cytoplasmic staining 
Retained at the apical junction 
Discrete nuclear staining 
E-cadherin - - Retained at the lateral membrane 
Actin ND 
Total levels largely  Loss of basal stress fibres 
unaffected Increased apical membrane levels 
 
Table 3.1: A summary of junction protein regulation following BRAF
WT/V600E
 expression. 
Reported effects of RAF/MEK/ERK activity on junction protein level and subcellular distribution 




. (↓) marginally downregulated, (↓↓↓) 
strongly downregulated, (↑) marginally upregulated, (-) unaffected, (ND) not determined. 
 
Protein levels of claudin-2, and to a lesser extent claudin-1, were decreased, as 
assessed by immunoblot and confocal microscopy. However, claudin-1 was maintained 
at the apical junction in BRAFV600E-expressing cells, as well as being present in 
cytoplasmic compartments. In contrast, following BRAFV600E expression, claudin-4 
immunostaining levels were increased. However, this may be a localised effect on 
claudin-4 distribution as this was not detectable by immunoblot. Although increased 
claudin-4 levels appeared throughout the cytoplasm, they were largely concentrated at 
areas of cell-cell contact following RAF/MEK/ERK activation. Overall levels of occludin 
and E-cadherin were not affected by expression of BRAFWT or BRAFV600E and although 
they exhibited increased diffuse cytoplasmic staining, both markers were largely 
conserved at areas of cell-cell contact. Similarly, ZO-1 was maintained at the apical 
junction, but also localised diffusely throughout the cytoplasm and was present as 
discrete punctae within the nucleus. This was accompanied by a concomitant transient 
increase in TER, which peaked at 24 hours after transduction with AdBRAFV600E, before 







falling again at later time points, indicating that epithelial barrier function was regulated 
by RAF/MEK/ERK activity in a manner dependent on signal duration. 
 
Claudin-1 is downregulated, but retained at cell-cell contacts, following 
RAF/MEK/ERK activation. 
By immunoblot, claudin-1 protein levels were marginally downregulated in response to 
BRAFV600E-expression. Immunostaining revealed that in BRAFV600E-expressing cells, 
claudin-1 was redistributed from the lateral membrane, with punctate staining visible 
throughout the cytoplasm. However, claudin-1 was retained at areas of cell-cell contact 
towards the apical side of the lateral membrane. Claudin-1 mRNA levels are not 
affected by EGF (Ikari et al., 2011c) HGF (Balkovetz 2004) or by the expression of a 
conditionally active ∆CRAF:ER fusion protein (Doehn et al., 2009). However, levels of 
claudin-1 protein, but not mRNA, are decreased in MDCKII cells after 24 hours of HGF 
treatment. Therefore, the downregulation of claudin-1 protein levels may proceed by 
post-transcriptional mechanisms. Alternatively, the redistribution of claudin-1 may 
influence its detergent-solubility and retrieval following cell lysis. Further experiments 
involving quantitative microscopy and lysis buffers containing stronger detergents are 
presented in chapter 5. 
 
The distribution of claudin-1 was also affected by ERK pathway activation. The normal 
lateral membrane-associated pool was largely lost, with punctate staining visible 
throughout the cytoplasm. Furthermore, claudin-1 was retained towards the apical side 
of the lateral membrane. Ras-transformed MDCKII cells exhibit the loss of adhesive 
cell junctions (Chen et al., 2000). Although some junction proteins like E-cadherin are 
transcriptionally repressed, claudin-1 is sequestered in the cytoplasm (Chen et al., 
2000). Furthermore, claudin-1 is rapidly restored to areas of cell contact following the 
addition of a MEK inhibitor, suggesting that RAF/MEK/ERK activity may influence the 
endocytic trafficking and subcellular distribution of claudin-1. 
 
In contrast, EGF treatment has been shown to increase the proportion of claudin-1 at 
the lateral membrane of MDCKII cells (Singh and Harris, 2004). This is not fully 
blocked by co-treatment with cycloheximide, suggesting that the translocation of 
existing claudin-1 protein contributes to this junctional accumulation (Singh and Harris, 
2004) . However, the mechanisms or changes in trafficking that are associated with this 
redistribution are currently unknown. Furthermore, EGF treatment and the expression 
of oncogenic Ras will activate multiple signalling pathways, and this highlights the 
requirement for using more specific tools that activate individual signalling pathways. 
This is desirable to study the unique contribution of each pathway to TJ regulation, in 







comparison to inhibitor-based studies that do not exclude combinatorial regulatory 
mechanisms. 
 
RAF/MEK/ERK activity leads to the downregulation of claudin-2 protein levels 
Expression of BRAFV600E led to a dramatic decrease in claudin-2 levels, as assessed 
by immunoblot and confocal microscopy, echoing studies showing that activation of the 
ERK pathway negatively correlates with renal claudin-2 mRNA and protein expression, 
both in vitro and in vivo (Lipschutz et al., 2005; Masaki et al., 2004). Treatment of 
MDCKII cells with EGF or HGF, or the expression of CA-MEK or ∆CRAF:ER, leads to 
the downregulation of claudin-2 at both the mRNA and protein level, in a MEK-
dependent manner (Doehn et al., 2009; Ikari et al., 2011c; Lipschutz et al., 2005). A 
genome-wide microarray utilising an inducible activity ∆CRAF:ER fusion protein further 
showed that claudin-2 is transcriptionally downregulated by specific activation of the 
RAF/MEK/ERK pathway (Doehn et al., 2009). Therefore, the observed decrease in 
claudin-2 levels is likely to be at least partially due to decreased mRNA levels and 
protein synthesis. In addition, recent studies implicate ERK signalling in the post-
translational regulation of claudin-2 protein levels; EGF is reported to accelerate its 
clathrin-mediated endocytosis and lysosomal degradation in a MEK-dependent manner 
(Ikari et al., 2011c).  However, the actual rates of these processes have not been 
measured. From the current microscopy data, it is unclear whether claudin-2 
accumulates intracellularly prior to its degradation, as immunofluorescence staining is 
almost completely lost by the time transgene levels become detectable. This makes it 
difficult to ascertain if specific activation of the ERK pathway regulates claudin-2 
internalisation or degradation rates. These aspects of claudin-2 regulation necessitate 
the use of inducible-activity constructs and are studied later in chapter 5. 
 
RAF/MEK/ERK activity increases junctional claudin-4 levels 
While immunoblots suggest that claudin-4 levels are not influenced by BRAFWT or 
BRAFV600E expression, the immunostaining data indicates that total claudin-4 levels are 
increased by BRAFV600E, and that the majority of this claudin-4 appears to be TJ-
associated. This junctional incorporation may underlie the apparent discrepancy 
between the immunoblot and immunostaining data; the incorporation of proteins into 
the TJ is associated with decreased detergent solubility (Nusrat et al., 2000). 
Therefore, following BRAFV600E expression, the majority of claudin-4 may exist in a 
relatively detergent-insoluble fraction that is inefficiently retrieved using lysis buffers 
containing mild detergents such as Triton X100, wich were used in the immunoblotting 
experiments. In addition to immunostaining, the relative distribution of claudin-4 could 







be further assessed by extracting detergent-soluble and insoluble fractions using 
stronger detergents, such as NP40 or SDS. 
 
RAF/MEK/ERK activity positively correlates with claudin-4 expression in MDCKII cells. 
EGF treatment increases claudin-4 levels in a Src- and MEK-dependent manner 
(García-Hernández et al., 2015; Ikari et al., 2009) and specific activation of the 
RAF/MEK/ERK pathway with ∆CRAF:ER also increases claudin-4 mRNA levels 
(Doehn et al., 2009). These reports suggest that ERK activity may increase CLDN4 
mRNA levels to increase claudin-4 protein synthesis. EGF treatment is also associated 
with promoting the incorporation of claudin-4 into cell-cell junctions (García-Hernández 
et al., 2015; Singh and Harris, 2004). This consistent with the presented confocal 
microscopy data, suggesting that claudin-4 was enriched at areas of cell-cell contact 
following BRAFV600E expression. The EGF-mediated increase in junctional claudin-4 is 
blocked by the co-treatment with cycloheximide, suggesting that its junctional 
accumulation is predominantly due to the synthesis of new protein (Singh and Harris, 
2004). Importantly, the specific roles of the ERK pathway, and its contribution to 
claudin-4 trafficking rates, have not been studied in detail. 
 
Occludin is maintained at the apical junction in following RAF/MEK/ERK 
activation 
Total occludin levels were unaffected by the expression of BRAFWT or BRAFV600E, either 
by immunoblot or confocal microscopy. Although increased diffuse cytoplasmic staining 
was observed following BRAFV600E expression, occludin remained mostly localised at 
the apical junction. Previous studies in rat salivary gland Pa-4 cells established that 
activation of the ERK pathway with ∆CRAF:ER results in the transcriptional 
downregulation of occludin and subsequent loss of protein expression (Li and Mrsny, 
2000), and a similar downregulation was reported in mouse hepatocytes (Lan et al., 
2004). However, studies in tissues of different origins may not be directly relevant as it 
is widely recognised that RAF/MEK/ERK activity exhibits tissue-specific regulation of 
individual TJ proteins (Inai et al., 2013). Occludin was not identified as an ERK-
regulated transcript in the ∆CRAF:ER genome-wide microarray in MDCKII cells (Doehn 
et al., 2009). Furthermore, the expression level and distribution of occludin is not 
affected by treatment with HGF, or the MEK inhibitor U0126 (Lipschutz et al., 2005). 
Taken together with the current data, these studies suggest that although occludin is 
transcriptionally regulated by the ERK pathway in some tissues, this is not conserved in 
MDCKII cells. This may be due to the tissue-specific expression of relevant 
transcription factors, or as a result of trafficking differences between cell types. In 
MDCKII cells, occludin is recycled to a far lesser extent than claudin-1 or -2, whereas 







significant and rapid recycling of occludin has been observed in other cell types 
including mouse mammary MTD-1A epithelial cells and basic hamster kidney (BHK) 
fibroblasts (Morimoto et al., 2005). 
 
In a manner similar to that of claudin-1, Ras-transformed MDCK cells maintain occludin 
in the cytoplasm, which is rapidly targeted to areas of cell contact upon MEK inhibition 
(Chen et al., 2000). This suggests that long-term activation of the ERK pathway may 
lead to the internalisation of occludin and its cytoplasmic sequestration. Cytoplasmic 
occludin staining following BRAFV600E expression is diffuse, compared to the distinct 
punctate staining of claudin-1. It is currently unclear if occludin and claudin-1 are 
redistributed in a complimentary manner. 
 
ZO-1 exhibits increased cytoplasmic and nuclear staining, but is largely 
conserved at the apical junction following RAF/MEK/ERK activation 
Although total levels of ZO-1 were not determined by immunoblot, the total levels were 
not significantly affected by immunofluorescence. BRAFV600E expression generated a 
similar response to that of occludin, where continuous junctional ZO-1 was maintained, 
despite an apparent increase in diffuse cytoplasmic staining. ZO-1 expression is 
maintained but confined to the cytoplasm of Ras-transformed MDCK cells. In a similar 
fashion to occludin and claudin-1, ZO-1 is rapidly translocated to areas of cell-cell 
contact upon MEK inhibition (Chen et al., 2000). Furthermore, MEK inhibition increases 
the half-life of ZO-1 by approximately 50%, suggesting that RAF/MEK/ERK activity may 
influence ZO-1 distribution and stability (Chen et al., 2000). As ZO-1 is a peripheral, 
rather than integral, membrane protein, its subcellular localisation is not necessarily 
governed by endocytic trafficking. However, as ZO-1 binds occludin and claudins via 
GUK and PDZ domain-mediated interactions, respectively (Fanning et al., 1998; Itoh et 
al., 1999), it could potentially be trafficked in complex with these, or other, TJ proteins. 
Alternatively, activation of the ERK pathway may lead to post-translational modification 
or altered protein-protein interactions at the TJ, which could potentially displace ZO-1 
from the junctional complex and result in its diffuse distribution through the cell. 
 
Interestingly, BRAFV600E expression also caused apparent accumulation of ZO-1 in the 
nucleus. ZO-1 may interact with nucleolar proteins under proliferative or promigratory 
conditions (Gottardi et al., 1996). This is associated with the G1/S transition and 
implicates ZO-1 as an important protein that can communicate signals between areas 
cell-cell contacts and nucleus (Benezra et al., 2007; Gottardi et al., 1996; Lopez-
Bayghen et al., 2006). 
 







RAF/MEK/ERK activity did not influence E-cadherin expression or distribution 
The total protein levels and subcellular distribution of E-cadherin were not affected by 
the expression of BRAFWT or BRAFV600E. Similar observations were made in MDCK 
cells stably expressing an inducible activity ∆CRAF:ER construct, where lateral E-
cadherin staining is preserved, even when cells undergo extensive morphological 
rearrangements (Hansen et al., 2000).The transcriptional downregulation of E-cadherin 
and disassembly of Adherens junctions is associated with cell transformation and the 
epithelial-mesenchymal transition (Huang et al., 2012). The current data therefore 
suggests that modulation of TJ protein expression and localisation is a relatively early 
event following the induction of RAF/MEK/ERK signalling. While ERK activity is 
sufficient to increase E-cadherin phosphorylation, co-treatment with TGFβ is required 
to induce its subsequent ubiquitination, endocytosis and degradation (Janda et al., 
2006). Even after this combined treatment, total E-cadherin levels are only significantly 
decreased after 2-3 days of treatment. This delayed post-translational regulation still 
precedes transcriptional downregulation, which only occurs after 5 days of cell 
treatment. Therefore, the simultaneous and sustained activation of multiple signalling 
pathways may be required to drive the redistribution and ultimate depletion of E-
cadherin associated with EMT. 
 
MDCKII barrier function is regulated by RAF/MEK/ERK signalling in a manner 
dependent on signal duration 
BRAFV600E expression generated a transient increase in TER, which was lost at later 
time points. The paracellular pathway, which is regulated by the TJ, is the major 
determinant of TER in low resistance monolayers, including those comprised of 
MDCKII cells (Kahle et al., 2004). Epithelial permeability can be regulated by the 
overexpression or RNAi-mediated depletion of individual claudins (Hou et al., 2006). 
Claudin-2 confers cation-selective permeability, and its depletion increases MDCKII 
TER from ~75Ω.cm2 to ~250Ω.cm2 (Hou et al., 2006). Conversely, claudin-4 depletion 
decreases TER to ~50Ω.cm2 and increases cation permeability (Hou et al., 2006). 
Therefore, the reciprocal downregulation of claudin-2 and upregulation of claudin-4 
protein levels is consistent with the observed increase in TER after 24 – 32 hours, 
although other claudins or TJ proteins may also contribute to the regulation of epithelial 
permeability. 
 
After 48 hours, TER levels began to decrease towards baseline levels, despite BRAF 
construct expression, ERK pathway activation and claudin-2 depletion being 
maintained at in this time frame. Therefore, this later decrease in TER is unlikely to be 
due to a reversal in cell phenotype. Long-term RAF/MEK/ERK pathway activation is 







associated with cell dedifferentiation and transformation (Chen et al., 2000; Hansen et 
al., 2000; Lemieux et al., 2009), which occurs through the disassembly of epithelial 
junctions and loss of epithelial barrier function (Huang et al., 2012). Therefore, the later 
decrease in TER is more likely to be due to the physical disruption of the monolayer as 
cell movement breaks contacts required for TJ formation between adjacent cells. 
 
This is consistent with studies involving the expression of a conditionally active 
ΔCRAF:ER fusion protein in MDCKII cells (Hansen et al., 2000), and reports 
concerning the differential effects of transient and sustained EGFR activation. While 
acute, transient EGFR activation results in increased TER (Singh and Harris, 2004), 
chronic activation through the stable expression of secreted heparin-binding EGF-like 
growth factor (hbEGF) resulted in cell transformation, increased cell proliferation, 
migration and loss of TER (Singh et al., 2004). Taken together with the current study, 
these data suggest that stimulus duration may affect the cellular response in terms of 
cell adhesion and barrier properties. 
 
RAF/MEK/ERK activity mediates actin cytoskeleton remodelling and cell 
morphology changes 
BRAFV600E expression led to the loss of epithelial organisation and dramatic changes in 
cell shape, which are associated with cell transformation. MDCKII cells normally form 
an organised monolayer, where individual cells adopt a compact polygonal shape. 
Expression of BRAFV600E caused cells to adopt a more elongated mesenchymal-like 
phenotype, and the formation of multi-layered structures. Although RAF/MEK/ERK 
activity is frequently insufficient for the transformation of melanocytes (Tsao et al., 
2012) and epithelial cells (Du et al., 2004), this phenotype is consistent with studies 
demonstrating that the expression of active RAF (Hansen et al., 2000) or MEK 
(Montesano et al., 1999) is sufficient to transform MDCK cells. 
  
These changes in cell morphology and organisation were accompanied by severe 
remodelling of the actin cytoskeleton. Unstimulated MDCK cells are characterised by 
stress fibres localised close to the basal membrane, which provide tension across the 
monolayer to promote the formation of focal adhesions (Guasch et al., 1998). Basal 
and lateral actin filaments also act to maintain a cylindrical cell shape (Nusrat et al., 
1995). The apical domain is comprised of a perijunctional actomyosin ring, which is 
thought to regulate TJ permeability, and an ordered array of bundles that stabilise the 
structure of the apical plasma membrane domain (Nusrat et al., 1995). Expression of 
BRAFV600E, and to some extent BRAFWT, led to the loss of basal stress fibres and 
increased cortical actin associated with the apical plasma membrane domain. The 







BRAF-induced stress fibre loss is likely to be mediated by modulation of Rho GTPase 
activity (Hansen et al., 2000) and be associated with decreased substrate adhesion 
and increased migratory capacity (Guasch et al., 1998). The increase in cortical actin 
may have a role in regulating the observed changes in epithelial permeability at these 
time points (Nusrat et al., 1995). 
 
Expression of BRAFV600E, and higher levels of BRAFWT, also increased MDCKII cell 
proliferation. This is consistent with studies where HGF treatment increased MDCKII 
cell proliferation in a MEK-dependent manner (Li et al., 2004). ERK activity, cell 
proliferation and cell density are inextricably linked; as MDCK cell density increases, 
ERK phosphorylation and growth rates decrease due to a process termed contact 
inhibition of proliferation (Li et al., 2004). Although high cell density and junction 
formation appear to downregulate ERK activity and restrain growth rates (Laprise et al., 
2004), expression of BRAFV600E, or high levels of BRAFWT, was sufficient to overcome 
contact inhibition of proliferation in MDCKII cells. From the current data, it is not 
possible to determine if increased proliferation rates are causative, or a consequence, 
of junction disassembly. Alternatively, TJ proteins and cell proliferation may be 
independently regulated when ERK activity is induced in confluent MDCKII 
monolayers. 
 
PD0325901 suppresses the expression of BRAFWT and BRAFV600E 
Attempts to inhibit or reverse the BRAF-mediated effects on claudin expression and 
distribution were confounded by the unexpected loss of transgene expression following 
the addition of the MEK inhibitor PD0325901. This appeared to be specific to the 
expressed BRAF transgenes as PD0325901 treatment did not affect the level of 
endogenously expressed GFP. As the expression of both the BRAF transgenes and 
GFP were driven by the same CMV promoter, this suggests repression may have been 
at the post-transcriptional level. Alternatively, expression from the CMV promoter may 
be sensitive to MEK inhibition, with differences in stability influencing the degradation 
rates of monomeric GFP and BRAF transgenes. However, there is a lack of data 
regarding the effects of small molecule inhibitors on the activity of commonly used 
promoters. This highlights the importance of confirming sustained transgene 
expression when assigning functional relevance to downstream signalling pathways 
based on the use of small molecule inhibitors. Although ERK phosphorylates RAF 
kinases in both positive and negative feedback loops, this is generally associated with 
altered RAF dimerisation and activity, rather than protein stability (Ritt et al., 2010; 
Sturm et al., 2010). Further work studying the effects of distinct MEK inhibitors on the 







half-lives of endogenous RAF kinases would be required to establish if RAF kinase 
stability is physiologically regulated in a MEK/ERK-dependent manner. 
 
3.5 Limitations and future work 
Expression of BRAFWT and BRAFV600E clearly indicates that specific activation of the 
RAF/MEK/ERK pathway induces TJ remodelling by differentially regulating the total 
level and subcellular distribution of individual TJ components. However, with the 
current experimental setup, it is hard to manipulate the duration of ERK signalling in a 
coordinated manner across the whole cell population. As a result, it is difficult to 
determine the relevant mechanisms of downregulation and redistribution. There are 
also wider ranging effects of RAF/MEK/ERK activation on MDCK cells, including 
changes in cell morphology, organisation and proliferation that are associated with cell 
transformation. It is therefore hard to distinguish mechanisms that may specifically 
regulate TJ remodelling in response to RAF/MEK/ERK pathway activation from 
consequences of gross changes in cell arrangement and interaction. Furthermore, 
mechanistic insights are limited by the surprising inhibition of BRAF construct 
expression levels through the treatment with the MEK inhibitor, PD0325901. 
 
TJ protein levels assessed by immunoblot may be influenced by their subcellular 
distribution and resulting detergent-solubility. It will be important to further investigate 
changes in TJ protein level using lysis buffers containing stronger detergents that will 
more fully solubilise TJ-associated proteins, or alternative microscopy and imaging 
based approaches. 
 
By the time that BRAF transgene becomes detectable, extensive changes in TJ protein 
expression and subcellular distribution have already occurred, making it impossible to 
determine the rates of degradation or endocytic trafficking that may underlie some of 
these changes. In order to achieve coordinated ERK activation with increased temporal 
control, inducible-activity RAF:ER fusion proteins will be generated in the next chapter, 
with the aim of studying the downstream effects on rates of TJ protein internalisation, 
degradation and recycling. This approach will potentially allow the study of ERK 
signalling on TJ remodelling, prior to broader changes associated with transformation 
and in a manner more amenable to pharmacological intervention than the current 
BRAFWT and BRAFV600E constructs. 
 








 Adenoviral vectors allow the efficient transduction of MDCKII cells and the 
expression of BRAFWT and BRAFV600E constructs that specifically activate the 
RAF/MEK/ERK pathway. 
 
 Specific activation of the RAF/MEK/ERK pathway is sufficient to cause a 
transient increase in TER, which occurs concurrently with the differential 
regulation of TJ protein levels and localisation. 
 
 Consistent with this increase in TER, claudin-2 protein levels are dramatically 
decreased, while junctional claudin-4 levels are increased. 
 
 Claudin-1, occludin, and ZO-1 are retained at the apical junction, but also 
exhibit varying degrees of intracellular staining. 
 
 TJ remodelling occurs prior to any changes in E-cadherin protein level or 
subcellular distribution. 
 
 RAF/MEK/ERK activity is also associated with a transformed phenotype 
consisting of cytoskeletal remodelling, changes in cell morphology and 
organisation and increased rates of proliferation, which may potentially 
contribute to TJ remodelling and epithelial barrier regulation. 
















Chapter 4: Generation of inducible-activity RAF:ER fusion 
proteins  





By studying the effects of BRAFWT and BRAFV600E expression, as described in chapter 
3, it is clear that RAF/MEK/ERK pathway activation has dramatic effects on TJ 
composition, as well as more widespread effects on cell proliferation and morphology 
associated with cell transformation. However, observations using these constructs are 
limited by the time required for transgene expression to become detectable. Studying 
ERK-mediated effects at earlier time points is complicated as it is difficult to establish 
when sufficient transgene expression levels are reached to elicit downstream activation 
of MEK and ERK. The ability to conditionally activate a protein of interest is desirable 
for studying temporal aspects of downstream signalling. In terms of this study, a 
conditionally active RAF kinase construct would allow the coordinated activation of the 
RAF/MEK/ERK pathway across a cell population, permitting the study of ERK-
dependent effects on rates of TJ protein trafficking, expression and degradation over 
shorter and tightly controlled time frames. 
 
Fusion of a protein of interest, typically a kinase or transcription factor, to the hormone-
binding domain (HBD) of a steroid receptor frequently yields a product which is 
regulated by the presence of the cognate steroid hormone in the culture medium 
(McMahon, 2001). The benefits of using HBD fusion proteins include: i) rapid and 
reversible activation of the protein of interest through posttranscriptional modes of 
activation, ii) the ability to titrate the activity of the protein of interest by varying the 
concentration of the cognate steroid hormone, and iii) the relative ease of construct 
generation and use. Inducible-activity RAF kinase constructs will allow specific 
activation of the RAF/MEK/ERK pathway independently of other signalling pathways. In 
contrast to the constitutively active constructs, these fusion proteins will allow the 
coordinated activation of the ERK pathway through the addition of 4-hydroxytamoxifen 
(4HT) to the culture medium, allowing tighter control of the point of activation and the 
duration of signalling across the whole cell population. 
 
A series of molecular tools have been generated by fusing RAF proteins to the HBD 
(residues 282-595) of the human estrogen receptor (hbER) (Pritchard et al., 1995; 
Samuels et al., 1993). RAF kinase activity can be regulated by 17β-estradiol, the 
physiological agonist of the estrogen receptor, 4-hydroxytamoxifen or 4HT, a selective 
estrogen receptor modulator (SERM) that can be agonistic or antagonistic in different 
contexts, or the ICI series of estrogen receptor “pure” antagonists (Feil et al., 1997). 
Various mutations have been introduced to improve selective fusion protein activation 
and alleviate “leaky” or undesirable activation by estrogen-like compounds, such as 
phenol red, which are common in cell culture media (Figure 4.1) (Feil et al., 1997). A 




G400V mutation (ERVG) reduces estradiol-sensitivity by approximately 10-fold, resulting 
in ERVG, which exhibits low baseline activity, but is strongly activated by estradiols, 4HT 
or ICI (Feil et al., 1997). Although useful in vitro, where sources of estradiols can be 
removed, the requirement to use these types of constructs in vivo drove the 
development of estradiol-insensitive ER mutants (Feil et al., 1997). ERGR/ERT was 
generated by a G525R mutation, which reduced estradiol sensitivity by approximately 
1000-fold but maintained the ability to be activated by 4HT or ICI (Feil et al., 1997). 
Two further estradiol-resistant ER mutants, L539A/L540A (ERT1) and M543A/L544A 
(ERT2) have been characterised and exhibit distinct sensitivities to 4HT and ICI, with 




Figure 4.1: ER domain mutants exhibit distinct sensitivities to activating ligands. Proteins 
fused to the hormone-binding domain of the estrogen receptor (hbER, residues 282-595 of the 





) have been introduced to reduce baseline activity and inappropriate 





iterations exhibit greater estradiol-resistance and can be potently and selectively activated by 
4HT or ICI compounds. (Y) Potently activated (EC50 ≤ 20nM), (Y*) activated, but activity did not 
plateau in presence of up to 250nM ligand (i.e. weakly activated), (N) not activated in presence 
of up to 250nM ligand. Figure and table adapted from Feil (1997). Sensitivity to different ligands 
is based on the in vitro activity of various Cre:ER recombinase mutants.  
  




ER domain optimisation has resulted in the generation of fusion proteins that exhibit 
lower baseline activity and has alleviated concerns regarding inappropriate activation 
by endogenous ligands, either in vitro or in vivo. Furthermore, activating ligands can be 
used at lower concentrations, reducing the potential for off-target effects while 
achieving more complete fusion protein activation. 
 
Cell lines have been generated that stably express these RAF:ER fusion proteins. 
However, the generation of stable cell lines is time-consuming and requires antibiotic 
selection, which can influence cell phenotype. Although the generation of stably 
transfected MDCKII lines has been reported, clonal selection can often result in altered 
epithelial permeability properties and claudin expression levels (Milatz et al., 2010). To 
allow a more flexible experimental setup, we aimed to generate adenoviruses to 
express RAF:ER fusion proteins in MDCKII cells, providing the benefits of high 
efficiency transduction and regulation of construct expression level, while avoiding the 
requirement for selection protocols. 
 
Initial RAF:ER fusion proteins consisted solely of the constitutively active truncated C-
terminal kinase domain fused to the ER domain (ΔRAF:ER) (Pritchard et al., 1995; 
Samuels et al., 1993). Subsequent studies indicated that full-length CRAF could be 
rendered hormone-dependent in a similar manner, although these full-length CRAF 
fusion proteins exhibit lower kinase activity than ΔCRAF:ER constructs (McMahon, 
2001). Mutation of the CRAF NtA from SSYY to SSDD increased the activity of 
CRAF:ER (Bosch et al., 1997), suggesting that full-length BRAF fusion proteins, which 
already harbour this sequence, may prove to be useful experimental tools. More 
recently, highly potent and pathophysiologically relevant full length BRAFV600E:ER 
fusions have successfully been used to study temporal aspects of RAF/MEK/ERK 
signalling (Cagnol and Rivard, 2012; Liu et al., 2007). To further the initial studies 
involving hormone-independent BRAFWT and BRAFV600E, we initially attempted to 
generate recombinant adenoviruses to efficiently express myc- and GFP-tagged 
BRAFWT:ER and BRAFV600E:ER fusion proteins in MDCKII cells. Characterisation of 
fusion protein activity and inducibility will primarily be achieved using high-content 
microscopy. The high-throughput nature of this approach will allow the efficient 
characterisation of a number of variables, including adenoviral titre, hormone 
concentration and time frame of downstream pathway activation. Furthermore, this 
approach will permit the study of RAF:ER activity on the single cell level, which will be 
important when studying the distribution of TJ proteins by confocal microscopy. 
 




4.2 Aims and objectives 
The aim of this chapter is to generate and characterise inducible-activity RAF:ER 
fusion proteins to permit the study of tight junction protein trafficking at earlier time 
points. This will be achieved by completing the following objectives: 
 
1. Generate recombinant adenoviruses to express hormone-dependent 
BRAFWT:ER and BRAFV600E:ER fusion proteins in MDCKII cells. 
 
2. Characterise basal construct activity and inducibility using immunostaining and 
high-content microscopy to assess downstream ERK phosphorylation. 
 
3. Optimise the experimental setup with respect to viral titres, hormone 
concentrations and timescales of fusion protein activation. 
 
  





4.3.1 Generation of full-length BRAF:ER fusion proteins 
Two inducible-activity BRAF:ER fusion constructs consisting of BRAFWT or BRAFV600E 
N-terminally tagged with GFP and myc, and fused to the T2 version of the ligand 
binding domain of the human estrogen receptor (ERT2) were expressed under the 
control of the cytomegalovirus (CMV) promoter. These fusion proteins are hence 
referred to as BRAFWT:ER and BRAFV600E:ER (Figure 4.2). Recombinant adenoviruses 









Figure 4.2: A schematic representation of inducible activity BRAF:ER fusion proteins. (A) 




are fused to the ER
T2
 
domain and N-terminally labelled with both eGFP and myc epitope tags. Constitutive expression 
is driven by the cytomegalovirus (CMV) promoter. (B) A proposed model for BRAF:ER 
activation. In the absence of activating ligand, the ER
T2 
domain is proposed to impair the 
catalytic activity of the kinase domain through steric inhibition. Rapid activation is achieved upon 
the addition of activating hormone ligands, such as 4-hydroxytamoxifen (4HT). While some ER 
fusion proteins are activated solely through increased protein stability, conformational changes 
underlie the rapid and protein synthesis-independent activation of RAF:ER proteins (McMahon, 
2001). 
  




To establish the relative activity and inducibility of the generated BRAF:ER fusion 
proteins, transduced and treated cells were fixed and immunostained to determine 
relative levels of fully active, dual phosphorylated ERK1/2 (ppERK1/2). Relative 
ppERK1/2 levels were quantified based on the immunostaining intensity using INCell 
Developer Toolbox software, using the segmentation and analysis strategy outlined in 
Chapter 3 (Figure 3.2). 
 
MDCKII cells were transduced to express either GFP alone, BRAFWT:ER or 
BRAFV600E:ER and treated with a range of 4HT concentrations for 2 hours. Both the 
localisation and expression level of each construct was determined based on GFP 
intensity (Figure 4.3). GFP alone localised uniformly throughout the cell, while 
BRAFWT:ER was unexpectedly concentrated at the plasma membrane at areas of cell-
to-cell contact (Figure 4.3A). BRAFV600E:ER was expressed throughout the cytoplasm, 
but was excluded from the nucleus and, in contrast to BRAFWT:ER, did not accumulate 
at the cell periphery (Figure 4.3A). 
 
4.3.2 RAF/MEK/ERK pathway activation by BRAFWT:ER and BRAFV600E:ER 
Surprisingly, high-content microscopy revealed that ppERK1/2 levels were not 
stimulated above basal nontransduced levels following the expression of BRAFWT:ER, 
in either the absence or presence of 4HT (Figure 4.3A). In contrast, ppERK1/2 levels 
were unexpectedly elevated following the expression of BRAFV600E:ER, in both control 
and 4HT-treated conditions (Figure 4.3A). Based on population mean values, 
quantification of ppERK1/2 immunostaining intensity revealed BRAFV600E:ER 
expression alone led to an approximate 4-fold increase in ppERK1/2 intensity, while 
BRAFWT:ER expression did not increase ppERK1/2 intensity beyond basal levels 
(Figure 4.3B). While BRAFWT:ER did not induce ERK phosphorylation at any 
concentration of 4HT tested, high basal BRAFV600E:ER activity could be further 
increased following the addition of 4HT at 0.1, 1 or 10µM 4HT for 2 hours (Figure 
4.3B). Therefore, neither BRAFWT:ER or BRAFV600E:ER exhibited desirable hormone-
dependent activity; BRAFWT:ER is an inactive kinase and BRAFV600E:ER exhibits 
unacceptable levels of basal or “leaky” activity in the absence of activating hormone. 
 
To determine whether high fusion protein expression levels were responsible for the 
inappropriate basal activity of BRAFV600E:ER in the absence of 4HT, individual cells 
were grouped into subpopulations, or “binned”, according to their GFP intensity as a 
measure of construct expression level (Figure 4.3C). Plotting BRAFV600E:ER expression 
level against ppERK1/2 output generated a sigmoidal response curve where increasing 
expression levels correlated with increased ppERK1/2 intensity (Figure 4.3C).  The 




relationship between BRAFV600E:ER expression level and ERK phosphorylation was 
identical between control and 4HT-treated conditions, with logEC50 values of 2.50, 
2.48, 2.47 and 2.46 at 0, 0.1, 1 and 10µM 4HT, respectively (Figure 4.3C). This 
indicates that BRAFV600E:ER exhibits equally potent activity in control and 4HT-treated 
conditions and that the high basal activity of BRAFV600E:ER observed was not a result 
of excessively high expression levels. BRAFWT:ER was unable to induce downstream 
ERK phosphorylation at any expression level or 4HT concentration (Figure 4.3C). 
 
4.3.3 BRAFWT:ER and BRAFV600E:ER activity is not influenced by phenol red 
The ERT2 domain used to generate these proteins is reportedly insensitive to estradiol-
mediated activation (Feil et al., 1997). Phenol red is a pH indicator commonly used in 
cell culture media, but is also a weak estrogen agonist (Samuels et al., 1993). The 
utilisation of ERT2 should eliminate the necessity to exclude phenol red from the culture 
medium and, as expected, both BRAFWT:ER and BRAFV600E:ER displayed similar 
properties when cells were cultured in phenol red-free media (Figure 4.4A). 
BRAFV600E:ER expression caused constitutive downstream phosphorylation of ERK1/2 
in the absence of 4HT (Figure 4.4B) and this was evident at all measured expression 
levels (Figure 4.4C). As all experiments were carried out in serum-free conditions to 
minimise the activation of other signalling pathways and simplify experimental analysis, 
the high basal activity of BRAFV600E:ER, could not be attributed to undue activation by 
phenol red or serum-associated estradiols (Figure 4.4). BRAFWT:ER was inactive under 
all experimental conditions (Figure 4.4B and C). As these full-length BRAF:ER fusions 
did not provide the desirable qualities of an inducible-activity system, alternative 














:ER fusion protein activity. 





:ER and treated with the indicated concentrations of 4HT for 2 hours. (A) 
Representative images of MDCKII cells immunostained for ppERK1/2, Construct expression 
level and localisation were assessed by GFP intensity. Downstream RAF/MEK/ERK pathway 
activation was assessed by the intensity of ppERK1/2 in the cytoplasm. (B) Mean cytoplasmic 
ppERK1/2 intensity measurements revealed that while GFP alone and BRAF
WT
:ER do not 
increase ERK phosphorylation, BRAF
V600E
:ER is highly active, in both the absence and 
presence of 4HT. (C) Cells were grouped into subpopulations based on transgene expression 
level. While BRAF
V600E
:ER expression positively correlates with ERK1/2 phosphorylation, it is 
equally potent in the control and 4HT-treated conditions. Images and data are representative of 














:ER activity in media lacking 





:ER and treated with 1µM 4HT for the indicated time periods. (A) Representative 
images of MDCKII cells fixed and immunostained for ppERK1/2. Construct expression level and 
localisation were assessed by GFP intensity. Downstream RAF/MEK/ERK pathway activation 
was assessed by the intensity of ppERK1/2 in the cytoplasm. (B) Mean cytoplasmic ppERK1/2 







:ER remains inactive and BRAF
V600E
:ER retains high basal activity even when phenol 
red is excluded from the culture medium. (C) MDCKII cells were grouped into subpopulations 





not affected by the presence of 4HT over a time period of 6 hours. Images and data are 
representative of two biological repeats. Scale bar = 20µm. 
  




4.3.4 Generation of ∆CRAF:ER fusion proteins 
As the previously described BRAF:ER fusion proteins were unsuitable for subsequent 
studies, alternative ΔCRAF:ER fusion proteins were generated. These earlier iterations 
have been widely used and are more fully characterised than full-length BRAF:ER 
fusion constructs (Pritchard et al., 1995; Samuels et al., 1993). ERT is fused to the C-
terminal of the human CRAF kinase domain (residues 305 – 648), which is N-terminally 
tagged with either eGFP, HA or myc epitope tags (Figure 4.5). The fusion proteins 















Figure 4.5: A schematic representation of eGFP-, HA- and myc-tagged inducible activity 
ΔCRAF:ER fusion proteins. The kinase domain (residues 305-648) of the human CRAF 
protein is fused to ER
T
 and N-terminally labelled with eGFP, HA or myc tags. Hormone-
dependent activation of ΔCRAF:ER fusion proteins is thought to proceed through rapid post-








4.3.5 eGFPΔCRAF:ER provides improved control of RAF/MEK/ERK activity 
Initial characterisation of eGFP∆CRAF:ER demonstrated that it exhibited improved 
properties, with lower basal activity that could be enhanced by 4HT treatment (Figure 
4.6A). MDCKII cells expressing eGFPΔCRAF:ER were treated with a range of 4HT 
concentrations for 1 hour prior to fixation. Quantification of immunostaining revealed a 
concentration-dependent increase in downstream ERK phosphorylation, with 
increasing cytoplasmic ppERK1/2 levels evident at 0.1µM 4HT, which then plateaued 
at a concentration of 1µM (Figure 4.6B). Increasing the 4HT concentration to 10µM did 
not further increase downstream ERK phosphorylation (Figure 4.6B). This 
concentration-dependent response was evident based on cell population means 
(Figure 4.6B) and when cells were “binned” according expression level (Figure 4.6C), 
indicating that maximal eGFPΔCRAF:ER activity was achieved using 1µM 4HT. 
Although increasing ΔCRAF:ER expression levels correlated with downstream ERK1/2 
phosphorylation (Figure 4.6C), mean cytoplasmic GFP intensity measurements 
revealed that cells generally express relatively low levels of eGFPΔCRAF:ER (Figure 
4.6D), and will exhibit the desired combination of low basal activity with rapid activation 
upon 4HT treatment.  
 
4HT treatment increased the amount of eGFP∆CRAF:ER protein that was detectable, 
both by high-content microscopy (Figure 4.6D) or by immunoblot (Figure 4.6E). As 
samples were either fixed or lysed simultaneously, this increase in expression level is 
due to 4HT treatment and not increased incubation times. Increased ERK 
phosphorylation preceded the observed increase in eGFP∆CRAF:ER expression 
(Figure 4.6E) and 4HT treatment clearly increased the specific activity of 
eGFP∆CRAF:ER (Figure 4.6C). Immunoblotting revealed that on a population level, 
eGFP∆CRAF:ER expression alone did not increase ppERK1/2 levels (Figure 4.6E). 
However, ppERK1/2 levels were dramatically increased by a 1 hour treatment with 1µM 
4HT (Figure 4.6E), which was sustained for at least 48 hours while 4HT was present in 
the culture medium (Figure 4.6E). Therefore, eGFP∆CRAF:ER has the required 
characteristics for the subsequent use in TJ trafficking studies. 
 
4.3.6 RAF/MEK/ERK pathway activation by HA- or myc-tagged ΔCRAF:ER  
Two additional versions of ΔCRAF:ER, with either an N-terminal HA or myc epitope tag 
(Figure 4.5), exhibited similar properties, where both mean ppERK1/2 levels and 
specific activity were increased following the addition of 4HT to the culture medium 
(Figure 4.7A). Each ∆CRAF:ER fusion protein had similar properties to 
eGFPΔCRAF:ER and exhibited low levels of intrinsic basal activity, which were rapidly 
increased upon the addition of 4HT to the culture medium (Figure 4.7B and C). 





Figure 4.6: Characterisation of eGFP∆CRAF:ER fusion protein activity. Confluent MDCKII 
cells were transduced to express eGFP∆CRAF:ER and treated with the indicated 
concentrations of 4HT for 1 hour. (A) Representative images of MDCKII cells fixed and stained 
for ppERK1/2. (B) Mean cytoplasmic ppERK1/2 intensity measurements reveal that 
eGFPΔCRAF:ER exhibits low basal activity, as values are not increased compared to 
nontransduced control cells in the absence of 4HT. ppERK1/2 levels are increased by 4HT in a 
concentration-dependent manner. (C) The specific activity of eGFPΔCRAF:ER is increased by 
4HT in a concentration-dependent manner, plateauing at 1µM. Although eGFPΔCRAF:ER 
expression correlates with cytoplasmic ppERK1/2 intensity, this aberrant activity is largely 
confined to those cells expressing higher levels of the fusion protein. (D) Mean GFP intensity 
measurements reveal that transgene expression levels are relatively low; as a result, basal 
activity is minimal, but also 4HT-responsive. Images and data are representative of two 
biological repeats. Scale bar = 20µm. 






Figure 4.7: Characterisation of HA- and myc-tagged ΔCRAF:ER fusion protein activity. 
ΔCRAF:ER was subcloned into pAd5CMV K-NpA using alternative forward primers to 
incorporate either an HA or myc epitope tag in place of eGFP. (A) Representative images of 
MDCKII cells expressing eGFP-, HA- or myc-tagged ∆CRAF:ER that have been fixed and 
immunostained for ppERK1/2. (B) Mean cytoplasmic ppERK1/2 measurements reveal that HA- 
and mycΔCRAF:ER exhibit similar properties to eGFPΔCRAF:ER, with low basal activity in the 
absence of 4HT, which is rapidly increased upon the addition of 4HT. (C) MDCKII cells were 
grouped into subpopulation based on transgene expression level, revealing that 4HT treatment 
increases the specific activity of each ∆CRAF:ER construct. Images and data are representative 
of two biological repeats. Scale bar = 20µm. 
  




4.3.7 4HT-dependent eGFPΔCRAF:ER-mediated changes in morphology 
As eGFPΔCRAF:ER displayed the required biochemical characteristics, its ability to 
recapitulate the biological effects of BRAFV600E expression was evaluated using 
confocal microscopy. Confocal microscopy revealed that eGFPΔCRAF:ER could 
phenocopy BRAFV600E-mediated changes in MDCKII morphology in a 4HT-dependent 
manner (Figure 4.8). The characteristic monolayer organisation and compact cell 
shape (Figure 4.8A) was maintained following the treatment of nontransduced cells 
with 4HT (Figure 4.8B), or following the expression of eGFPΔCRAF:ER in the absence 
of 4HT (Figure 4.8C). Cell elongation was clearly evident after 24 hours of 4HT 
treatment (Figure 4.8D) with multi-layered structures observed in some areas (Figure 
4.8E). Therefore, eGFPΔCRAF:ER provides a conditionally active tool that can be used 
to model RAF/MEK/ERK pathway activation, providing the regulation of signal initiation 
and duration required for subsequent studies into TJ protein trafficking rates. 
  







Figure 4.8: eGFPΔCRAF:ER disrupts MDCKII monolayer organisation in a 4HT-dependent 
manner. Representative images are presented of MDCKII cells expressing eGFPΔCRAF:ER  
treated with or without 1µM 4HT for 24 hours. (A) Nontransduced MDCKII cells adopt a compact 
cell shape and form an organised monolayer. This is maintained in nontransduced cells treated 
with 4HT (B), or eGFPΔCRAF:ER–expressing cells cultured in the absence of 4HT (C). After 24 
hours of stimulation, eGFPΔCRAF:ER–expressing cells form extended protrusions (D) and form 
multi-layered structures (E), phenocopying the effects of BRAF
V600E
 expression reported in 
chapter 3. Images are representative of three biological repeats. Scale bar = 20µm.  





This chapter has outlined the successful design and characterisation of a series of 
ΔCRAF:ER fusion proteins that exhibit hormone-regulated activity, providing the ability 
to specifically activate the RAF/MEK/ERK pathway in an inducible manner. Neither of 
the initially proposed BRAF:ER fusion proteins displayed the required properties of an 
inducible-activity system. BRAFWT:ER was unable to induce downstream ERK 
phosphorylation, while BRAFV600E:ER exhibited unacceptably high basal activity, 
indicating that the intrinsic kinase activity was not suitably restrained through fusion to 
the ERT2 domain. In contrast, eGFP-, HA- and myc-tagged ΔCRAF:ERT fusions each 
exhibited low activity in the absence of 4HT, but could be activated in a rapid and 
sustained manner following the addition of 4HT. Furthermore, eGFPΔCRAF:ER was 
capable of inducing cell transformation in a similar fashion to BRAFV600E, in a 4HT-
dependent manner. Therefore, eGFPΔCRAF:ER provides coordinated and tight control 
over signal duration required for the proposed TJ protein trafficking assays in chapter 
5. 
 
BRAFV600E:ER induces 4HT-independent activation of the RAF/MEK/ERK pathway 
The use of full length BRAFV600E:ER fusion proteins has been reported elsewhere 
(Cagnol and Rivard, 2012; Liu et al., 2007) and is desirable to study the impact of the 
pathologically relevant oncogenic BRAFV600E mutation in a temporally regulated 
manner. These studies involved the generation of stably transfected cell lines, where 
uniform expression levels are likely to be observed between cells. One advantage of 
using adenoviruses is the ability to modulate transgene expression by varying the viral 
titre used. However, heterogeneous expression levels are observed between cells in a 
commonly transduced population, and a subpopulation of cells will express more 
transgene than the population average. Therefore, low levels of basal activity could 
potentially have been magnified through BRAFV600E:ER overexpression. Although 
downstream ERK phosphorylation positively correlated with level of transgene 
expressed, this expression level-response relationship was not affected by the addition 
of 4HT. This indicates that the specific activity of BRAFV600E:ER was not increased by 
hormone stimulation and that the desired inducible properties were not evident even at 
low expression levels. 
 
It therefore remains unclear why BRAFV600E:ER is constitutively active. BRAFV600E:ERT1 
and BRAFV600E:ERT2 have been used in IEC-6 intestinal epithelial cells and Melan-A 
melanocytes, respectively, to study spatiotemporal aspects of RAF/MEK/ERK 
signalling (Bergeron et al., 2010; Cagnol and Rivard, 2012; Liu et al., 2007), validating 
the initial proposed use of BRAFV600E:ER fusion proteins in these studies. Although 




BRAF:ER fusion proteins have not been used in MDCKII cells, this cell line has 
repeatedly been used in conjunction with ΔCRAF:ER constructs to study 
RAF/MEK/ERK-mediated epithelial transformation (Doehn et al., 2009; Hansen et al., 
2000; Lehmann et al., 2000). This suggests that MDCKII cells are amenable to the use 
of similar RAF:ER fusion proteins. 
 
The length and specific nature of linker sequence between BRAFV600E and the N-
terminal of ERT2 may differ between the generated construct and those reported 
elsewhere. Unfortunately, the full sequences of the fusion proteins used in these 
studies are unavailable. Alternatively, the transgene selection process involved in 
generating stable cell lines may have resulted in adaptation to downregulate basal ERK 
activity. The results of this chapter indicate the need to carefully characterise such 
systems prior to use. 
 
BRAFWT:ER is incapable of inducing downstream activation of the RAF/MEK/ERK 
pathway 
BRAFWT:ER was unable to induce downstream ERK phosphorylation at any expression 
level, indicating that low expression levels were not responsible for this apparent lack 
of activity. Furthermore, the activity of BRAFWT:ER was not influenced by the exclusion 
of serum and phenol red from the cell culture medium. Of note, BRAFWT:ER 
accumulated at the plasma membrane. Following activation of cell surface receptors, 
endogenous BRAF is recruited to the plasma membrane by Ras, where it is activated 
by phosphorylation at a number of sites by various kinases. Therefore, BRAFWT:ER 
may associate with some of these proteins at the plasma membrane, while retaining an 
inactive conformation, potentially acting in a dominant negative manner to prevent 
activation of endogenous RAF proteins. In a similar vein, BRAFWT:ER may potentially 
dimerise with endogenous RAF protomers, but lack transactivation ability. However, 
the ability to activate the RAF/MEK/ERK pathway through alternative means in 
BRAFWT:ER-expressing cells was not investigated, and therefore the designation of 
BRAFWT:ER as a dominant negative construct would require additional work. 
 
BRAFD594A, BRAFD594V and the catalytic lysine mutant BRAFK483A lack kinase activity but 
retain the ability to transactivate CRAF and constitutively phosphorylate MEK in the 
presence of active Ras (Heidorn et al., 2010). Furthermore, RAF/MEK/ERK signalling 
can be impaired through the expression of catalytically inactive MEKK97R or ERKK52R or 
by the treatment with a growing number of inhibitors that act at each level of the kinase 
cascade (Poulikakos and Solit, 2011; Roberts and Der, 2007). Therefore, it would be 
difficult to justify using BRAFWT:ER to impair RAF/MEK/ERK signalling in an 




experimental setting, when so many established and well-characterised alternative 
approaches are available. 
 
ΔCRAF:ER fusion activate the RAF/MEK/ERK pathway in a 4HT-dependent 
manner 
In contrast to the full-length BRAF:ER fusion proteins, a series of alternatively tagged 
ΔCRAF:ER constructs exhibited low levels of basal activity, but could be induced by 
4HT treatment in a rapid and sustained manner. HA-, myc- and eGFP-tagged 
ΔCRAF:ER behaved in a similar fashion, providing a diverse range of molecular tools 
that have the potential to be used in conjunction with a variety of other tagged 
constructs, lending flexibility to experimental design. Further characterisation of 
eGFPΔCRAF:ER has revealed the kinetics of activation, highlighting important 
considerations for future TJ trafficking experiments.  
 
ΔCRAF:ER fusion proteins exhibit low basal activity 
Downstream phosphorylation of ERK positively correlated with eGFPΔCRAF:ER 
expression, even in the absence of 4HT, indicating a degree of “leaky” basal activity. 
However, there is a clear increase in the specific activity of eGFPΔCRAF:ER at all 
expression levels. Furthermore, on a population level, basal activity is extremely low, 
as assessed either by immunoblot or by mean values from immunostaining data. This 
indicates that the viral titre of approximately 10pfu/nl achieves suitable levels of 
transgene expression. Measurement of the average GFP intensity, a measure of 
construct expression, revealed that the majority of cells express relatively low levels of 
transgene, where basal activity is low, but is dramatically increased upon 4HT addition. 
As the majority of assays to be performed depend on population averages, this basal 
activity is unlikely to influence future results. However, it is worth considering, 
especially when studying individual cells by microscopy. Furthermore, control 
treatments involving transduced but unstimulated cells will be included wherever 
possible. 
 
Kinetics and mechanisms of ΔCRAF:ER activation 
Upon the addition of 4HT, downstream ERK phosphorylation is rapidly induced, with a 
clear increase evident within 15 minutes of 4HT addition. ERK phosphorylation is 
sustained for up to 48 hours while 4HT is present in the media. ΔCRAF:ER activation is 
reported to be reversible upon the removal of 4HT from the culture medium. This has 
the potential to allow the study of the junction reformation when normal levels of ERK 
signalling are reinstated.  
 




High-content microscopy and immunoblotting revealed that eGFPΔCRAF:ER 
expression levels increased over time when stimulated with 4HT. As cells were fixed or 
lysed at the same time, this was not a result of increased time in culture. Similar 
hormone-mediated increases in transgene level have been observed with ΔCRAF:ER, 
ΔBRAF:ER, ΔARAF:ER and MEK1:ER (Greulich and Erikson, 1998; McMahon, 2001; 
Pritchard et al., 1995; Samuels et al., 1993). This increase in expression level is at 
least in part, a consequence of increased stability of RAF:ER fusion proteins upon 
hormone binding, with initial reports indicating a 4 – 5-fold increase in ΔCRAF:ER half-
life following estradiol treatment (McMahon, 2001). While the inducible activity of 
MEK1:ER is largely regulated by this increase in expression level over 6 – 12 hours 
(Greulich and Erikson, 1998), expression-activity plots reveal a clear increase in the 
specific activity of each ΔCRAF:ER fusion protein within 15 minutes of 4HT addition. 
Furthermore, ΔCRAF:ER activation is reported to be insensitive to cycloheximide 
(Samuels et al., 1993), and hormone removal leads to rapid inactivation of ΔCRAF:ER, 
without the concurrent loss of transgene expression. These observations indicate that 
the activation is independent of protein neosynthesis and that a more rapid 
conformational change is the most relevant mechanism of hormone-mediated RAF:ER 
activation. This may involve the removal of the heat shock protein 90 (hsp90) 
chaperone from the hbER portion of the fusion protein, possibly permitting ΔCRAF:ER 
dimerisation and downstream pathway activation. Interestingly, although BRAFV600E can 
form dimers, it is active in a monomeric state. Therefore, dimerisation alone is probably 
inadequate to explain the hormone-dependent activity of BRAFV600E:ER constructs 
described elsewhere (Bergeron et al., 2010; Cagnol and Rivard, 2012; Liu et al., 2007). 
Alternatively, 4HT binding may relieve steric hindrance of the CRAF active site to 
increase MEK substrate access (McMahon, 2001). 
 
Although the three identified RAF isoforms ARAF, BRAF and CRAF have conserved 
structural similarities, they exhibit distinct biochemical properties, with BRAF exhibiting 
greater endogenous kinase activity than CRAF, and in turn ARAF. This is partially 
explained by a pair of tyrosine residues in CRAF and ARAF, which are phosphorylated 
when these kinases are activated. The analogous residues in BRAF are both replaced 
with aspartic acid, conferring a constitutive negative charge to this region. An additional 
serine residue within the N-region is constitutively phosphorylated in BRAF, but not 
ARAF or CRAF. The constitutive negative charge in the N-region primes BRAF for 
activation and consequently the basal activity of BRAF is considerably higher than that 
of ARAF and CRAF (Mason et al., 1999). This hierarchy of RAF kinase activity is 
maintained when ER fusion proteins are generated using their respective kinase 
domains. ΔBRAF:ER is 10-fold more potent than ΔCRAF:ER, which is in turn 50-fold  




more potent than ΔARAF:ER (Pritchard et al., 1995). Unpublished observations 
suggest that ΔBRAF:ER may exhibit increased nuclear localisation and therefore 
behave differently to both BRAFWT and BRAFV600E, which are primarily cytoplasmic. 
Cytoplasmic ΔCRAF:ER still exhibits high specificity for MEK, leads to downstream 
phosphorylation of ERK, and is capable of phenocopying BRAFV600E by inducing 
MDCKII transformation. This suggests that their modes of action and potency are 
relatively consistent. The discrepancy between the specific activity of BRAF and CRAF, 
and their respective ER fusion proteins, is unlikely to be relevant in this study; pathway 
output is determined by ΔCRAF:ER expression level, which can be regulated by 
varying the adenoviral titre.  
 
Potential off-target effects of 4HT 
4HT increased the activity of eGFPΔCRAF:ER in a concentration-dependent manner. 
Maximal activation was achieved at a concentration of 1µM 4HT, with partial activation 
achieved at lower concentrations. Increasing the concentration to 10µM 4HT failed to 
increase either mean or specific activity. Tamoxifen has been reported to reduce 
MDCK cell viability by increasing intracellular calcium concentrations, [Ca2+]i. This is 
achieved by triggering the release of Ca2+ from multiple intracellular stores and through 
Ca2+ influx from the extracellular space (Jan et al., 2000). 4HT has been reported to 
mediate a similar ATP-dependent increase in [Ca2+]i through the upregulation of protein 
phosphatase 1 alpha (PP1alpha) and the inositol 1,4,5-triphosphate receptor (IP3R) 
(Bollig et al., 2007). Therefore, at high concentrations, ER antagonists can exhibit non-
estrogen receptor mediated toxicity. Effects on calcium handling are of particular 
importance as cell adhesion is calcium-dependent (Hirano et al., 1987). Furthermore, 
cadherin-cadherin interactions induce transient fluxes of [Ca2+]i, which are associated 
with actin remodelling and the reinforcement of cell contact through catenin and 
cadherin recruitment (Ko et al., 2001). However, in MDCKII cells, [Ca2+]i was not 
increased by 1µM tamoxifen, although a minor decrease in viability was evident (Jan et 
al., 2000). Of note, 1µM tamoxifen, but not 1µM 4HT, induces apoptosis in mammary 
epithelial cells (Dietze et al., 2001). This suggests that tamoxifen and 4HT are not 
entirely equivalent in terms of function or undesirable side effects. Importantly, the use 
of 1µM 4HT to activate RAF:ER fusion proteins in MDCK cells in this work is consistent 
with previous studies, where no off-target effects have been reported (Doehn et al., 
2009; Hansen et al., 2000). However, for subsequent experiments, it will be important 
to include 4HT control treatments of nontransduced cells wherever possible to account 
for potential effects of calcium handling or decreased cell viability. 
 
  




Specificity of RAF:ER fusion proteins 
The only bona fide substrates of RAF proteins are MEK kinases (Matallanas et al., 
2011), which selectively phosphorylate ERK (Roskoski, 2012). Previous 
characterisation of RAF:ER fusion proteins using a variety of estrogen receptor 
agonists and antagonists have indicated that the reported biological effects are not due 
to activation of endogenous estrogen receptors (Pritchard et al., 1995). Activation of 
the ERK pathway is rapid, but additional phosphorylation and activation of the JNK 
pathway has been reported 24-48 hours after RAF:ER activation (Pritchard et al., 
1995). This is thought to occur as a result of ERK-mediated secretion of heparin-
binding EGF (hbEGF), which activates the JNK pathway in an autocrine fashion 
(Pritchard et al., 1995). Of note, JNK signalling is required for TER development in 
airway epithelia and can promote TJ formation downstream of CDC42 (Tanos et al., 
2015). This is still a biologically relevant effect of long-term RAF/MEK/ERK pathway 
activation, and JNK signalling represents just one of many potential mediators that may 
execute ERK-mediated changes in TJ structure and function. As RAF:ER activation is 
independent of protein neosynthesis, immediate-early and delayed transcriptional 
responses can be distinguished through the use of cycloheximide. In contrast to the 
full-length BRAF constructs described in chapter 3, subsequent experiments presented 
in chapter 5 indicate that PD0325901 effectively blocks ERK phosphorylation 
downstream of eGFP∆CRAF:ER activation, without causing a complete loss of 
transgene expression. This may be due to the counteracting increase in 
eGFP∆CRAF:ER stability following hormone addition (McMahon, 2001). Therefore, 
there is also scope to use small molecule inhibitors to probe the requirement for 
different downstream signalling pathways on specific TJ-associated effects of 
∆CRAF:ER activation. 
 
Broad utility of generated vectors 
As well as providing the ability to activate the RAF/MEK/ERK pathway in a specific and 
rapid fashion, ΔCRAF:ER proteins provide a potential tool for studying the role of RAF 
regulation and feedback. ΔCRAF:ER consists solely of the kinase domain and lacks 
the N-terminal regulatory region. ΔCRAF:ER therefore lacks five out of six ERK 
phosphorylation sites, making it resistant to ERK-mediated feedback regulation 
(Samuels et al., 1993; Sturm et al., 2010). The ability to break these feedback loops 
can help to determine their biological significance. BRAFV600E is immune to ERK-
mediated negative feedback, so recognising the underlying biology has important 
implications for understanding the pathogenesis of BRAFV600E-driven tumours. This is 
also the first instance of developing inducible-activity RAF:ER fusion proteins in 
adenoviral vectors. These vectors have broad utility as the constructs can easily and 




efficiently be expressed in a wide array of cell types that express the coxsackie 
adenovirus receptor (CAR), without requiring stable transfection. This has the potential 
for achieving specific ERK pathway modulation in cell lines that are typically hard to 
transfect, such as neurones or primary human cells. 
 
4.5 Limitations and future work 
Adenoviral vectors have the potential to allow ΔCRAF:ER expression in a variety of 
cells types. This will allow the study of RAF/MEK/ERK signalling with increased control 
of signal strength and duration in a broad variety of conditions. eGFP∆CRAF:ER does 
exhibit a relative degree of leaky activity in the absence of hormone, and although this 
appears to be largely limited to a small proportion of cells expressing high levels of 
transgene, this must be considered when analysing images of individual transduced 
cells. It will be important to include eGFP∆CRAF:ER-expressing cells that have not 
been stimulated with 4HT as a control wherever possible. This leaky activity should 
prove less of an issue on the population level, as increased ppERK1/2 levels are not 
detectable in the absence of hormone by immunoblot. Going forward, ΔCRAF:ER 
fusion proteins will therefore allow coordinated activation of the RAF/MEK/ERK 
pathway to study temporal aspects of TJ protein regulation, in terms of expression and 




 BRAFV600E:ER exhibits unacceptably high levels of basal activity, while 
BRAFWT:ER is unable to induce ERK phosphorylation. 
 
 HA-, myc- or eGFPΔCRAF:ER exhibit relatively low levels of basal activity but 
are activated upon the addition of 4HT. 
 
 Maximal ΔCRAF:ER activation is achieved using 1µM 4HT, a concentration that 
is unlikely to have significant off-target effects. 
 
 ΔCRAF:ER activation is rapid and sustained while 4HT is present in the culture 
medium.















Chapter 5: Tight junction regulation by ΔCRAF:ER 
 





RAF/MEK/ERK activity negatively correlates with claudin-2 expression, both at the 
mRNA and protein level (Doehn et al., 2009; García-Hernández et al., 2015; Ikari et al., 
2011c; Singh and Harris, 2004). Activation of ∆CRAF:ER leads to the downregulation 
of CLDN2 mRNA, indicating that its downregulation is at least partially due to 
decreased transcription. Additionally, recent studies involving EGF and small molecule 
MEK inhibitors implicate the RAF/MEK/ERK pathway in increasing claudin-2 protein 
turnover (Ikari et al., 2011c). The loss of claudin-2 protein downstream of EGFR 
activation is effectively complemented by inhibition of clathrin-mediated endocytosis or 
lysosomal function (Ikari et al., 2011c). These observations alone indicate that the 
existing membranous claudin-2 protein pool must be turned over by trafficking from the 
cell surface and along the degradative pathway (Ikari et al., 2011c). In the same study, 
EGF induced a MEK-dependent decrease in claudin-2 stability in the presence of 
cycloheximide, while earlier reports concluded that cycloheximide did not influence the 
EGF-mediated decrease in claudin-2 protein levels, in detergent-soluble or -insoluble 
fractions (Singh and Harris, 2004). Therefore, the consequences of EGF treatment, 
and specifically the downstream role of the RAF/MEK/ERK pathway, on claudin-2 
degradation rates need to be addressed. Furthermore, the actual rates of claudin-2 
internalisation and recycling have not been determined. It is therefore unclear to what 
extent RAF/MEK/ERK activity regulates claudin-2 protein synthesis, trafficking and 
turnover. 
 
While sustained activation of the RAF/MEK/ERK pathway by long-term expression of 
oncogenic Ras or soluble HB-EGF results in the loss of barrier function and the 
cytoplasmic sequestration of various TJ proteins, transient activation with EGF leads to 
the junctional accumulation of claudin-1, -3 and -4. The EGF-mediated junctional 
accumulation of claudin-3 and -4 is largely blocked by cycloheximide, suggesting that 
increased junctional levels are mainly due to increased protein synthesis. In contrast, 
junctional fraction levels of claudin-1 still increased in the presence of cycloheximide, 
suggesting that post-translational mechanisms may underlie the translocation of 
existing claudin-1 protein. Although altered endocytic trafficking is proposed as a 
potential mechanism for claudin redistribution, this has not been studied in any detail. 
Furthermore, these effects were not attributed to any specific downstream signalling 
pathway and it is unclear if specific activation of the RAF/MEK/ERK pathway is 
sufficient to drive similar changes in the distribution of claudin-1, -3 and -4. Increased 
junctional levels of claudin-1, -3 and -4 could potentially be mediated by reduced rates 
of endocytosis or increased recycling, rather than degradation, of internalised protein.  
 




The generation of adenoviruses to express hormone-dependent ∆CRAF:ER constructs 
provides the ability to conditionally activate the RAF/MEK/ERK pathway in a 
coordinated manner across a whole cell population. Therefore, these constructs permit 
the immediate effects of RAF/MEK/ERK pathway activation to be studied, prior to gross 
changes in epithelial morphology elicited by longer-term expression of oncogenic 
BRAFV600E.observed in chapter 3. Most importantly, the initiation and duration of 
signalling can be tightly regulated through the addition and removal of 4HT to culture 
medium, allowing the biochemical analysis of claudin protein degradation, 
internalisation and recycling rates.  
 
5.2 Aims and objectives 
The aims of this chapter are to establish how specific activation of the RAF/MEK/ERK 
pathway affects the rates of claudin internalisation, degradation and endocytic 
trafficking. This will be achieved by completing the following objectives: 
 
1. Characterise the time course of claudin regulation by ∆CRAF:ER activation 
using a combination of immunoblotting, confocal microscopy and high-content 
imaging. 
 
2. Evaluate the time scale of changes in epithelial barrier function through 
transepithelial electrical resistance measurements. 
 
3. Determine the specific effect of RAF/MEK/ERK activity on relevant CLDN 
mRNA levels using real-time quantitative PCR. 
 
4. Assess the impact of RAF/MEK/ERK activity on the subcellular distribution and 
rates of internalisation, degradation and recycling using a surface-biotinylation 









5.3.1 ΔCRAF:ER activation differentially regulates claudin expression 
To characterise ΔCRAF:ER-mediated changes in TJ protein levels, confluent MDCKII 
cells were transduced with AdCMVeGFPΔCRAF:ER and treated with 1µM 4HT for 1 – 
48 hours (Figure 5.1A). ΔCRAF:ER expression was confirmed by GFP immunoblot 
(Figure 5.1A). As demonstrated in the previous chapter, ΔCRAF:ER expression levels 
increased between 6 and 48 hours (Figure 5.1B). ppERK1/2 levels were more rapidly 
increased within 1 hour of 4HT addition, and maintained for at least 48 hours while 4HT 
was present in the culture medium (Figure 5.1C). Levels of ppERK1/2 were not 
affected in nontransduced cells treated with 1µM 4HT for up to 48 hours (Figure 5.1C), 
indicating that RAF/MEK/ERK pathway activation was due to targeted activation of 
ΔCRAF:ER. Total levels of ERK1/2 were unaffected, indicating regulation by 
phosphorylation rather than at the total protein level (Figure 5.1D). 
 
Claudin protein levels were determined by immunoblot under the same conditions. 
Protein levels of claudin-1 and -2 gradually decreased between 6 and 48 hours of ERK 
activation (Fig. 5.1E and F), whereas claudin-4 levels were largely unaffected (Figure 
5.1G).  
 
Claudin levels were also determined by high-content microscopy. 4HT-treated cells 
were fixed and immunostained for claudin-1, -2 and -4 (Figure 5.2). The average 
immunofluorescence intensity across each image was quantified and used to compare 
relative claudin protein levels between different experimental conditions (Figure 5.3). In 
∆CRAF:ER-expressing cells, claudin-2 intensity decreased after 6 – 24 hours of 4HT 
treatment. Claudin-2 intensity had decreased by approximately 60% after 24 hours 
(Figure 5.3B). Claudin-1 intensity was not affected under the same conditions (Figure 
5.3A), but a minor yet significant increase of approximately 20% in claudin-4 intensity 
was observed (Figure 5.3C). Claudin-1, -2 and -4 intensity levels were not affected by 
either ∆CRAF:ER expression or 4HT treatment alone (Figure 5.3, top row). 
 
Altered claudin protein levels occurred with a concomitant 1.5 – 2-fold increase in TER, 
before beginning to decrease towards baseline levels at later time points (Figure 5.4D). 
The TER of nontransduced cells was stable over this 24 hour period (Figure 5.4A) and 
was not affected by 4HT treatment (Figure 5.4B). ∆CRAF:ER expression alone led to a 
minor yet gradual increase in TER over 48 hours, but this did not reach statistical 
significance when compared to untreated MDCKII monolayers (Figure 5.4C). 
 
 







Figure 5.1: ΔCRAF:ER activation differentially regulates protein levels of claudin-1, -2 
and -4. Confluent MDCKII cells were transduced to express ΔCRAF:ER and treated with 1µM 
4HT for the indicated times, prior to cell lysis. (A) Cell lysates were subjected to SDS-PAGE and 
immunoblot to determine downstream ERK1/2 phosphorylation and effects on claudin protein 
levels. ΔCRAF:ER expression was confirmed by immunoblotting for GFP (B). Increased 
ppERK1/2 levels were detected within 1 hour of 4HT addition (C), while total ERK1/2 levels 
were not affected (D). Increased ERK1/2 phosphorylation correlated with decreased total levels 
of claudin-1 (E) and claudin-2 (F), while claudin-4 levels were unaffected (G). The following 
pairs of immunoblots were obtained from the same gel: ERK1/2 and claudin-1, ppERK1/2 and 
claudin-2. Data is presented from a single biological repeat. Similar results are reported in 
Figure 5.5. 
  









































































































































































































































































































































































































































Figure 5.3: ΔCRAF:ER activation differentially affects claudin immunostaining intensity. 
Nontransduced or ∆CRAF:ER-expressing MDCKII cells were fixed and immunostained for 
claudin-1 (A), -2 (B) or -4 (C). The average immunostaining intensity for each marker was 
quantified using INCell Developer Toolbox software and used to compare claudin levels 
between experimental conditions. 4HT treatment did not affect claudin intensity in 
nontransduced cells (top row). ERK activation did not affect claudin-1 intensity, but led to a 
gradual decrease in claudin-2 intensity after 6 – 24 hours of 4HT treatment. In contrast, claudin-
4 intensity was increased by approximately 20% under the same conditions. Data are presented 
as mean values ±s.e.m. from three biological repeats. Data were compared to nontransduced -
4HT conditions at each time point using a two-way ANOVA with Bonferroni post-test, * p<0.05, 
** p<0.01. Representative images are presented in Figure 5.2. 
 
 
Figure 5.4: ΔCRAF:ER activation increases MDCKII transepithelial resistance. The 
epithelial permeability of MDCKII monolayers were determined by measuring transepithelial 
resistance (TER). TER was stable over the course of the experiment in nontransduced cells, in 
either the absence (A) or presence (B) of 1µM 4HT. Expression of ∆CRAF:ER caused a minor 
yet insignificant increase in TER (C). ∆CRAF:ER activation with 1µM 4HT caused a significant 
increase in TER between 12 and 24 hours after treatment commenced (D). TER began to 
decrease at later time points, but remained elevated compared to basal conditions. Data are 
presented as mean values ±s.e.m. from three biological repeats. Data were compared at each 
time point using a repeated measures two-way ANOVA with Bonferroni post-test, * p<0.05, ** 
p<0.01. 




To confirm that the observed decrease in claudin-2 protein levels was due to activation 
of the ERK pathway, transduced cells were treated with 4HT in combination with the 
MEK inhibitor, PD0325901 (Figure 5.5A). 24 hour 4HT treatment led to a consistent yet 
statistically insignificant decrease in claudin-1 levels (Figure 5.5B). This apparent 
decrease was not evident when cells were treated with 4HT in combination with either 
PD0325901 or chloroquine (Figure 5.5B). This suggests that any minor decrease in 
claudin-1 levels driven by ∆CRAF:ER is dependent on elevated MEK activity and 
proceeds via lysosomal degradation. 24 hour 4HT treatment significantly decreased 
claudin-2 protein levels by approximately 80%, and this was completely blocked by co-
treatment with PD0325901 (Figure 5.5C). Claudin-2 protein depletion was also 
effectively blocked by co-treatment with chloroquine, an inhibitor of lysosomal 
degradation (Figure 5.5C). Interestingly, treatment with chloroquine alone led to an 
increase in levels of claudin-1 and -2, which was not evident when cells were also 
treated with 4HT (Figure 5.5C). This suggests that ∆CRAF:ER activation may inhibit 
the synthesis of claudin-1 and -2. 
 
In contrast, claudin-4 levels were not affected by ∆CRAF:ER activation (Figure 5.5D). 
However, claudin-4 levels did increase following treatment with chloroquine. Which was 
marginally potentiated by the addition of 4HT (Figure 5.5D). Taken together with the 
immunostaining data (Figure 5.3C), this suggests that a minor increase in total claudin-
4 levels may be as a result of increased claudin-4 synthesis. 
 
Altered mRNA levels could potentially account for changes in claudin protein level. The 
effect of RAF/MEK/ERK activity on CLDN transcript levels was therefore determined by 
RT-qPCR. CLDN1 and CLDN4 mRNA levels were not significantly affected following 
the treatment of ΔCRAF:ER-expressing cells with 1µM 4HT for 24 hours (Figure 5.6A 
and C). Under the same conditions, CLDN2 mRNA levels were decreased by over 8-
fold in comparison to control (Figure 5.6B). ∆CRAF:ER expression or 4HT treatment 
alone failed to affect any CLDN mRNA transcript level (Figure 5.6). To conclude, 
activation of the RAF/MEK/ERK pathway alone is sufficient to drive an increase in 
MDCKII TER, which occurs concurrently with the differential regulation of claudin-1, -2 
and -4. Claudin-2 is depleted at both the mRNA and protein level, claudin-4 protein, but 
not mRNA, levels are marginally increased and claudin-1 protein levels are marginally 














Figure 5.5: Combined effects of ∆CRAF:ER activation, MEK inhibition and chloroquine 
treatment on claudin protein levels. ∆CRAF:ER-expressing MDCKII cells were treated with 
1µM 4HT, 5µM PD0325901 (MEKi) or 100µM chloroquine (CQ) (a lysosomal inhibitor) for 24 
hours as indicated. (A) Cells were lysed and relative claudin levels were determined by 
immunoblot. Claudin-2 depletion was effectively blocked by treatment with either PD0325901 or 
chloroquine (C). MEK inhibition did not significantly alter levels of claudin-1, -2 or -4. Claudin-1 
and -2 accumulate in the presence of chloroquine alone, but not when co-treated with 4HT. 
Conversely, chloroquine-mediated claudin-4 accumulation is potentiated by 4HT. Immunoblots 
are representative of three biological repeats. Data is presented as mean values ±s.e.m. from 
three independent experiments. The following pairs of blots were obtained from the same gel: 
ERK1/2 and claudin-1, ppERK1/2 and claudin-2. Data were compared to control conditions 
using a one-way ANOVA with Dunnett’s post-test, * p<0.05. 
  






Figure 5.6: Levels of CLDN1, CLDN2 and CLDN4 mRNA are differentially regulated by 
ΔCRAF:ER activation. Nontransduced or ∆CRAF:ER-expressing MDCKII cells were treated 
with  or without 1µM for 24 hours prior to total RNA isolation.. Relative CLDN mRNA levels were 
determined by RT-qPCR RAF/MEK/ERK activity decreased mRNA levels of CLDN2 (B) without 
affecting those of CLDN1 (A) or CLDN4 (C). Data are presented as mean fold changes ±s.e.m. 
from three independent experiments. Data were compared to control treatments using a one-





5.3.2 RAF/MEK/ERK activity causes claudin-2 protein depletion without inducing 
its prior accumulation in the cytoplasm 
To establish if RAF/MEK/ERK activity influences claudin-2 protein localisation in 
addition to expression levels, its subcellular distribution was determined by confocal 
microscopy. Claudin-2 normally localised to the apical-most tip of the lateral membrane 
(Figure 5.7A), consistent with its localisation at the TJ. This distribution was maintained 
in nontransduced cells treated with 4HT (Figure 5.7B) or those expressing ΔCRAF:ER 
(Figure 5.7C). 24 hours after 4HT addition, claudin-2 intensity was almost completely 
lost in cells expressing ΔCRAF:ER, while apical junction staining was maintained in 
neighbouring nontransduced cells (Figure 5.7D), indicating that activation of the 
RAF/MEK/ERK pathway alone caused claudin-2 protein depletion in a cell-autonomous 
manner. Moreover, the reduction in TJ-localised claudin-2 did not coincide with a 
concomitant increase in cytoplasmic claudin-2 (Figure 5.8), indicating that junctional 
claudin-2 was not endocytosed en masse prior to its degradation.  
  










Figure 5.7: ΔCRAF:ER activation causes the cell-autonomous depletion of claudin-2 
protein. Nontransduced or ∆CRAF:ER-expressing MDCKII cells were treated with 1µM 4HT for 
24 hours prior to fixation. Claudin-2 distribution was assessed by immunostaining and confocal 
microscopy. Each condition shows an overhead projection of multiple Z-slices, with an 
orthogonal cross section taken through indicated plane (dashed line). (A) In control conditions, 
claudin-2 localises to the apical-most tip of the lateral membrane, and this is maintained in 
nontransduced cells treated with 4HT (B) or in those expressing ∆CRAF:ER (C). Following 
∆CRAF:ER activation with 4HT, claudin-2 is almost completely lost in ∆CRAF:ER-expressing 
cells, while it is maintained in adjacent nontransduced cells. Images are representative of three 
independent experiments. Scale bar = 20µm. 
  






Figure 5.8: Claudin-2 does not accumulate internally prior to degradation. Confluent 
MDCKII cells expressing ∆CRAF:ER were treated with 1µM 4HT for the indicated times. Cells 
were fixed and stained for claudin-2. Junctional claudin-2 intensity gradually decreases over 24 
hours, without a concomitant increase in cytoplasmic claudin-2 staining. This suggests claudin-2 
is not internalised en masse prior to degradation. Images are representative of three biological 
repeats. Scale bar = 10µm. 
 
5.3.3 RAF/MEK/ERK activity causes claudin-1 and -4 to accumulate at the tight 
junction 
By immunoblot, total claudin-1 levels were marginally downregulated (Figure 5.1), 
although not to a statistically significant level (Figure 5.5). Claudin-1 distribution was 
determined using confocal microscopy to establish if RAF/MEK/ERK signalling had 
more pronounced effects on its subcellular localisation. In contrast to claudin-2, which 
localised to the apical junction, claudin-1 was predominantly localised along the lateral 
membrane (Figure 5.9A). Claudin-1 staining was continuous, but overlapped minimally, 
with that of ZO-1, a peripheral protein commonly used as a TJ marker (Figure 5.9A). 
This localisation pattern was maintained in nontransduced cells treated with 4HT 
(Figure 5.9B) or cells expressing ΔCRAF:ER (Figure 5.9C). However, there was a clear 
change in distribution following ΔCRAF:ER activation; claudin-1 was depleted from the 
lateral membrane and accumulated at the apical junction, where it colocalised with ZO-
1 (Figure 5.9D). Strong junctional ZO-1 staining was maintained under these 
conditions, although increased diffuse cytoplasmic staining was also evident (Figure 
5.9D). Confocal microscopy revealed a redistribution of claudin-4 similar to that of 
claudin-1 (Figure 5.10). Under each control condition, cells maintained weak lateral 
membrane claudin-4 staining (Figure 5.10A – C) but there was a striking accumulation 
of claudin-4 at the apical junction following ΔCRAF:ER activation (Figure 5.10D). 







Figure 5.9: ΔCRAF:ER  activation causes claudin-1 to accumulate at the apical junction 
and throughout the cytoplasm. Confluent ΔCRAF:ER-expressing MDCKII cells were treated 
with 1µM 4HT for 24 hours prior to fixation and immunostaining for claudin-1 and ZO-1. Images 
are overhead projections of multiple Z-slices. Orthogonal views were taken in the indicated 
plane (dashed line). Confluent MDCKII cells expressing ∆CRAF:ER  were treated with or 
without 1µM 4HT for 24 hours prior to fixation. (A) Claudin-1 is normally associated with the 
lateral plasma membrane, where it localises basally to the apical junction marker, ZO-1. This 
immunostaining pattern is maintained in nontransduced cells treated with 4HT (B), or in 
ΔCRAF:ER-expressing cells cultured in the absence of 4HT (C). (D) Following ΔCRAF:ER 
activation, claudin-1 accumulates at the apical junction, colocalising with ZO-1. Punctate 
claudin-1 staining is also visible throughout the cytoplasm. Continuous junctional ZO-1 staining 
is conserved following ΔCRAF:ER activation, although diffuse cytoplasmic staining is also 
visible. Images are representative of three independent experiments. Scale bar = 20µm.  
  








Figure 5.10: ΔCRAF:ER  activation causes claudin-4 to accumulate at the apical junction 
and throughout the cytoplasm. Confluent ΔCRAF:ER-expressing MDCKII cells were treated 
with 1µM 4HT for 24 hours prior to fixation and immunostaining for claudin-4. Images are 
overhead projections of multiple Z-slices. Orthogonal views were taken in the indicated plane 
(dashed line). Confluent MDCKII cells expressing ∆CRAF:ER  were treated with or without 1µM 
4HT for 24 hours prior to fixation. (A) Claudin-4 is normally associated with the lateral plasma 
membrane, and this is maintained in nontransduced cells treated with 4HT (B), or in 
ΔCRAF:ER-expressing cells cultured in the absence of 4HT (C). (D) Following ΔCRAF:ER 
activation, claudin-4 accumulates at the apical junction. Increased claudin-4 staining is also 
visible throughout the cytoplasm. Images are representative of three independent experiments. 
Scale bar = 20µm. 
  




5.3.4 Claudin-1 and -4 colocalise at the apical junction and in common 
cytoplasmic compartments 
In addition to increased junctional staining, ∆CRAF:ER activation induced the 
accumulation of claudin-1 and -4 in discrete cytoplasmic punctae (Figures 5.9D and 
5.10D). MDCKII cells were costained for claudin-1 and -4 to determine if they 
colocalised following treatment. In control-treated cells, claudin-1 and -4 extensively 
colocalised along the lateral membrane (Figure 5.11A – C). Following ∆CRAF:ER 
activation, claudin-1 and -4 also colocalised at the apical junction and in common 
cytoplasmic compartments (Figure 5.11D).  
 
To determine if this internal accumulation represented universal or bulk internalisation 
of all TJ components, MDCKII cells were costained for claudin-1 and occludin under 
the same experimental conditions (Figure 5.12). Occludin was predominantly 
concentrated at the apical junction, with weaker lateral plasma membrane staining that 
partially colocalised with that of claudin-1 (Figure 5.12A). This staining pattern was 
maintained in nontransduced cells treated with 4HT (Figure 5.12B), or in ΔCRAF:ER-
expressing cells cultured in the absence of 4HT (Figure 5.12C). Following 24 hours of 
ΔCRAF:ER activation, claudin-1 exhibited increased junctional staining and was 
present in discrete cytoplasmic structures (Figure 5.12D). However, the subcellular 
distribution of occludin was largely unaffected; apical junction and lateral membrane 
staining were conserved, and although there was a slight diffuse cytoplasmic signal, 
occludin did not colocalise with claudin-1 in the cytoplasm (Figure 5.12D). Therefore, in 
a similar manner to BRAFV600E expression, ΔCRAF:ER activation has distinct effects on 
the subcellular distribution of individual TJ components. RAF/MEK/ERK activation 
appears to drive the loss of claudin-2 expression and specifically increase the 
junctional levels of claudin-1 and -4, but not occludin or ZO-1. 
  








Figure 5.11: Claudin-1 and -4 extensively colocalise in both control and 4HT-treated 
conditions. Confluent ΔCRAF:ER-expressing MDCKII cells were treated with 1µM 4HT for 24 
hours prior to fixation. Images are representative of cells costained for claudin-4 and claudin-1. 
Overhead projections are shown with orthogonal views taken in the indicated plane (dashed 
line). (A) Claudin-1 and -4 normally colocalise along the lateral plasma membrane, and this 
staining pattern is maintained in nontransduced cells treated with 4HT (B), or in unstimulated 
ΔCRAF:ER-expressing cells (C). (D) Following activation of ∆CRAF:ER with 4HT, claudin-1 and 
-4 colocalise at the apical junction, along the lateral membrane and in common cytoplasmic 
compartments. Images are representative of two independent biological repeats. Scale bar = 
10µm. 
  








Figure 5.12: Occludin does not accumulate with claudin-1 at the apical junction or in 
cytoplasmic punctae. Confluent ΔCRAF:ER-expressing MDCKII cells were treated with 1µM 
4HT for 24 hours prior to fixation. Images are representative of cells costained for occludin and 
claudin-1. Overhead projections are shown with orthogonal views taken in the indicated plane 
(dashed line). (A) Occludin normally accumulates at the apical junction, with weaker lateral 
membrane staining that partially colocalised with claudin-1. This staining pattern is maintained 
in nontransduced cells treated with 4HT (B), or in unstimulated ΔCRAF:ER-expressing cells (C). 
After 24 hours of ΔCRAF:ER activation, claudin-1 exhibited increased localisation at the apical 
junction and in discrete cytoplasmic punctae (D). However, occludin was maintained at the 
lateral membrane and apical junction and did not colocalise with claudin-1 in the cytoplasm (D). 
Images are representative of two independent biological repeats. Scale bar = 10µm. 
  




5.3.5 Characterisation of a surface-biotinylation biochemical trafficking assay 
A surface-biotinylation-based biochemical trafficking assay was utilised to determine 
the effects of ΔCRAF:ER activation on the rates of claudin internalisation, degradation 
and endocytic recycling. The assay was initially validated by assessing the trafficking 
rates of the transferrin receptor (TfR), a cell surface protein commonly used as a 
marker that undergoes rapid and constitutive endocytic recycling (Fuller and Simons, 
1986). Surface TfR was labelled with a membrane-impermeant biotin moiety, which 
could be retrieved by neutravidin pulldown (Figure 5.13A). Immunoblots revealed that 
the α-TfR antibody detected a single major band of approximately 100kDa, consistent 
with its predicted molecular weight ~90kDa (Figure 5.13A) (Fuller and Simons, 1986). 
A band of the same molecular weight was retrieved following neutravidin pulldown of 
surface-biotinylated, but not mock-labelled cells, indicating the specificity of the 
pulldown for biotinylated proteins (Figure 5.13A). Furthermore, cytoplasmic ERK1/2 
was not detectable in pulldown samples, indicating the specificity of the biotinylation 
label for cell surface proteins (Figure 5.13B).  Biotin was efficiently removed from 
labelled TfR with 2-mercaptane ethane sulphonate (MESNA), a membrane-impermeant 
reducing agent. To assess endocytosis, surface proteins were biotinylated on ice and 
incubated at 37°C to allow trafficking to resume. Biotin was stripped from remaining 
surface proteins, while internalised proteins were protected by the intact plasma 
membrane. After 1 hour, approximately 40% of surface-biotinylated TfR was resistant 
to surface-stripping, compared to less than 10% in strip control conditions, indicating 
the relative degree of TfR internalisation (Figure 5.13A). 
 
The fate of internalised TfR was investigated by surface-labelling and subjecting cells 
to the endocytosis assay before a second 20-minute incubation at 37°C to allow 
recycling back to the plasma membrane. Cells were then lysed, either before or after 
surface-stripping, to assess the relative extent of TfR degradation and recycling over 
the course of the second incubation. This revealed that the vast majority of internalised 
TfR was recycled rather degraded (Figure 5.13A). Interestingly, significantly more TfR 
and E-cadherin were initially labelled after 24 hours of ΔCRAF:ER activation (Figure 
5.13A and C). In MDCKII cells, TfR and E-cadherin are largely confined to the 
basolateral membrane (Fuller and Simons, 1986; Miranda et al., 2001), and the ability 
to label more of these proteins with apically applied biotin suggests that ΔCRAF:ER 
activation increases leak pathway biotin permeability. However, the proportion of 
labelled TfR that is endocytosed, degraded and recycled was similar in both control 
and 4HT-treated conditions. Furthermore, E-cadherin underwent negligible endocytosis 
under any experimental condition (Figure 5.13C), indicating the ability of the surface-








Figure 5.13: ΔCRAF:ER  activation does not influence the endocytic trafficking of claudin-1, -2 or -
4. Confluent MDCKII cells expressing ΔCRAF:ER were treated with or without 1µM 4HT for 24 hours. Cells 
were surface-biotinylated and subjected to the biochemical trafficking assay. The “label” lane indicates the 
amount of protein initially biotinylated at the cell surface. Internalised protein is resistant to surface-
stripping. Relative degradation is shown by a minor reduction in signal between internalisation and 
degradation lanes. (A) The assay was validated by measuring endocytic trafficking of the transferrin 
receptor (TfR), a cell-surface protein that undergoes rapid and constitutive recycling. Approximately 40% 
of surface-labelled TfR is endocytosed after 1 hour. The majority of this internalised TfR is subsequently 
recycled back to the plasma membrane within 20 minutes allowing its removal by a second surface-strip. 
Increased amounts of basolateral TfR were labelled following ΔCRAF:ER activation, despite TfR lysate 
input levels remaining constant. (B) Surface-biotinylation was specific to cell-surface proteins as 
cytoplasmic ERK1/2 was only detectable in whole cell lysates, and not neutravidin pulldowns. (C) The 
increase ability to apically biotinylate the basolateral proteins E-cadherin and TfR suggest that ΔCRAF:ER 
activation increases paracellular leak pathway permeability to biotin. (D) The amount of claudin-2 retrieved 
by neutravidin pulldown was decreased by approximately 50% following ΔCRAF:ER activation at each 
stage of the assay. Whole cell lysate levels were decreased by a similar extent and quantification 
presented in Figure 5.14 indicates that claudin-2 trafficking was unaffected by ΔCRAF:ER activation. 
Similar conclusions were drawn for claudin-1 (E) and -4 (F); despite increased initial surface-labelling, the 
proportion of this labelled protein that was internalised, degraded and recycled was not affected by 
ΔCRAF:ER activation (see Figure 5.15 and 5.16, respectively). Immunoblots are representative of three 
independent biological repeats. Claudin-1 and ERK1/2 lysate immunoblots were obtained from the same 
gel. 




5.3.6 RAF/MEK/ERK activity does not influence claudin-2 trafficking  
Although claudin-2 did not appear to accumulate in the cytoplasm prior to its loss 
(Figure 5.8), internalised claudin-2 could potentially have been degraded at a rate 
sufficient to prevent its internal accumulation. To address the possibility that 
accelerated protein turnover acts in concert with reduced mRNA synthesis to 
downregulate claudin-2 levels, the surface-biotinylation based trafficking assay was 
utilised to track the rates of claudin-2 trafficking and degradation. In unstimulated 
ΔCRAF:ER-expressing cells, claudin-2 was successfully retrieved by neutravidin 
pulldown following biotinylation, but not in the “no biotin” control sample, and was 
efficiently removed by surface-stripping with MESNA (Figure 5.13D). After 1 hour, 
approximately 40% of surface-biotinylated claudin-2 was resistant to surface-stripping, 
compared to approximately 20% in strip control conditions, indicating the relative 
degree of claudin-2 internalisation (Figure 5.13D). Following the second incubation, the 
majority of internalised claudin-2 was recycled, while a small amount was degraded 
(Figure 5.13D). 
 
The biotinylation assay was performed in parallel with ΔCRAF:ER-expressing cells that 
had been pre-treated with 1µM 4HT for 24 hours (Figure 5.13D and 5.14). The amount 
of surface-biotinylated claudin-2 retrieved by neutravidin pulldown was decreased by 
approximately 50% at each step of the biotinylation assay (Figure 5.14A). However, the 
amount of claudin-2 in the whole cell lysates was decreased by a similar amount 
(Figure 5.14B). When the pulldown levels were normalised to those in the whole cell 
lysate, there was no significant difference in the amount of claudin-2 that was initially 
surface-labelled (Figure 5.14C). Furthermore, the proportion of surface-biotinylated 
claudin-2 that was internalised, degraded and recycled was identical in both control 
and 4HT-treated conditions (Figure 5.14D). This indicates that although ΔCRAF:ER 
activation decreased total claudin-2 levels, the proportion of the remaining claudin-2 
pool existing at the cell surface was not affected. Moreover, this surface-biotinylated 
claudin-2 underwent similar rates of internalisation, degradation and recycling 

















Figure 5.14: ΔCRAF:ER activation causes claudin-2 depletion without affecting its 
subcellular distribution or endocytic trafficking. The data presented are quantified values of 
the biotinylation assay immunoblots presented in Figure 5.13. Confluent MDCKII cells 
expressing ΔCRAF:ER were treated with or without 1µM 4HT for 24 hours. Cells were surface-
biotinylated and subjected to the trafficking assay. The “label” lane indicates the amount of 
claudin-2 initially biotinylated at the cell surface. Internalised protein is resistant to surface-
stripping. Relative degradation is shown by a minor reduction in signal between internalisation 
and degradation lanes. Recycling is indicated by the reduction of signal in the recycling lane 
relative to the degradation lane. ∆CRAF:ER  activation reduces claudin-2 pulldown (A) and 
lysate levels (B) by approximately 50%. (C) Normalisation of claudin-2 pulldown and lysate 
levels reveals the proportion of remaining claudin-2 that is surface-biotinylated is identical 
between control and 4HT-treated conditions. (D) Normalisation of each stage of the biotinylation 
assay to the relevant surface-label control reveals that claudin-2 was internalised, degraded and 
recycled to similar extents in control and 4HT-treated conditions. Data are presented as mean 
values ±s.e.m. from three independent experiments. 4HT and control treatments were 
compared at each stage of the assay using a two-way ANOVA with Bonferroni post-test, * 
p<0.05, *** p<0.001. 
 
  




5.3.7 RAF/MEK/ERK activity does not influence the endocytic trafficking of 
claudin-1 or -4 
The confocal microscopy data raised the possibility that ERK activation caused a shift 
of claudin-1 and -4 from lateral membrane domains into the apical junction. To 
determine if altered rates of endocytic trafficking contributed to this altered distribution 
pattern, the rates of claudin-1/-4 internalisation, degradation and recycling were 
investigated using the surface-biotinylation assay. Approximately twice as much 
claudin-1 was labelled by apically applied biotin following 4HT treatment (Figures 5.13 
and 5.15A). Under the same conditions, there was no significant change to claudin-1 
levels in the whole cell lysate (Figures 5.13 and 5.15B). Therefore, when pulldown 
levels were normalised to those in the whole cell lysates, the amount of claudin-1 that 
was labelled at the apical cell surface was still increased by approximately 60% 
following 4HT treatment (Figure 5.15C). Although this could potentially reflect the 
increased amount of claudin-1 in an apically accessible pool, the increased labelling of 
basolateral TfR and E-cadherin under the same conditions suggests it is at least 
partially due to increased access to the basolateral plasma membrane domain (Figure 
5.13). 
 
A relatively small amount of the surface-biotinylated claudin-1 was endocytosed after 1 
hour compared to the strip control lane (Figure 5.15A). However, a reduction in signal 
in the recycling lane suggests that this claudin-1 was rapidly recycled. Importantly, 
ΔCRAF:ER activation did not affect the relative amount of claudin-1 retrieved by 
neutravidin pulldown or in the whole cell lysates at the internalisation, degradation or 
recycling stages of the biotinylation assay (Figure 5.15A and B). When each stage of 
the trafficking assay was normalised to the relevant surface-label, rates of endocytic 
trafficking and degradation were identical under control and 4HT-treated conditions 
(Figure 5.15D).  
 
Similar results were obtained for claudin-4. After 24 hours of ΔCRAF:ER, more claudin-
4 was initially labelled at the cell surface (Figures 5.13 and 5.16A), probably due to 
increased access of apically applied biotin to basolateral pools. In contrast to claudin-1 
and -2, the biotinylation trafficking assay revealed that claudin-4 did not undergo 
detectable endocytosis over the course of this experiment in either control or 4HT-
treated conditions (Figures 5.13 and 5.16A). Although ΔCRAF:ER activation increased 
the total amount of claudin-4 in the whole cell lysates (Figures 5.13 and 5.16B), the 
nature of the assay distinguishes between the trafficking of existing protein and the 
effects of newly synthesised protein. Importantly, after normalising each step of the 
trafficking assay to the relevant surface-label control, ΔCRAF:ER activation had no 




detectable effect on the degree of claudin-4 internalisation. This prevented the 
subsequent assessment of degradation and recycling rates. Taken together with the 
confocal imaging, these data indicate that RAF/MEK/ERK activity is sufficient to drive 
the accumulation of claudin-1 and -4 at the apical junction, but that this proceeds 
without any concomitant changes in the rates of their endocytic trafficking to and from 
the plasma membrane.  
 
Figure 5.15: ΔCRAF:ER activation does not affect the endocytic trafficking rates of 
claudin-1. The data presented are quantified values of the biotinylation assay immunoblots 
presented in Figure 5.13. Confluent ΔCRAF:ER-expressing MDCKII cells were treated with or 
without 1µM 4HT for 24 hours. Surface-biotinylation and trafficking assays were performed as 
previously described. (A) ∆CRAF:ER activation increases the amount of claudin-1 initially 
labelled at the cell surface, and at each stage of the trafficking assay. (B) ΔCRAF:ER activation 
did not affect the whole cell lysate claudin-1 levels. (C) Normalisation of claudin-1 pulldown and 
lysate levels revealed that an increased proportion of whole cell claudin-1 pool is surface-
biotinylated at the cell surface following ∆CRAF:ER activation. (D) However, normalisation of 
each stage of the trafficking assay to the relevant surface-label control reveals that claudin-1 
underwent similar rates of internalisation, degradation and endocytic recycling in control and 
4HT-treated conditions. Data are presented as mean values ±s.e.m. from three independent 
experiments. 4HT and control treatments were compared at each stage of the assay using a 
two-way ANOVA with Bonferroni post-test, * p<0.05, *** p<0.001. 
 
  













Figure 5.16: ΔCRAF:ER activation does not affect the endocytic trafficking rates of 
claudin-4. The data presented are quantified values of the biotinylation assay immunoblots 
presented in Figure 5.13. Confluent ΔCRAF:ER-expressing MDCKII cells were treated with or 
without 1µM 4HT for 24 hours. Surface-biotinylation and trafficking assays were performed as 
previously described. (A) ΔCRAF:ER activation increased the amount of claudin-4 initially 
labelled at the cell surface. (B) ΔCRAF:ER activation consistently increased whole cell lysate 
claudin-4 levels. (C) Normalisation of claudin-4 pulldown and lysate levels revealed that an 
increased proportion of whole cell claudin-4 pool is biotinylated at the cell surface under these 
conditions. (D) Normalisation of each stage of the assay to the relevant surface-label condition 
revealed that claudin-4 underwent negligible internalisation or trafficking under control or 4HT-
treated conditions. Data are presented as mean values ±s.e.m. from three independent 
experiments. 4HT and control treatments were compared at each stage of the assay using a 
two-way ANOVA with Bonferroni post-test, * p<0.05, *** p<0.001. 
  




After 24 hours of ERK activation, the remaining claudin-2 protein pool could have been 
confined to nontransduced cells, exhibiting normal claudin-2 distribution and trafficking. 
However, claudin-2 trafficking was unaffected in a similar surface-biotinylation assay 
where transduced cells were surface-biotinylated prior to the initial addition of 4HT 
(Figure 5.17A). The relative amounts of claudin-2 retrieved by neutravidin pulldown 
(Figure 5.18A) and present in the whole cell lysates (Figure 5.18B) were identical in 
control and 4HT-treated conditions. The rates of claudin-2 internalisation, degradation 
and recycling were identical between control and 4HT-treated samples when pulldown 
levels were normalised to whole cell lysate levels (Figure 5.18C). Therefore, 
RAF/MEK/ERK activity caused the depletion of claudin-2 protein without increasing its 
rate of internalisation or degradation, or by blocking its recycling back to the plasma 
membrane.  
 
Similar results were observed for claudin-1 and -4 (Figure 5.17B and C). Surface-
biotinylated claudin-1 underwent minimal endocytosis, but again appeared to be 
recycled (Figures 5.17B and 5.18D). ΔCRAF:ER activation did not influence the total 
levels of claudin-1 (Figures 5.17 and 5.18E) or the rate of claudin-1 trafficking (Figure 
5.18F). Claudin-4 underwent negligible endocytosis (Figures 5.17 and 5.18G) and total 
levels of claudin-4 were not affected at this earlier time point (Figures 5.17 and 5.18H). 
ΔCRAF:ER activation did not influence the extent of claudin-4 internalisation (Figure 
5.18I), and as a result, the rates of degradation and recycling could not be established. 
In summary, ΔCRAF:ER activation did not influence the trafficking rates of claudin-1 or 
-4, prior to, or following observed changes in subcellular distribution. 
  












Figure 5.17: Altered claudin trafficking rates do not precede ΔCRAF:ER-mediated 
changes in tight junction composition. Claudin trafficking rates were determined at earlier 
time points by surface-biotinylating confluent ΔCRAF:ER-expressing MDCKII cells prior to the 
initial addition of 4HT. The trafficking assay was performed as previously described. (A) 4HT 
treatment did not influence the basal rates of internalisation, degradation or recycling of claudin-
2 (A), -1 (B) or -4 (C). Whole cells lysate levels of each claudin and ERK1/2 were not influenced 
by ΔCRAF:ER activation over this time frame. The following pairs of immunoblots were obtained 
from the same gel: Immunoblots are representative of three independent biological repeats. 
Immunoblot quantification is presented in Figure 5.18. Claudin-1 and ERK1/2 lysate 
immunoblots were obtained from the same gel. 
  






Figure 5.18: ΔCRAF:ER activity does alter claudin trafficking rates prior to changes in 
tight junction. The trafficking assay was carried out in ΔCRAF:ER-expressing cells that were 
surface-biotinylated prior to the initial addition of 4HT. 4HT was then added for the duration of 
each incubation. Under these conditions, ∆CRAF:ER activation did not affect claudin-2 pulldown 
(F) or whole cell lysate levels (G). (H) Normalisation of pulldown to lysate levels indicates that 
claudin-2 undergoes similar rates of internalisation, degradation and endocytic recycling in 
control and 4HT-treated conditions. Data are presented as mean values ±s.e.m. from three 
independent experiments. Immunoblots are representative of these three biological repeats. 
4HT and control treatments were compared at each stage of the assay using a two-way ANOVA 
with Bonferroni post-test, * p<0.05, *** p<0.001. 
 
. 




5.3.8 RAF/MEK/ ERK activity does not influence claudin turnover rate  
To address whether ERK activity influenced claudin turnover rates over longer time 
frames, the endocytosis assay was modified to assess claudin internalisation and 
degradation rates over a 6 hour period. To assess cumulative internalisation, surface-
biotinylated cells were incubated at 37°C for either 1 or 6 hours, in the presence or 
absence of 4HT. Surface biotin was then stripped, so remaining levels of biotinylated 
proteins reflected the relative amount of protein internalised during incubation. Surface-
biotinylated claudin-2 was internalised after 1 and 6 hours, but this was not increased 
by the addition of 4HT (Figure 5.19A and C), although total claudin-2 levels decreased 
by approximately 50% (Figure 5.19C). Therefore, RAF/MEK/ERK activity can drive 
claudin-2 protein depletion without increasing its rate of internalisation. 
 
The internalisation rates of claudin-1/-4 were assessed to determine if decreased rates 
of internalisation could explain their junctional accumulation. Surface-biotinylated 
claudin-1/-4 underwent minimal internalisation compared to the strip control after both 1 
and 6 hours, and this was not affected by activation of ΔCRAF:ER with 4HT (Figure 
5.19A,B and D). Although whole cell lysate claudin-4 levels increased following 4HT 
treatment (Figure 5.19D), the nature of the assay allows the discrimination between 
previously existing and newly synthesised protein. As changes in internalisation rates 
of claudin-1/-4 were not detectable, their accumulation at the TJ cannot be attributed to 
decreased rates of internalisation of these proteins from the cell surface.  
 
Increased ERK activity could potentially modulate the degradation rate of internalised 
claudins. In order to assess claudin degradation rates over longer time periods, the 
endocytosis assay was modified such that surface-biotinylated cells were lysed 
immediately after incubation at 37°C, without surface-stripping of remaining biotin. 
Thus, any decrease in pulldown level could be attributed to protein degradation rather 
than altered localisation. Claudin-2 pulldown levels were gradually depleted over a 6-
hour period, but the rate of decline was not accelerated by ΔCRAF:ER activation 
(Figure 5.20A and C). However, after 6 hours, total claudin-2 levels were reduced by 
approximately 50% (Figure 5.20C), indicating that ERK activity drives claudin-2 protein 
depletion by decreasing its synthesis (Figure 5.6), without increasing its degradation 
rate. Claudin-1/-4 degradation rates were assessed to determine if an increase in 
protein stability could explain their increased presence at the TJ. Claudin-1 and -4 
pulldown levels decreased over 6 hours, but the rate of decline was not influenced by 
ΔCRAF:ER activation (Figure 5.20A, B and D). To summarise, RAF/MEK/ERK activity 
did not alter the overall stability of surface-biotinylated claudin-1 or -4. 
 






Figure 5.19: Internalisation rates of claudin-1, -2 and -4 are not influenced by ΔCRAF:ER 
activation. Confluent ∆CRAF:ER-expressing MDCKII cells were surface-biotinylated and 
incubated with or without 1µM 4HT for the indicated times. Remaining surface biotin was 
stripped, whereas internalised biotinylated protein was resistant to the surface strip. (A) 
Biotinylated and total claudin-1, -2 and -4 levels were determined by immunoblot. Immunoblots 
are representative of three biological repeats. (B) Quantification of claudin-1 immunoblots 
revealed that ∆CRAF:ER activation did not alter claudin-1 internalisation (top panel) or total 
levels (bottom panel). (C) ∆CRAF:ER  activity does not affect claudin-2 internalisation (top 
panel), but does cause depletion of total claudin-2 levels after 6 hours (bottom panel). (D) 
∆CRAF:ER activation does not alter claudin-4 internalisation (top panel), but does increase total 
claudin-4 levels after 6 hours (bottom panel). Claudin-1 and ERK1/2 lysate immunoblots were 
obtained from the same gel. Data is presented as mean values ±s.e.m. from three independent 
experiments. Relative internalisation at 1 and 6 hours was compared using a two-way ANOVA 
with Bonferroni post-test, * p<0.05.  
 






Figure 5.20: ΔCRAF:ER activation does not influence the degradation rate of surface-
biotinylated claudin-1, -2 or -4. Confluent ∆CRAF:ER-expressing MDCKII cells were surface-
biotinylated and incubated with or without 1µM 4HT for the indicated times. Cells were lysed 
without surface-stripping, so any decrease in biotinylated protein is attributed to protein 
degradation. (A) Biotinylated and total claudin-1, -2 and -4 levels were determined by 
immunoblot. Immunoblots are representative of three independent biological repeats. 
Quantification of immunoblots revealed ∆CRAF:ER activation did not alter the degradation rate      
of surface-biotinylated claudin-1 (B, top panel), claudin-2 (C, top panel) or claudin-4  (D, top 
panel). Total claudin-2 levels were decreased after 6 hours of 4HT treatment (C, bottom panel). 
Claudin-1 and ERK1/2 lysate immunoblots were obtained from the same gel. Data are 
presented as mean values ±s.e.m. from three biological repeats. Relative claudin levels are at 
each time point were compared using a two-way ANOVA with Bonferroni post-test, *p<0.05. 




Covalent modification of claudins with biotin could potentially influence the rate at 
which they are degraded. Therefore, claudin degradation rates were also determined in 
a biotinylation-free assay by blocking protein neosynthesis with cycloheximide. Claudin 
degradation rates were initially determined using high-content microscopy (Figures 
5.21 and 5.22). Total levels of claudin-1, -2 and -4 were gradually depleted over a 24 
hour period when cells were treated with cycloheximide (Figures 5.21 and 5.22).The 
depletion rates of claudin-1, -2 and -4 were not influenced by co-treatment with 4HT 
(Figure 5.22A, B and C, respectively). However, high-content imaging revealed that 
prolonged treatment of MDCKII cells with cycloheximide caused clear changes in cell 
area and shape (Figure 5.21). MDCKII cells normally adopt a compact cylindrical 
shape as cells pack tightly into a monolayer. After 12 – 24 hours of cycloheximide 
treatment, cell area had increased, and cell contacts were straighter and more angular 
than in control conditions (Figure 5.21). As these morphological changes could have an 
unpredictable influence on the quantification of immunostaining images, claudin 
degradation rates were also assessed by immunoblot (Figure 5.23A).  
 
In ΔCRAF:ER-expressing MDCKII cells, 4HT treatment successfully induced 
downstream phosphorylation of ERK1/2 over a 12 hour period (Figure 5.23B) without 
affecting total ERK1/2 levels (Figure 5.23C). Claudin-1 levels were gradually depleted 
over this 12-hour period in cells treated with 30µM cycloheximide (Figure 5.23D). After 
12 hours, total claudin-1 levels were significantly lower in samples co-treated with 
cycloheximide and 4HT compared to cycloheximide treatment alone (Figure 5.23D). 
This suggests that ΔCRAF:ER activation increases the degradation rate of claudin-1. 
Total levels of claudin-2 (Figure 5.23E) and claudin-4 (Figure 5.23F) also decreased 
over a 12 hour period when treated with cycloheximide, but in contrast to claudin-1, the 
rate of their depletion was not influenced by co-treatment with 4HT, suggesting that 
ΔCRAF:ER activation does not influence their rate of degradation. The small increase 
in claudin-1 degradation rate assessed by immunoblot may underlie the observed 
minor and statistically insignificant decrease in total claudin-1 levels (Figures 5.1 and 
5.5). However, both the small decrease in claudin-1 level and increase in degradation 
rate were only observed when cells were lysed in triton-based lysis buffers. Claudin 
level and degradation rate were not affected when studied by high-content microscopy 
or in assays where cells were lysed in SDS-based biotinylation assay lysis buffer. This 
suggests that both the minor decrease in claudin-1 levels and increase in claudin-1 
degradation rate are likely due to decreased detergent-solubility and inefficient retrieval 
in the triton-based lysis buffer. 
 
 




























































































































































































































































































































































































































































































































































































Figure 5.22: ΔCRAF:ER activity does not affect the rate of loss of claudin 
immunostaining intensity in the presence of cycloheximide. Confluent ΔCRAF:ER-
expressing MDCKII cells were treated with 1µM 4HT and 30µM cycloheximide (CHX) as 
indicated, prior to fixation and immunostaining. Average claudin intensity was measured using 
INCell Developer Toolbox software. The average intensity of claudin-1 (A), claudin-2 (B) and 
claudin-4 (C) each decreased at similar rates when treated with cycloheximide, either alone or 
in combination with 4HT. Representative images are presented in Figure 5.21. Data are 
presented as mean values ±s.e.m. from three independent experiments. Treatments were 
compared at each time point using a two-way ANOVA with Bonferroni post-test. Representative 
images are presented in Figure 5.21. 
 
  






Figure 5.23: ΔCRAF:ER activation increases the degradation rate of whole cell claudin-1, 
but not claudin-2 or -4. Confluent MDCKII cells expressing ∆CRAF:ER were incubated with 
30µM cycloheximide (CHX), either alone or in combination with 1µM 4HT for the indicated 
times. (A) Cells were lysed and relative claudin levels were determined by immunoblot. 
Immunoblots are representative of three independent experiments. (B) 4HT treatment 
successfully induced downstream phosphorylation of ERK1/2 without affecting total ERK1/2 
levels (C). Quantification of immunoblots revealed that ∆CRAF:ER activation with 4HT 
increased the rate of claudin-1 depletion in the presence of cycloheximide (D) without affecting 
the rate of claudin-2 (E) or claudin-4 (F) loss. The following pairs of immunoblots were obtained 
from the same gel: ERK1/2 and claudin-1, ppERK1/2 and claudin-2. Data are presented as 
mean values ±s.e.m. from three independent experiments. Treatments were compared at each 
time point using a two-way ANOVA with Bonferroni post-test, * p<0.05, *** p<0.001. 
 





The results in this chapter indicate that RAF/MEK/ERK activity is sufficient to increase 
MDCKII transepithelial resistance, which occurs with the concurrent modulation of TJ 
claudin composition through surprisingly diverse mechanisms (summarised in Table 
5.1). Claudin-1, -2 and -4 are each controlled by a distinct mode of regulation. Claudin-
2 is downregulated at the mRNA and protein level, but turned over by normal rates of 
internalisation and degradation. By contrast, claudin-4 is redistributed from the lateral 
membrane to the apical junction and throughout the cytoplasm, which occurs with a 
concomitant increase in protein, but not mRNA levels. Claudin-1 also accumulates at 
the apical junctional and in the cytoplasm, although its degradation rate is actually 
increased. This novel redistribution of the barrier-promoting claudins -1 and -4 from the 
lateral membrane to the apical junction proceeds in a manner independent of changes 
in protein level or endocytic trafficking rates. 
 
TJ protein mRNA level Protein level Distribution Degradation rates 




Claudin-2 ↓↓↓ ↓↓↓ 
Lost from the apical 
junction without prior 
internal accumulation 
- 




Occludin ND - 
Retained at the apical 
junction and lateral 
membrane 
ND 
ZO-1 ND - 






Table 5.1: A summary of ΔCRAF:ER-mediated regulation of individual tight junction 
proteins. RAF/MEK/ERK activity regulates claudin-1, -2 and -4 through distinct and unique 
modes of regulation.  Claudin-1 accumulates at the TJ, but total levels and degradation rate are 
unaffected. In contrast, claudin-2 is downregulated at both the mRNA and protein level, with the 
existing claudin-2 protein pool turned over by normal rates of internalisation and degradation. 
Claudin-4 levels are marginally upregulated, without a concomitant increase mRNA level. 
However, junctional claudin-4 accumulation cannot be fully accounted for by this increase in 
protein level. The total levels and intramembrane distribution of occludin and ZO-1 are not 
affected by. ΔCRAF:ER activation does induce a diffuse cytoplasmic staining pattern for 
occludin and ZO-1, but they do not appear in the same discrete cytoplasmic compartments as 
claudin-1 and -4. RAF/MEK/ERK activity therefore has distinct claudin-specific effects on protein 
synthesis, degradation and subcellular distribution. (-) no change, (↓) marginally decreased, (↑) 
marginally increased, (↓↓↓) dramatically decreased (ND) not determined. 
 




ΔCRAF:ER activity negatively regulates claudin-2 synthesis, but the existing 
protein pool is turned over by normal rates of endocytosis and degradation 
RAF/MEK/ERK activity caused a decrease in CLDN2 mRNA levels, which is likely due 
to downregulated transcription, and this was mirrored by a significant depletion of 
claudin-2 protein. Claudin-2 protein depletion was sensitive to chloroquine, suggesting 
a requirement for lysosomal degradation. Immunofluorescence imaging revealed a 
progressive decrease in junctional claudin-2 intensity, but this did not occur with a 
concurrent increase in cytoplasmic claudin-2 staining. Furthermore, ΔCRAF:ER 
activation had no effect on the cumulative internalisation or degradation of claudin-2 
protein using either surface-biotinylation- or cycloheximide-based assays. To conclude, 
ERK activity decreases claudin-2 protein synthesis, but the existing claudin-2 pool is 
turned over by normal rates of internalisation from the cell surface and degradation in 
the lysosome. 
 
This was unexpected as EGF has been reported to decrease claudin-2 protein stability 
in the presence of cycloheximide in a MEK-dependent manner (Ikari et al., 2011c). The 
EGF-mediated decrease in claudin-2 mRNA and protein is at least partially prevented 
by treatment with either the Src inhibitor, PP2, or the MEK inhibitor, U0126 (García-
Hernández et al., 2015). As well as being involved in EGFR-mediated activation of the 
RAF/MEK/ERK pathway, Src is an established effector of endocytic trafficking 
(Mellman and Yarden, 2013) and may therefore drive EGF-mediated changes in 
claudin-2 internalisation and/or trafficking in a manner that cannot be recapitulated by 
activation of the  RAF/MEK/ERK pathway alone. Although RAF/MEK/ERK activity may 
be required to alter claudin-2 protein turnover downstream of EGFR activation, alone it 
is not sufficient to elicit the same response. 
 
ΔCRAF:ER activation leads to the accumulation of claudin-4 at the apical 
junction, without affecting rates of endocytic trafficking 
Activation of ∆CRAF:ER led to a consistent increase in claudin-4 protein levels of 
approximately 1.5 to 2-fold, as assessed by immunoblot, which is supported by a 
significant increase in claudin-4 intensity using high-content microscopy. The lysis 
buffer used in the biotinylation asays contains SDS, a strong detergent, which will 
solublise TJ-associated proteins (Singh and Harris, 2005). Under these conditions, 
∆CRAF:ER activation increased total claudin-4 levels after 24 hours, which is 
consistent with the increase observed both by high-content and confocal microscopy.  
Increased claudin-4 mRNA and protein levels have been reported following stimulation 
of the RAF/MEK/ERK pathway, both in response to EGF (García-Hernández et al., 
2015; Ikari et al., 2009) and ∆CRAF:ER activation  (Doehn et al., 2009). After 24 hours 




of ∆CRAF:ER activation, claudin-4 mRNA levels were not affected by RT-qPCR. 
However, an earlier transient increase in claudin-4 synthesis may underlie the 
observed increase in claudin-4 protein levels (Ikari et al., 2009). Interestingly, confocal 
microscopy revealed a striking increase in junctional claudin-4 intensity, which cannot 
be accounted for by increased claudin-4 levels alone. Therefore, the accumulation of 
claudin-4 at the TJ appears to proceed via additional post-translational mechanisms. 
 
ΔCRAF:ER activation leads to the accumulation of claudin-1 at the apical 
junction 
ΔCRAF:ER activation caused a marginal decrease in total claudin-1 protein levels by 
immunoblot, though this never reached statistical significance. By contrast, total 
claudin-1 levels were not influenced by ∆CRAF:ER activation when cells were lysed in 
the SDS-based biotinylation assay lysis buffer, which is consistent with the high-
content microscopy data, suggesting that ∆CRAF:ER activation influences claudin-1 
distribution but not total level. Taken together with the confocal microscopy, the data 
suggests that ∆CRAF:ER activation drives the redistribution of claudin-1 and -4 from 
the lateral membrane into the TJ. While total claudin-4 levels are marginally increased, 
its rate of internalisation and degradation and not affected. Claudin-1 degradation rates 
were not affected as assessed by surface-biotinylation assays, using SDS-based lysis 
buffers, or in cycloheximide chase experiments using high-content microscopy. This 
suggests that both the minor decrease in claudin-1 levels and increase in claudin-1 
degradation rate are likely due to decreased detergent-solubility and inefficient retrieval 
in the triton-based lysis buffer. To concldude, the altered distribution of claudin-1 is not 
accompanied by a change to total claudin-1 levels or turnover rates.  
 
Claudin-1 mRNA levels were not affected by RAF/MEK/ERK pathway activation. This 
echoes studies in immortalised mouse hepatic cells, where the stable expression of 
CRAF causes a significant depletion of claudin-1 protein, while mRNA levels are 
unaffected (Lan et al., 2004). Other studies have failed to detect any change in claudin-
1 levels following growth factor treatments (Ikari et al., 2009) or in response to 
ΔCRAF:ER activation (Doehn et al., 2009). However, sustained ERK signalling, 
associated with epithelial-mesenchymal transition, may result in transcriptional 
downregulation of claudin-1 via E-box transcription factors (Martínez-Estrada et al., 
2006). 
 
Ras-transformed MDCK cells exhibit cytoplasmic inclusions of occludin, claudin-1 and 
ZO-1, which are rapidly recruited to the cell membrane following treatment with the 
MEK inhibitor, PD98059 (Chen et al., 2000). This suggests that long-term activation of 




the RAF/MEK/ERK pathway may cause the cytoplasmic sequestration of claudin-1. 
Claudin-1 did accumulate in cytoplasmic compartments, but it is unclear how this tallies 
with its apparent accumulation at the TJ. Acute EGFR activation causes TJ 
remodelling, while chronic activation drives TJ disassembly associated with 
dedifferentiation (Singh et al., 2007), suggesting that variation in ERK signal duration 
may influence the TJ response. Cytoplasmic claudin-1 may represent partial TJ 
disassembly, coinciding with a decrease in TER at later time points, following an earlier 
redistribution into the TJ. To conclude, RAF/MEK/ERK activity causes the redistribution 
of claudin-1 from the lateral membrane into the apical junction, but this occurs 
independently of changes in claudin-1 synthesis or trafficking rates. 
 
The accumulation of claudin-1 and -4 at the TJ is consistent with the reported effect of 
EGF on their relative triton solubility (Singh and Harris, 2004). Treatment with EGF 
increased the amount of claudin-1, -3 and -4 in the triton-insoluble fraction, suggesting 
increased junctional incorporation, even in the absence of protein neosynthesis (Singh 
and Harris, 2004). The presented data shows that RAF/MEK/ERK activity alone can 
specifically regulate the distribution of TJ proteins in different plasma membrane 
domains to increase the junctional pool of claudin-1/-4. Interestingly, recent studies 
involving the TALEN-mediated knockdown of claudin-2 in MDCKII cells suggest that 
co-expressed claudin species may be incorporated into the TJ following claudin-2 
depletion. This suggests that RAF/MEK/ERK-mediated depletion of claudin-2 may have 
complex effects on TJ composition, potentially through altering the interactions of 
existing proteins within the junctional domain. This is further discussed in Chapter 6. 
 
Surface-biotinylation-based assays can be used to assess rates of endocytic 
trafficking and degradation 
Rates of claudin internalisation and recycling were not affected by ΔCRAF:ER 
activation. However, the surface-biotinylation assay accurately reported the trafficking 
of the established recycling cargo, TfR. Furthermore, the basal rates of claudin-1, -2 
and -4 trafficking are largely consistent with those previously reported; claudin-1 and -2 
are constitutively recycled, while claudin-4 does not accumulate internally over the 
same time frame (Dukes et al., 2011b; Dukes et al., 2012). Large changes in trafficking 
rates are not necessarily required to mediate profound effects in cell surface protein 
distribution. For example, depletion of Rab14 causes a 50% reduction in claudin-1 
levels at areas of cell-cell contact, due to a relatively modest 10% increase in 
internalisation detected using a similar surface-biotinylation assay (Lu et al., 2014). In 
the same study, a 10% increase in occludin recycling increased junctional occludin 
levels by approximately 20% (Lu et al., 2014). Furthermore, altered rates of recycling 




and degradation are frequently reflected in the extent of initial internal accumulation. 
For example, treatment of MDCKII cells with the PIKfyve inhibitor, YM201636, doubles 
the amount of claudin-2 that is initially internalised, by blocking recycling of the 
internalised protein back to the cell surface (Dukes et al., 2012). These observations 
indicate that the net distribution of cell surface proteins is highly sensitive to small 
changes in trafficking rates. However, the presented data indicate that ΔCRAF:ER 
activation consistently failed to induce even minor changes in claudin recycling, either 
prior to, or after dramatic changes in TJ composition, suggesting that alternative 
mechanisms are involved. 
 
Potential mechanisms for claudin-1/-4 redistribution 
Following RAF/MEK/ERK pathway activation, claudin-2 expression is lost, while 
claudin-1 and -4 accumulate at the apical junction (Figure 5.24A). Of note, the TALEN-
mediated knockout of claudin-2 caused the subsequent accumulation of claudin-1, -3, -
4 and -7 at the apical junction (Tokuda and Furuse, 2015). This suggests that 
competitive interactions between individual claudin species at the apical junction may 
underlie their initial spatial segregation. The subsequent depletion of claudin-2 may 
then permit the incorporation of claudin-1 and -4 (and other claudin species) into the 
apical junction. However, the increased labelling of basolateral proteins by apically 
applied biotin suggests that leak pathway permeability is also increased, which cannot 
be explained based on the observations of claudin-2 knockdown and knockout studies 
(Hou et al., 2006; Tokuda and Furuse, 2015; Van Itallie et al., 2008). 
 
There are at least three potential mechanisms that could account for the accumulation 
of claudin-1 and -4 at the TJ (Figure 5.24). Following ∆CRAF:ER activation, newly 
synthesised claudin-1/-4 may be delivered preferentially to the TJ rather than lateral 
membrane, while existing claudin-1/-4 are turned over at normal rates (Figure 5.24B). 
This model would result in increased junctional localisation of claudin-1/-4 without the 
redistribution of existing protein. Alternatively, activation of the RAF/MEK/ERK pathway 
could stabilise claudins in the TJ or increase the mobility of claudins within the lateral 
membrane to affect the net claudin distribution (Figure 5.24C). Finally, RAF/MEK/ERK 
signalling may cause claudin-1 and -4 to be specifically internalised from the 
basolateral membrane and undergo transcytosis to the apical junction via an as yet 
unidentified endosomal compartment, reflecting a change in trafficking routes rather 
than rates (Figure 5.24D). 
 
Activation of the RAF/MEK/ERK pathway with ΔCRAF:ER did not influence the rates of 
internalisation or recycling of claudin-1, -2 or -4. However, this does not necessarily 




rule out a role for endocytic trafficking in mediating the redistribution of claudin-1 and -4 
to the apical junction. Access to basolateral proteins will be severely restricted by the 
presence of an intact TJ, which will block the paracellular passage of apically applied 
biotin based on its molecular weight and negative charge in solution. Therefore, 
RAF/MEK/ERK activity could potentially mediate altered trafficking of a specific apically 
inaccessible claudin-1/-4 pool. However, after 24 hours of ΔCRAF:ER activation, 
increased amounts of claudin-1/-4, as well as the basolateral proteins TfR and E-
cadherin, were initially surface-labelled with apically applied biotin. Despite the 
increased labelling of these basolateral pools, the rates of claudin-1/-4 internalisation, 
degradation and recycling were unaffected by ΔCRAF:ER activation. However, 
transcytosis would involve the rerouting of internalised claudin-1/-4 from the basolateral 
domain to the apical domain via an as yet unidentified endosomal compartment, and 
would not necessarily be reflected in increased rates of internalisation or recycling. 
 
This hypothesis would be potentially difficult to test using the biochemical techniques 
employed in these studies. However, increased biotinylation of the basolateral pool 
could be achieved by growing MDCKII cells on transwell permeable filters. This would 
allow basolateral application of biotin, providing increased access to the major pools of 
claudin-1 and -4. Differential trafficking of junctional and lateral membrane pools could 
then be determined by comparing trafficking rates of apically and basolaterally labelled 
claudins. Basolateral labelling could be combined with surface-stripping, exclusively of 
the apical domain, so only proteins that had undergone transcytosis to the apical 
membrane would become amenable to the surface-strip. However, this approach is 
likely to be complicated by the apparent effect of RAF/MEK/ERK activity on the MDCKII 
leak pathway, as ΔCRAF:ER activation increased access of apically applied biotin to 
basolateral protein pools. Alternatively, approaches using live cell imaging and 
fluorescently-tagged claudins may be useful in distinguishing modes of dynamic 
claudin regulation. 
  

















Figure 5.24: Potential mechanisms of ΔCRAF:ER-mediated tight junction remodelling. (A) 
MDCKII cells are characterised by the expression of claudin-2 specifically at the apical junction 
(red) and claudin-1 and -4 along the lateral membrane (dark blue). Specific activation of the 
RAF/MEK/ERK pathway leads to downregulation of claudin-2 synthesis and turnover of the 
existing protein pool by normal rates of endocytosis and degradation. Claudin-1 and -4 
accumulate at the apical junction, as well as in discrete compartments throughout the 
cytoplasm. Junctional accumulation of claudin-1 and -4 cannot be fully attributed to changes in 
protein expression level or altered rates of endocytic trafficking. (B) Lateral claudin-1 and -4 
may be endocytosed and degraded by normal turnover rates, while newly synthesised claudin-1 
and -4 are specifically targeted to the apical junction. (C) Lateral claudin-1 and -4 may diffuse 
within the plasma membrane to occupy the apical junction region. (D) Claudin-1 and -4 may be 
endocytosed from the lateral membrane, undergo transcytosis, and be delivered specifically into 
the apical junction. 
 
  




ΔCRAF:ER activation increases the amount of claudin-1/-4, TfR and E-cadherin 
labelled with apically applied biotin 
The initial biotinylation assays revealed that ΔCRAF:ER activation increased the 
amount of claudin-1 and -4 that were initially labelled when biotin was added to apical 
side of MDCKII monolayers, without affecting the relative extent of internalisation, 
degradation or recycling. This appeared to be consistent with the redistribution of 
claudin-1 and -4 from the basolateral membrane to the apical junction, which would 
increase their presence in the apically accessible pool. However, a similar increase in 
apical labelling was observed with TfR and E-cadherin, two well-established 
basolateral protein markers (Fuller and Simons, 1986; Miranda et al., 2001). This 
suggests that the increased protein labelling may be at least partially accounted for by 
increased access of apically applied biotin to the basolateral plasma membrane 
domain and does not necessarily reflect the change in claudin-1/-4 distribution that is 
so apparent in confocal microscopy images.  
 
Biotin moieties have been extensively used as tracer molecules to probe the TJ leak 
pathway permeability in various in vitro and in vivo systems (Ding et al., 2011). 
Therefore, the ability to label increased amounts of basolateral proteins suggests that 
RAF/MEK/ERK pathway activation increases the permeability of the paracellular leak 
pathway, which regulates the passage of larger molecular weight solutes, as well as 
the pore pathway that determines ionic conductance and can be assessed by TER 
measurement. Increased epithelial permeability to large non-electrolytes could also be 
explained by more general disruption of the monolayer due to the detachment of cells 
(Mullin et al., 2005). A similar increase in MDCK leak pathway permeability was 
reported following Ras expression (Mullin et al., 2005). In this case, permeability was 
specifically attributed to leak pathway modulation as increased permeability was limited 
to tracers of up 10kDa, indicating the presence of a limiting pore size (Mullin et al., 
2005). Further characterisation of MDCKII permeability to different sized molecular 
tracers will be required to further characterise leak pathway modulation by ΔCRAF:ER 
activation. 
 
Interestingly, leak pathway permeability is be regulated by ZO-1 and occludin (Shen et 
al., 2011). Although these proteins were largely retained at the apical junction following 
ΔCRAF:ER activation, both markers also appeared to be distributed diffusely across 
the cytoplasm. Unfortunately, surface-biotinylated occludin was undetectable following 
neutravidin pulldown, preventing the assessment of its endocytic trafficking rates. The 
reasons for this are unclear as occludin has successfully been studied using similar 
approaches elsewhere (Dukes et al., 2011b; Morimoto et al., 2005; Nishimura and 




Sasaki, 2008). As ZO-1 is a peripheral cytoplasmic protein, it cannot be surface-
biotinylated, excluding it from these surface-biotinylation-based approaches. Altered 
stability of these proteins at the TJ may underlie the minor changes in their subcellular 
distribution and altered leak pathway permeability. 
 
Even when taking the increase in initial labelling into account, the proportion of initially 
labelled claudin-1 and -4 that is internalised, and subsequently degraded and recycled, 
is identical in control and 4HT-treated conditions. Furthermore, endocytic trafficking of 
these claudins was not affected by ΔCRAF:ER activation when cells were labelled 
under common conditions, prior to the initial addition of 4HT and the associated 
changes in TJ composition and paracellular permeability. Therefore, claudin-1 and -4 
appear to accumulate at the apical junction, as assessed by confocal microscopy, but 
this cannot be accounted for by altered rates of endocytic trafficking over the time 
frames studied. 
 
5.5 Limitations and future work 
Inducible-activity ΔCRAF:ER constructs have permitted the study of RAF/MEK/ERK 
signalling on rates of TJ protein internalisation, degradation and recycling, with clear 
changes in TJ composition and the distribution of individual TJ components. However, 
the unique contribution of each TJ protein is unclear, as the overall epithelial barrier 
properties are governed by the specific repertoire of proteins that are expressed and 
incorporated into the junction. This could potentially be addressed by re-expressing or 
depleting individual claudins to determine which ΔCRAF:ER-associated phenotypes 
are modified. Although this study implicates transcriptional downregulation of claudin-2 
as the major mechanism driving its depletion, the molecular basis for the increased 
junctional incorporation of claudin-1 and -4 is unclear. ΔCRAF:ER activation did not 
induce any changes in their internalisation or recycling rates, and the increased 
degradation of claudin-1 appears unlikely to contribute directly to its altered subcellular 
distribution. Future studies, potentially involving fluorescently-tagged TJ proteins, will 
be required to determine if RAF/MEK/ERK-mediated changes in the dynamics and 
molecular interactions of TJ proteins underlie the observed changes in TJ composition 
and barrier function. 
 
  






 RAF/MEK/ERK activity alters MDCKII epithelial barrier properties; ΔCRAF:ER 
activation causes a transient increase in TER, followed by decreased readings 
at later time points. Paracellular leak pathway permeability is also increased. 
This coincides with complex changes in TJ composition. 
 
 RAF/MEK/ERK activity drives the depletion of claudin-2 protein in a cell-
autonomous manner. 
 
 CLDN2 mRNA levels are downregulated, but the existing claudin-2 protein pool 
is turned over by normal rates of internalisation from the cell surface and 
degradation in the lysosome. 
 
 Claudin-1 and -4 are redistributed from the lateral membrane to the apical 
junction, which may be a direct result of claudin-2 depletion. 
 
 Claudin-1 and -4 also accumulate in cytoplasmic compartments, independently 
of occludin and ZO-1. 
 
 The junctional accumulation of claudin-1 and -4 cannot be fully accounted for by 
changes in their total levels, increased protein stability or apparent changes in 
endocytic trafficking rates. 
 
 MDCKII TJs are regulated by a surprisingly diverse array of claudin-specific 
regulatory mechanisms that act in a coordinated manner to determine epithelial 
permeability properties.  
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How are RAF/MEK/ERK-mediated changes in barrier function regulated on 
different timescales? 
MDCKII paracellular permeability appears to be regulated by RAF/MEK/ERK signalling 
in a manner dependent on signal duration. Activation of the RAF/MEK/ERK pathway, 
either through BRAFV600E expression or ΔCRAF:ER activation, caused a transient 
increase in TER after approximately 24 hours of signalling, followed by a subsequent 
decrease at later time points. This is despite the sustained repression of claudin-2 
expression, and maintained expression of other TJ components after peak TER levels 
were reached. These observations are consistent with previous studies involving the 
activation of ΔCRAF:ER in MDCKII cells (Hansen et al., 2000). Therefore, 
RAF/MEK/ERK activation appears to generate an early “tightening” of the epithelia, 
while sustained activation is associated with the loss of barrier function. 
 
The observed early increase in TER is consistent with claudin-2 loss-of-function studies 
(Hou et al., 2006; Ikari et al., 2011a). The increased junctional incorporation of claudin-
1 and -4 may also play a role in the RAF-mediated increase in TER, as they each have 
barrier-promoting roles (Ikari et al., 2012b; Inai et al., 1999). Therefore, the combined 
effects of changes in TJ claudin composition are likely to underlie the initial TER 
increase. As the subsequent decrease in TER does not appear to be due to a reversal 
in claudin phenotype, alternative mechanisms are likely to be responsible. Sustained 
activation of the RAF/MEK/ERK pathway is associated with complete disassembly of 
cell-cell junctions and the complete loss of epithelial barrier function (Chen et al., 
2000). At these later time points, gross morphological changes are evident, with cells 
losing epithelial characteristics and gaining mesenchymal traits. Therefore, it is likely 
that later decreases in TER are as a result of increased cell movement and the loss of 
cell-cell contacts required for trans-interactions of TJ components and the formation of 
a functional paracellular seal. This loss of cell-cell contact may cause the observed 
internalisation of TJ components and their sequestration in cytoplasm following 
complete transformation (Chen et al., 2000). More detailed analysis of epithelial 
permeability with tracers of different molecular weights would be required to determine 
if this later loss of TER is consistent with an increase in size-selective leak pathway 
permeability or a more general loss of barrier function due monolayer disruption by cell 
detachment. 
 
It is currently unclear how these distinct effects of RAF/MEK/ERK signalling are 
mediated on different timescales. One potential mechanism is the delayed activation of 
the JNK pathway, which occurs 24 – 48 hours after RAF:ER activation as a result of 
ERK-mediated secretion of heparin-binding EGF (hbEGF), which acts in an autocrine 
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fashion (Pritchard et al., 1995). Of note, JNK interacts with Cdc42, which is required for 
TJ formation and development in airway epithelia (Tanos et al., 2015). Conversely, 
constitutively active Cdc42V12 disrupts the barrier function of confluent MDCKII 
monolayers, causing a decrease in TER and increase in paracellular flux to large 
uncharged solutes (Bruewer et al., 2004). Furthermore, HGF leads to TJ disassembly 
by activating Cdc42 in an ERK-dependent manner (Togawa et al., 2011), linking 
sustained RAF/MEK/ERK signalling to more wide-ranging effects on the cytoskeleton 
and TJ disassembly.  
 
What are the biological consequences of RAF/MEK/ERK-mediated TJ 
remodelling? 
As RAF/MEK/ERK pathway activity positively correlates with the degree of epithelial 
sealing along the renal nephron, the decreased paracellular permeability induced at 
early time points may reflect a physiologically relevant mechanism for regulating ionic 
homeostasis in the kidney. Furthermore, relative changes in claudin expression may be 
involved in renal regeneration and repair. Renal tubules are frequently exposed to 
hyperosmotic conditions, heavy metals and drugs that damage the epithelium. Injured 
cells are eliminated from the monolayer, but cell-cell contact must be maintained, or 
rapidly restored, to maintain a functional barrier. In a similar fashion to specific 
activation of the RAF/MEK/ERK pathway, hyperosmotic concentrations of NaCl, 
mannitol or urea each cause the depletion of claudin-2 in MDCKII cells, which 
increases migratory capacity in an MMP9-dependent manner (Ikari et al., 2011a). 
Therefore, the rapid downregulation of claudin-2 expression may facilitate renal tubule 
repair by promoting the migration of adjacent cells into damaged areas. 
 
Subsequent studies have established that hyperosmotic conditions can elicit a delayed 
upregulation of claudin-4 expression and increase the junctional levels of claudin-1 and 
-3 (Ikari et al., 2012b). Functionally, this results in increased TER and decreases the 
migration rate of MDCKII cells (Ikari et al., 2012b). Therefore, hyperosmotic stress 
appears to generate a biphasic response; initial claudin-2 downregulation serves to 
promote cell migration and epithelial repair, whereas a delayed increase in cell-cell 
contact decreases cell migration in an attempt to maintain the integrity of the epithelial 
barrier.  
 
Although a specific requirement for RAF/MEK/ERK signalling in the hyperosmolarity 
response has not been demonstrated, EGFR signalling plays a key role in mediating 
renal epithelial repair; waved-2 mice, which harbour an EGFR point mutation that 
reduces RTK activity by >90%, exhibit reduced tissue repair in response to acute 
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nephrotoxic injury (Wang et al., 2003). EGF is present in high concentrations in the 
urine, while EGFR expression is confined to the basolateral membrane of epithelial 
cells in the distal nephron, ureter and bladder (Harris, 1991). Therefore, ligand and 
receptor are normally segregated by an intact TJ. Additionally, heparin-binding EGF-
like growth factor, HB-EGF, is expressed as a membrane-bound precursor, proHB-
EGF, which is activated by proteolytic cleavage induced by immune cells in damaged 
tissues to yield a potent soluble mitogen, sHB-EGF (Singh et al., 2004). Therefore, 
epithelial damage increases activation of basolateral EGFR through at least two 
processes: i) increased access of EGF in the urine to basolateral receptors and ii) 
increased tissue concentrations of sHB-EGF.   
 
The results presented in chapters 3 and 5 indicate that specific activation of the 
RAF/MEK/ERK pathway can recapitulate many aspects of EGF-mediated changes in 
TJ composition, with particular respect to claudin expression levels and distribution. 
Therefore, the EGFR/RAF/MEK/ERK signalling axis may play an important role in 
mediating the renal tissue damage response by coordinating a complex claudin-based 
program, which in turn mediates changes in cell migration and barrier function that 
serve to maintain epithelial integrity. Although ERK was phosphorylated under 
hyperosmotic conditions, the decrease in claudin-2 protein was not blocked by a MEK 
inhibitor, suggesting that additional regulatory mechanisms are also involved (Ikari et 
al., 2011a). Further studies will be required to establish if an EGFR/RAF/MEK/ERK 
signalling axis mediates the cellular repair in response to other types of renal damage. 
 
Furthermore, in a similar manner to later effects of BRAFV600E expression and 
ΔCRAF:ER activation, chronic administration of EGF leads to MDCKII dedifferentiation, 
TJ disassembly and the complete loss of TER (Singh and Harris, 2004; Singh et al., 
2004; Singh et al., 2007). Epithelial dedifferentiation is associated with neoplastic 
transformation, but is also recognised as a necessary step in regeneration following 
epithelial injury (Singh et al., 2007). Therefore, the more dramatic changes in cell 
morphology observed at later time points may represent a more rigorous tissue 
damage response to severe epithelial damage. This is pertinent as tumours are 
frequently regarded as wounds that fail to heal (Flier et al., 1986). Gene expression 
data from tissue microarrays have been used to compare gene expression changes in 
models of renal regeneration and repair (RRR) and renal cell carcinoma (RCC) (Riss et 
al., 2006). The majority (77%) of genes expressed in RRR and RCC tissues were 
concordantly regulated, indicating there is an extensive overlap of molecular features 
and regulatory mechanisms between these two processes. Another study detected 
increased expression of claudin-1, -3 and -7 and downregulation of claudin-2, in a 
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model of murine renal ischemia (Kieran et al., 2003). Therefore, there appear to be 
striking similarities in the claudin response involved in tissue repair, renal carcinoma 
and some aspects of RAF-driven TJ remodelling. Claudin-based alterations in epithelial 
permeability and integrity, as well as cell migration, which are normally engaged to 
induce renal repair, may be co-opted during tumourigenesis to permit uncontrolled 
growth and invasion. 
 
What are the unique contributions of each TJ protein to the epithelial barrier? 
Specific activation of the RAF/MEK/ERK pathway leads to complex changes in TJ 
composition through the simultaneous yet differential regulation of individual claudin 
species. Both the downregulation of claudin-2, and the increased junctional expression 
of claudin-1 or -4, are each independently sufficient to drive the observed increase in 
TER, making the exact contribution of each species difficult to determine. This could 
potentially be addressed by studying the effects of RAF/MEK/ERK activation in MDCKI 
cells, which lack endogenous claudin-2 expression. Although this approach has been 
used to distinguish biological effects that are dependent on the loss of claudin-2, 
MDCKI and MDCKII cells are likely to have diverged and have additional differences in 
addition to claudin-2 expression. For example, a related high-resistance MDCK C7 
strain expresses lower levels of claudin-2 and -7, but increased levels of claudin-4 
compared to the low-resistance MDCKII strain (Van Itallie et al., 2008). Targeted 
deletion using TALENs (Tokuda and Furuse, 2015) or Cas9/CRISPR could be used to 
generate isogenic MDCKII cell lines that differ only in their expression levels of claudin-
2. Alternatively, the re-expression of claudin-2 from an exogenous promoter would 
reveal which aspects of barrier change, for example, the increase in TER or 
redistribution of claudin-1/-4, could be reversed or blocked through the restoration of 
claudin-2 protein levels. 
 
The RAF-mediated downregulation of claudin-2 was effectively blocked by the co-
treatment with small molecule inhibitors of either MEK or RSK kinases (Doehn et al., 
2009). In contrast, the concurrent upregulation of claudin-4 and -7 are independent of 
RSK function (Doehn et al., 2009). Therefore, the role of claudin-2 downregulation 
could potentially be addressed by combining the ∆CRAF:ER/4HT approach with 
specific RSK inhibitors. The activation of ERK, but not RSK, is sufficient to execute the 
loss of polarity, downstream activation of RSK is required for the weakening of cell to 
cell contact and increased cellular migration (Čáslavský et al., 2010). Therefore, 
temporal differences in activation of ERK and RSK could potentially contribute to the 
dynamic changes in epithelial permeability on different timescales. 
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How are claudin-claudin interactions dynamically regulated? 
Claudin-claudin interactions 
The redistribution of claudin-1 and -4 does not represent regulation of the TJ en masse, 
as ZO-1 and occludin do not exhibit the same cytoplasmic staining pattern as claudin-1 
and -4. The extensive colocalisation of claudin-1 and -4 along the lateral membrane, at 
the apical junction and in common cytoplasmic compartments following RAF/MEK/ERK 
pathway activation, suggests that they may interact at the molecular level. Although 
claudin-1 and -4 cannot interact in trans (Daugherty et al., 2007), they are thought to 
interact heteromerically in cis (Koval, 2013). The extent to which claudin-2 can interact 
in cis with claudin-1 or –4 is currently unclear; reported homo- and heteromeric 
interactions of claudins expressed in MDCKII cells are summarised in Table 6.1. When 
two transfected fibroblast populations are co-cultured, claudin 1- or claudin 2-based 
strands do not laterally associate with each other (Furuse et al., 1999), and are 
therefore considered to be heterotypically incompatible (Daugherty et al., 2007).  
 
Claudin 1 2 3 4 7 
1 Y (ND) Y Y Y 
2   Y N (ND) N 
3     Y/N* Y N* 
4       N* N* 
7         Y 
Table 6.1: A summary of homo- and heteromeric claudin interactions. Claudins can 
interact with each other in a species-specific manner. Cis-interactions have been reported using 
FRET or Y2H studies. (Y) strong interaction, (N) no interaction, (N*) no interaction by FRET, 
(Y/N*) interaction by FRET, no interaction by Y2H, (ND) not determined. Table adapted from 
Koval et al (2013). 
 
Claudin incompatibility may result in the spatial segregation of claudin-2 and claudin-1/-
4 under normal conditions. This could potentially be mediated through mutually 
exclusive protein-protein interactions, for example with ZO-1 or occludin, which are 
largely confined to the apical junction. Claudin displacement due to incompatibility has 
been demonstrated where exogenous claudin-8 expression displaces claudin-2 from 
MDCKII tight junctions (Angelow et al., 2007).  
 
The overall level and distribution of claudin-1, -3, -4 and -7 were not affected in initial 
claudin-2 knockdown experiments (Ikari et al., 2011b). However, recent studies 
involving the TALEN-mediated knockout of claudin-2 in MDCKII cells revealed a 
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subsequent increase in levels of claudin-1, -3, -4 and -7 specifically at the level of the 
TJ (Tokuda and Furuse, 2015). In contrast, the distribution of ZO-1, occludin, F-actin 
and myosin was similar between control and claudin-2 knockout cells (Tokuda and 
Furuse, 2015). Furthermore, the junctional accumulation of these claudins was 
reversed upon the re-expression of FLAG-claudin-2 (Tokuda and Furuse, 2015). This 
study suggests that the observed increase in junctional claudin-1 and -4 following 
ΔCRAF:ER activation is a direct result of claudin-2 depletion. However, the apparent 
upregulation of claudin-4 expression levels suggests that additional regulatory 
mechanisms, in addition to claudin-2 suppression, are involved in the ΔCRAF:ER-
mediated response. Re-expression of claudin-2 using an exogenous constitutive 
promoter, similar to the FLAG-claudin-2 construct used in the TALEN claudin-2 
knockout study (Tokuda and Furuse, 2015), would determine if claudin-2 depletion is 
necessary for the junctional accumulation of claudin-1 and -4 following ΔCRAF:ER 
activation. This claudin-2 expression would not be subject to endogenous 
transcriptional regulation, so these experiments would also provide further insight into 
whether RAF/MEK/ERK activity can influence the distribution or trafficking of claudin-2 
at the post-transcriptional level. 
 
Claudins that dissociate from ZO-1 migrate diffusely into the lateral membrane (Lee et 
al., 2008). Claudin-16 normally localises discretely at the TJ with ZO-1, but C-terminal 
ZO-binding sequence mutants widely distribute along the lateral membrane (Ikari et al., 
2004). Furthermore, the overexpression of a claudin-1-myc fusion protein, but not non-
epitope tagged claudin-1, induces the aberrant formation of TJ strands along the lateral 
surface of MDCK cells (McCarthy 2000). Of note, there is no ZO-1 associated with 
these strands (McCarthy 2000). Therefore, abrogation of the interaction between 
claudin-1 and ZO-1 through the addition of a C-terminal epitope causes claudin-1 to 
accumulate along the lateral membrane (McCarthy 2000). RAF/MEK/ERK-mediated 
claudin-2 depletion could potentially permit the incorporation of claudin-1/-4 into 
junctional strands through the liberation of previously occupied TJ-associated ZO 
proteins (Figure 6.1B). Alternatively, differential post-translational modification of C-
terminal claudin YV motifs, similar to phosphorylation of claudin-4 caused by EphA2 
activity (Tanaka et al., 2005), may influence junctional interactions. Future studies will 
be required to establish if RAF/MEK/ERK activity dynamically regulates claudin-ZO 
protein-protein interactions or the phosphorylation state of these TJ proteins. 
 
The junctional claudin repertoire was altered both by BRAFV600E expression and 
ΔCRAF:ER activation, while ZO-1 and occludin were largely retained at TJ. Claudins 
bind to ZO protein PDZ domains through a conserved C-terminal YV motif (Itoh et al., 
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1999). By contrast, occludin binds to the U5-GUK domain of ZO-1 (Raleigh et al., 2011; 
Schmidt et al., 2004). Occludin and ZO-1 appear to respond in a similar manner 
following activation of the RAF/MEK/ERK pathway. Both markers are retained at the 
apical junction, with a continuous staining pattern encircling each cell. In addition, both 
occludin and ZO-1 exhibit increased cytoplasmic staining, in a diffuse pattern that is 
distinct from the discrete punctate compartments that contain both claudin-1 and -4. 
This raises the possibility that occludin and ZO-1 are regulated together as a complex, 
while its association with individual claudin species may vary over time. Initially, 
claudin-2 may bind to ZO-1 via its PDZ domain, generating an occludin:ZO-1:claudin-2 
complex (Figure 6.1A). Following RAF/MEK/ERK pathway activation and the depletion 
of claudin-2, claudin-1 and -4 may bind the ZO-1 PDZ domain, leading to their 
junctional accumulation (Figure 6.1B). At later time points, further post-translational 
modification of claudin-1/-4, occludin or ZO-1 may lead to the dissociation of 
occludin:ZO-1 from claudin-1/-4, leading to distinct distribution of these proteins in the 
cytoplasm (Figure 6.1C). Coimmunoprecipitation assays involving ZO-1 would reveal 




Figure 6.1: A putative model of dynamic changes in protein-protein interactions following 
RAF/MEK/ERK pathway activation.  Under unstimulated conditions, ZO-1, occludin and 
claudin-2 are all confined to the apical junction, while claudin-1 and -4 are predominantly 
associated with the lateral membrane. Following RAF/MEK/ERK pathway activation, claudin-2 
protein levels are depleted and claudin-1 and -4 accumulate with ZO-1 and occludin at the 
apical junction. Claudin-1 and -4 are also present in discrete cytoplasmic compartments, 
independently of ZO-1 and occludin. This may reflect a relatively late disassembly of the 
junctional complex, potentially due to post-translational modification of constituent proteins that 
specifically influence interactions between the C-terminal YV claudin motif and the PDZ1 
domain of ZO-1. 
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Subdomain organisation of the tight junction 
Lateral, rather than junctional, claudin-1 has been observed in various MDCK strains 
(Amasheh et al., 2002; Dukes et al., 2011b) and has been associated with adhesion 
and  interaction with cell surface receptors (Günzel and Yu, 2013). This lateral claudin 
pool may also act as a reserve that allows cells to rapidly alter TJ properties in 
response to diverse stimuli. However, reports suggest that subapical claudins can form 
functional TJ stands that contribute to epithelial barrier function. In the inner ear, 
claudins partition into claudin-14 and claudin-9/-6 subdomains, which are 
distinguishable as areas with distinct strand morphology (Nunes et al., 2006). Lateral 
claudin-1/-4 may therefore contribute to TJ permeability under normal conditions. 
Importantly, lateral claudins have been observed in vivo (Rahner et al., 2001) 
suggesting that this is not an artefact of cultured cell lines. The altered claudin-1/-4 
distribution could potentially be accompanied by altered TJ strand architecture, and in 
turn, permeability, but further work will be required to elucidate any fine changes in TJ 
fibril architecture that are mediated by RAF/MEK/ERK activity. 
 
Post-translational modification of TJ proteins 
The C-terminal tail of claudin-2 is multiply phosphorylated on serine, threonine and 
tyrosine resides (Van Itallie et al., 2012b). S208 phosphorylation promotes the retention 
of claudin-2 at areas of cell-cell contact. By contrast, phosphomimetic S208E mutants 
are targeted less efficiently to the cell surface and accumulate in lysosomal 
compartments. It appears that S208 phosphorylation may promote retention at, or 
recycling back to, the plasma membrane, while dephosphorylation is associated with 
lysosomal trafficking. The amino acids surrounding S208 meet the requirements of a 
consensus PKCι site, suggesting that PKCι may directly phosphorylate claudin-2 to 
promote its localisation at the TJ through Rab14-directed trafficking (Lu et al., 2015). 
These studies directly link claudin-2 phosphorylation and altered trafficking rates. The 
data presented here indicate that specific activation of the RAF/MEK/ERK pathway 
causes claudin-2 depletion without affecting endocytic trafficking. As previously 
discussed, this is in contrast with a reported MEK-dependent increase in claudin-2 
internalisation and degradation in response to EGF treatment (Ikari et al., 2011c). 
Further studies may reveal that differential regulation of claudin-2 phosphorylation and 
Rab14/PKCι interactions underlie differences between EGFR activation and specific 
activation of the RAF/MEK/ERK pathway. 
 
Disease-causing WNK mutants have been shown to bind and phosphorylate claudins -
1, -2, -3, -4 and -7 on both serine (Tatum et al., 2007) and threonine residues (Ohta et 
al., 2006). Although hyperphosphorylation of claudin C-terminal domains mediated by 
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WNK overexpression or mutation is associated with increased paracellular Cl- 
permeability, the specific residues and direct consequences of phosphorylation are 
unknown (Kahle et al., 2004; Ohta et al., 2006; Tatum et al., 2007; Yamauchi et al., 
2004). EphA2 phosphorylates claudin-4 in the conserved YV motif that is required for 
PDZ domain-mediated binding of ZO-1, thereby reducing the junctional incorporation of 
claudin-4 (Tanaka et al., 2005). It is currently unclear how widely YV motif 
phosphorylation is conserved as a regulatory mechanism between different claudin 
species. However, this raises the possibility that claudin-specific kinases and 
phosphatases mediate differential claudin YV phosphorylation to regulate their 
interaction with ZO-1 at the apical junction. 
 
Unfortunately, there are few commercially available phosphosite-specific antibodies 
that target claudins. However, recent studies have utilised phosphate-affinity SDS-
PAGE with an acrylamide-pendant “Phos-tag™” reagent (Van Itallie et al., 2012b). 
Covalent incorporation of this ligand generates a gel matrix, which specifically retards 
the migration of phosphorylated proteins during electrophoresis (Kinoshita-Kikuta et al., 
2007). This approach allows the identification of differentially phosphorylated claudin 
species under different experimental conditions. Specific phosphorylated residues can 
be identified by combining Phos-tag™ SDS-PAGE with anti-phosphotyrosine, -
phosphoserine or -phosphothreonine antibodies or site-directed mutagenesis. Studies 
like these may reveal that differential regulation of claudin-1 and/or claudin-4 
phosphorylation accompanies their translocation downstream of RAF/MEK/ERK 
activation. 
 
How are differential responses to common stimuli achieved in specific tissues? 
Regulation of TJs and paracellular permeability is essential in various body organs in 
addition to the kidneys. For example, a functional seal must be maintained in the 
intestine to provide a barrier against luminal antigens (Dhawan et al., 2011). Defective 
intestinal epithelial barriers are considered to be an important contributor to intestinal 
inflammation, inflammatory bowel disease (IBD) and cancer. Therefore, the TJ 
remodelling reported in this thesis may have relevance to diseases of other tissues, 
especially given the particularly high incidence of colorectal tumours that exhibit 
constitutive activation of the RAF/MEK/ERK pathway. For example, 35 – 45% of 
colorectal cancers have mutations to KRAS (Britten, 2013), up to 20% have mutations 
to EGFR (Oh et al., 2011) and 5 – 15 % have BRAF mutations (Britten, 2013). 
However, individual TJ components appear to be differentially regulated by 
RAF/MEK/ERK signalling in a striking tissue-dependent manner. 
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While RAF/MEK/ERK activity leads to the loss of claudin-2 in the kidney, it promotes its 
expression in colorectal tissues (Inai et al., 2013). Furthermore, claudin-2 expression is 
significantly increased in colorectal cancer and correlates with cancer progression 
(Dhawan et al., 2011). The resulting increase in paracellular permeability is postulated 
to increase basolateral access of luminal carcinogens and growth factors to promote 
tumourigenesis (Dhawan et al., 2011). However, the different biological mechanisms 
that underlie the tissue-specific regulation of claudin-2 are currently unclear, but the 
exact repertoire of transcription factors that are expressed is likely to be a contributing 
factor. Claudin-2 expression is upregulated by transcription factors including Cdx1, 
Cdx2, HNF-1α and GATA-4 in intestinal cells (Sakaguchi et al., 2002). However, 
Cdx1/2 expression is confined to the intestine, while HNF-1α is required for claudin-2 
expression in liver and intestine, but not in the kidneys (Sakaguchi et al., 2002). 
Claudin-2 expression is increased by an EGFR/MEK/ERK/c-Fos pathway in lung 
adenocarcinoma cells (Ikari et al., 2012a). In MDCKII cells, the EGF-mediated 
downregulation of claudin-2 and upregulation of claudin-4 are both sensitive to 
inhibition of STAT3 (García-Hernández et al., 2015) and claudin-4 upregulation is also 
mediated by the transcription factor Sp1 (Ikari et al., 2009), although other transcription 
factors may be involved. These studies indicate that RAF/MEK/ERK activity regulates 
claudin-2 expression in a manner dependent on tissue-specific transcription factors. 
Further work will be required to determine the tissue-specific effects of RAF/MEK/ERK 
activity on the expression, and subcellular distribution, of other claudin species.  
 
Differential claudin expression has been reported in various cancers (Kwon, 2013). For 
example, a claudin-low subtype has been identified as particularly aggressive form of 
triple negative breast cancer, characterised by low expression of luminal markers and 
high expression of EMT markers, immune response genes and cancer stem cell-like 
features (Prat et al., 2010). In addition, increased claudin-4 expression has been 
identified in pancreatic and ovarian cancer (Neesse et al., 2012; Nichols et al., 2004), 
with reports suggesting it can be either a positive or negative prognostic factor; claudin-
4 expression inhibits primary tumour growth (Lin et al., 2013; Shang et al., 2012; Shang 
et al., 2014) but may promote growth at metastatic sites (Jiwa et al., 2014). Claudin-4 
overexpression is therefore a candidate diagnostic biomarker and also a potential 
target for delivering optical tracers or anticancer drugs conjugated to molecules that 
specifically bind to claudin-4 (Neesse et al., 2012). 
 
  




In conclusion, regulation of epithelial permeability through TJ remodelling is being 
increasingly recognised as an important process, in both physiological settings and 
pathological conditions like inflammatory disease and cancer. The work in this thesis 
demonstrates that RAF/MEK/ERK activity causes TJ remodelling through surprisingly 
diverse mechanisms, which has important consequences for understanding how 
epithelial permeability is dynamically regulated during tissue repair and in 
tumourigenesis. Future work will be required to address the following key biological 
questions: 
 
 How do claudins and other proteins interact at the tight junction? 
 
 What are the mechanisms underlying RAF/MEK/ERK-mediated claudin 
redistribution?  
 
 What are the biological consequences of RAF/MEK/ERK-mediated tight 
junction remodelling during tissue repair and tumourigenesis? 
 
 How are components of the tight junction dynamically regulated to alter 
epithelial permeability during tumourigenesis in different tissues? 
 
 Can tissue-dependent claudin signatures be identified that have useful 
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Figure A1: Plasmid map of pJET1.2. pJET1.2 is provided as a blunt cloning vector with the 
CloneJET PCR Cloning Kit (Thermo Scientific). Blunt-ended PCR products can be directly 









Figure A2: Plasmid map of pacAd5 9.2 – 100 sub 360. This is the adenoviral shuttle vector. 
After PacI digestion, this vector is cotransfected with the required shuttle vector into HEK293 







Figure A3: Plasmid map of pAd5 K-NpA. pAd5 K-Npa is an adenoviral shuttle vector. For the 
generation of recombinant adenovirus, the transgene of interest must be subcloned into the 
multiple cloning site of this vector. Subsequent digestion with PacI and cotransfection with the 
pacAd5 9.2 – 100 sub360 adenoviral backbone vector is required for recombination in an E1-








Figure A4: Plasmid map of pAd5CMVeGFP. The cytomegalovirus (CMV) promoter and eGFP 
were ligated in to the pAd5 K-NpA shuttle vector for the generation of the control GFP 
adenovirus. pAd5CMVeGFP cloning and adenovirus production were carried out by Dr. Jim 













 were cloned between the SpeI and NotI sites of pAd5CMV K-NpA. An analytical 
SpeI/NotI digest produces the predicted bands of 6.2kb (pAd5 CMV vector) and ~3kb (GFP-
myc-BRAF) for BRAF
WT
 (clones 1 – 6) and BRAF
V600E 
(clones 7 – 12). An N-terminally truncated 
∆BRAF construct was also produced and a SpeI/NotI digest generated bands of 6.2kb and 
~1.8kb, corresponding to truncated ∆BRAF. The ∆BRAF construct was not used for 










 ER fusion proteins were cloned between the BspEI and NotI sites of the existing 
pAd5CMV GFP-myc-BRAF vectors (Figure A5). An analytical AvrII/SpeI digest produces the 
predicted bands of 7.2kb (pAd5 CMV vector) and ~3.1kb for BRAF
WT





(clones 9 – 16). The reference lane represents the parent pAd5CMV GFP-myc-
BRAF
WT 
vector digested with AvrII/SpeI. The parent vector lacks the AvrII restriction site and 
generates a band corresponding to the SpeI-linearised ~9.3kb vector. The larger molecular 














Figure A7: Details of the pCMVNeoMyc1∆Raf-1:ER* vector. This vector was a kind gift from 
Dr. Simon Cook (Babraham Institute, Cambridge, UK) and was used for cloning 









Figure A8: Analytical digests of pAd5CMV∆CRAF:ER constructs. (A) ∆CRAF:ER was 
subcloned from the parent pCMVNeoMyc1∆Raf-1:ER* vector into pAd5CMVeGFP using a 
single BamHI restriction digest. A XhoI digest was used to screen clones. The reference lane 
represents the parent pCMVNeoMyc1∆Raf-1:ER* vector digested with BamHI and XhoI. This 
generates three bands: a large molecular weight vector and two were molecular bands of 
~1.5kb and 0.7kb (see Figure A7).  A single XhoI digest reveals the orientation of ∆CRAF:ER 
cloning. The correctly orientated ∆CRAF:ER generates a band of 1.5kb (clones 5 and 13), while 
the reverse orientation produces a band of 0.7kb (clone 15). The remaining clones do not 
contain a valid insert. Clone 5 was subsequently sequenced and used for adenovirus 
generation. (B) Both myc- and HA-tagged ∆CRAF:ER products were generate by PCR  and 
subcloned between the SpeI and NotI sites of pAd5CMV GFP-myc-BRAF
WT
. An analytical 
SpeI/NotI digest generated a predicted band of ~2kb for myc∆CRAF:ER (all clones except clone 
6 and 10) and HA∆CRAF:ER (clones 6 and 7). The reference lane shows the parent 
pAd52.CMV GFP-myc-BRAF
WT

















Figure A9: Validation of primers used in RT-qPCR. Primer pairs targeting CLDN1, CLDN2, 
CLDN4 and GAPDH were validated by performing PCR reactions with serial dilutions of 
template cDNA. Each primer pair generated a linear standard curve of threshold cycle (CT) 
plotted against log10[cDNA]. R
2 
values are displayed on each plot. Amplification efficiency (E) 
was calculated from the gradient of each standard curve using the formula:             . 
Amplification was not detected within 35 cycles for control “no reverse transcriptase” PCR 
reactions, indicating successful removal of genomic DNA contaminants. Melt curve analysis 
revealed a single PCR product was generated by each primer pair. 
